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ABSTRACT 
 
Globally, the incidence of infection caused by Neisseria gonorrhoeae is the second highest 
among the bacterial sexually transmitted infections. In Canada, declining rates during the 1990s 
suggested progress toward curbing gonorrhea; however, those have been increasing since 1999, 
with rates in Saskatchewan among the highest in the country. Infection can cause serious 
complications in men and women, and reported resistance to third-generation cephalosporins 
could lead to potentially untreatable infections. Increased understanding of gonorrhea 
transmission dynamics, sexual networks, and predictors of antimicrobial resistance development 
is needed to inform the development of improved approaches to prevention and treatment. 
The research presented herein draws upon data from Shanghai, China, and Saskatchewan, 
Canada, to compare and contrast varying epidemiologic approaches to enhancing understanding 
of gonorrhea in the two settings. Using traditional statistical approaches, multi-level statistical 
modeling, social network analysis, and dynamic simulation modeling, questions related to sexual 
behavior, partner presentation, and antimicrobial resistance development are explored. Each 
technique is evaluated for its potential contribution to overall understanding of the issues related 
to the ongoing gonorrhea epidemic, globally, and in Saskatchewan. 
The relative strengths and limitations of the application of the analytical approaches in the 
different settings are described. Socio-demographic characteristics provided useful indicators of 
antimicrobial resistant infection among patients with gonorrhea from Shanghai. Further, socio-
demographic characteristics were also useful for predicting presentation of a partner for testing 
and treatment and the use of condoms during intercourse, among this study population. In 
Saskatchewan, socio-demographic characteristics were useful in predicting coinfection with 
gonorrhea and chlamydia at the time of diagnosis as well as repeat infection with gonorrhea. 
Social network analysis of the Saskatchewan dataset provided little additional understanding of 
the gonorrhea epidemic in the province. This result was largely related to how STI data are 
collected and stored in the province. The utility of dynamic simulation modeling to investigate 
the potential impact of antimicrobial resistance in Saskatchewan was also limited due to the same 
data constraints.  However, the insight gained from the model building process and findings from 
the working model did offer a starting point for conversations around the best ways to postpone 
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the development of antimicrobial resistance in N. gonorrhoeae in Saskatchewan, as well as 
contribute additional information about how the ways in which STI data are collected and stored 
in the province considerably restrict the applicability of otherwise powerful epidemiologic tools. 
With persistently high rates of disease transmission, and the threat of untreatable infections due 
to antimicrobial resistance, N. gonorrhoeae remains a substantial public health threat locally and 
globally. The research presented herein describes various approaches to understanding and 
controlling this disease, applied in contrasting settings. There are a wide variety of elements that 
should be considered when choosing the appropriate tool(s) to address gonorrhea in a given 
population; there is no “one size fits all” solution. The local epidemiology of disease, cultural 
and behavioural norms, the characteristics of the notifiable disease reporting and information 
systems, and the availability of suitable data all affect the relative strengths and weaknesses of 
the available analytic methods and disease control approaches. 
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CHAPTER 1: INTRODUCTION 
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Infections caused by Neisseria gonorrhoeae have plagued humankind since ancient times. 
Gonorrhea was likely known to the authors of the Bible, which describes gonorrhea-like 
symptoms in the book of Leviticus; extensive descriptions of the disease date back at least to the 
time of Hippocrates (460-377 BC). Galen (130-200 AD), a Greek physician, is credited with 
giving the disease its name, based on the Greek words for “flow of semen (1).” The etiologic 
agent wasn’t discovered, however, until 1879, by Albert Neisser, a German physician (2). 
N. gonorrhoeae is a gram negative bacterium that only infects humans. It is relatively fragile, 
and unable to survive long outside the human body. The organism is spread by close physical 
contact with an infected individual’s mucosal surfaces, and is transmitted almost exclusively 
through sexual partnerships. Gonococcal infection causes localized infections of the eyes, mouth, 
throat, rectum, and/or urogenital tract of both males and females.  
1.1 Clinical features of infection 
1.1.1 Men 
Urethral gonorrhea in men generally causes painful urination and/or urethral discharge, typically 
appearing two to five days after infection (3). In the absence of treatment, most cases of urethral 
infection will resolve over a period of several weeks (4). Potential complications for men include 
epididymitis (4), which may cause testicular or scrotal pain. In rare cases, epididymitis can lead 
to infertility in men. While less common among men than among women, many men experience 
asymptomatic gonorrhea (5), potentially increasing their chance of complications due to failure 
to seek treatment. 
1.1.2 Women 
Urogenital infections in women occur primarily in the endocervical canal, and are often 
asymptomatic. When symptoms do occur, they generally occur within 10 days of exposure. 
Symptoms may include painful urination, increased vaginal discharge, or mid-cycle vaginal 
bleeding (4). However, symptoms are generally mild and may be mistaken for other conditions 
such as bladder or vaginal infections (6). Even in asymptomatic infections, serious complications 
can occur as a result of gonococcal infection in women. If the infection spreads to the uterus or 
fallopian tubes, pelvic inflammatory disease (PID) may occur. PID can cause internal abscesses, 
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chronic pelvic plain, and damage to the fallopian tubes may result in infertility or increased risk 
of ectopic pregnancy (7).  
Gonorrhea during pregnancy is of particular concern; an infected woman may pass the infection 
on to her baby during delivery. This can result in ophthalmic infection for the baby, possibly 
leading to blindness (8). Disseminated gonococcal infection (DGI) is another serious potential 
complication of gonorrhea in newborns, usually occurring within one to four weeks of birth (8). 
1.1.3 Men and women 
Rectal and pharyngeal infections can occur in both sexes, and are particularly common among 
men who have sex with men (MSM) (4). Rectal infection can be asymptomatic, or can present 
with discharge, soreness, bleeding, itching, and/or painful bowel movements (9). Pharyngeal 
infection is typically asymptomatic, but can cause a sore throat (10). In both men and women, 
untreated gonorrhea can lead to DGI, which is potentially life-threatening. Men and women 
diagnosed with gonorrhea are commonly coinfected with chlamydia as well (11,12). 
Additionally, studies have shown that infection with gonorrhea and other STIs enhances HIV 
transmission (13,14).  
1.2 Gonorrhea control 
In the absence of a vaccine to prevent infection, control of gonorrhea depends on a combination 
of rapid diagnosis, appropriate treatment, and case-finding/partner notification.  
1.2.1 Diagnosis and treatment 
Laboratory diagnosis relies upon the identification of N. gonorrhoeae isolates recovered from the 
site(s) of infection by examination of stained smears, by culture, or by genetic or 
immunochemical tests. Increasingly, non-culture methods are becoming the primary method of 
diagnosis in North America and Western Europe; however, culture remains the standard in many 
other locations (4). In Canada, laboratory testing to confirm diagnosis of gonorrhea is generally 
done using nucleic acid amplification tests (NAAT), which can be performed on urine samples.  
Although NAAT is less invasive and more convenient than taking swabs for culture, to date there 
is no established method of identifying antimicrobial resistance (AMR) in N. gonorrhoeae using 
NAAT or other non-invasive techniques. Therefore, cultures are recommended to enable 
effective surveillance of (AMR) trends (15,16). Additionally, the Public Health Agency of 
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Canada (PHAC) recommends that all suspected treatment failures be investigated using culture 
(17). 
Because of increasing rates of AMR, treatment guidelines are continuously updated to ensure 
that the most effective available antibiotics are used. Resistance varies in different geographic 
areas of the world, and treatment guidelines are developed regionally. In China, national 
guidelines recommend the use of ceftriaxone (250 mg IM) and spectinomycin (2g IM); the cost 
of antibiotics is covered by public health (Dr. Weiming Gu, personal communication 2015). In 
Canada, dual therapy is recommended due to increasing rates of AMR, as well as to address 
concomitant chlamydia infection. At the time of writing, combination ceftriaxone (250 mg IM in 
a single dose) and azithromycin (1 g po in a single dose) OR cefixime (800 mg po in a single 
dose) and azithromycin (1 g po in a single dose) were recommended as the preferred treatment 
for anogenital and pharyngeal infection, along with repeat screening 6 months after treatment.  A 
recent Canadian report shows that this combination therapy is more effective than monotherapy 
with oral cefixime (18). Directly observed therapy—where the treatment is administered during 
the clinical visit and observed by the clinician—is recommended for all cases, as is test of cure 3-
7 days after treatment in certain cases (17). In Saskatchewan, approved antibiotics to treat 
bacterial STIs are provided to patients without cost (19).   
1.2.2 Reporting and partner notification 
Along with diagnosis and treatment, partner notification is an important aspect of disease 
control. Gonorrhea is a notifiable disease in many countries, including both China and Canada—
the two geographic settings for the data analyzed and presented in this dissertation (20,21). This 
means that all laboratory-confirmed cases must be reported to the appropriate public health 
authorities to support monitoring and control efforts.  In China, the National Center for STD 
Control, in Nanjing, is responsible for surveillance of STIs. Law requires that all new cases of 
gonorrhea are reported to this national surveillance system (20,22). In Canada, cases are reported 
to the Canadian Notifiable Disease Surveillance System (CNDSS), on a voluntary basis, by 
provincial public health authorities who are responsible for notifiable disease surveillance and 
follow up (21). 
PHAC guidelines include case-finding and partner notification for all positive gonorrhea cases, 
with a trace-back period of 60 days. If needed, local public health authorities may assist in 
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partner notification and follow up. It is recommended that all sexual partners who are located are 
tested, and presumptively treated, regardless of the existence of signs and symptoms. Further, 
recommended follow up of all positive cases includes repeat testing 6 months after treatment. In 
certain circumstances—including pharyngeal infection, persistent signs and symptoms after 
treatment, re-exposure, and poor compliance, among others—test of cure is recommended 3-7 
days (for culture) or 2-3 weeks (for NAAT) after initial treatment (17). 
1.2.3 High risk groups 
PHAC identifies several populations at risk for gonorrhea. These include contacts of a confirmed 
case, individuals who have had unprotected sex with a resident of an area with high rates of 
disease and/or high rates of AMR, individuals who have previously been infected with an STI 
(including HIV), sex workers and their partners, sexually active individuals under 25 years of 
age, the street-involved and homeless, MSM, and those with multiple sex partners (23). These 
groups may warrant heightened surveillance or specific, targeted interventions. 
1.3 Epidemiology of gonorrhea 
Globally, gonorrhea rates have been increasing. Incidence of gonorrhea is the second highest 
among the bacterial STIs, with an estimated 78 million new cases each year according to the 
most recent data from the World Health Organization (24). Because gonorrhea is often 
asymptomatic, it is possible that the true burden of disease is actually much higher. Rates of 
gonorrhea are typically highest among younger individuals. In the US, most infections are 
diagnosed among women 15-24 and men 20-24 (25), while in Canada, data indicate women 15-
19 and men 20-24 exhibit the highest infection rates (17).  
1.3.1 China 
Rates of bacterial STIs, including gonorrhea, are high in China. After intensive control efforts 
led to a reduction in rates during the 1980s, subsequent social and economic changes have led to 
a rebound in rates since then. While incomplete reporting systems and lack of diagnostic 
capabilities in many regions limit the ability to estimate the true burden of disease (26), a 
national population-based study reported gonorrhea prevalence of 80 per 100,000 among 
women, and 20 per 100,000 among men (27). Rates of gonorrhea are especially high among 
high-risk subgroups of the population, including female sex workers and MSM (20,27).  
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1.3.2 Canada and Saskatchewan 
Incidence of gonorrhea has been increasing in Canada since the 1990s, with a 38.9% increase 
between 2003 and 2012 (28). Gonorrhea is more common among young women than young men 
(age <25) in Canada, but the reverse is true for older age groups. In 2012, the Canadian national 
rate was 36.2 cases per 100,000. Saskatchewan’s rate was 93.6 per 100,000—second only to 
Manitoba among the provinces, three times the rate of Ontario, Quebec, and British Columbia, 
and over twice the national rate (Figure 1.1) (28).  
 
Data source: PHAC and iPHIS; modified from: http://communityview.ca/infographic_SHR_sti_2014.html  
Figure 1.1 Gonorrhea in Canada and Saskatchewan, 2004-2012 
 
1.4 Antimicrobial resistance in N. gonorrhoeae 
Effective treatment for gonococcal infection is a crucial component of efforts to control disease 
transmission, and is the only way to eliminate disease. Unfortunately, treatment options have 
dwindled over time as resistance to each new class of antibiotics introduced has developed (29). 
AMR in N. gonorrhoeae develops either through plasmid-mediated mechanisms, chromosomal 
mutations, or both. Plasmid-mediated mechanisms confer resistance to penicillin and/or 
tetracycline, while accumulated chromosomal mutations may lead to either single-drug or multi-
drug resistance (30). Over time, most AMR N. gonorrhoeae originated in the World Health 
Organization’s (WHO) Western Pacific Region and eventually spread around the globe (31). 
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According to World Health Organization recommendations, an antibiotic must have a cure rate 
of 95% to be recommended (32). In other words, when the treatment failure rate is 5% or higher 
for a given antibiotic, it is no longer recommended for use. In spite of continuous monitoring and 
frequently updated treatment guidelines,  N. gonorrhoeae has rapidly developed resistance to 
every class of drugs used for treatment since sulphanomides were introduced in 1936 (33) 
(Figure 1.2).  By the mid-1940s, resistance to sulphanomides was already common (34). 
Penicillin was introduced at around this time, and was initially shown to be highly effective 
against gonorrhea (35); within 10-15 years, however, effectiveness was decreasing (36), and by 
1989 was no longer recommended for treatment (33). At around the same time, resistance to 
tetracycline also removed it as a treatment option (37), where it had been used prior for patients 
in whom penicillin was contraindicated (33). Resistance to fluoroquinolones such as 
ciprofloxacin, also once highly effective against gonorrhea, was beginning to be reported in the 
1990s (38–41); by 2007, they were removed as a treatment option (42). Azithromycin resistance 
also became widespread at around the same time (33). At this point, third-generation 
cephalosporins were left as the only monotherapeutic treatment options that could be generally 
recommended, and were still effective at relatively low concentrations (33). In recent years, 
resistance to the last line of recommended drugs has been observed in several regions (43–45), 
potentially ushering in an era of untreatable infections (31), and prompting recommendations to 
use dual therapy (33). 
1.4.1 AMR in China 
In China, years of over-the-counter antibiotic availability, coupled with poor antibiotic 
management and prescribing practices, have resulted in widespread AMR (46). Data from 1,398 
isolates collected from STD clinics in 15 cities in China confirm that rates AMR in N. 
gonorrhoeae are high. Almost half (48.5%) exhibited plasmid-mediated tetracycline resistance 
(TRNG), 37.4% were penicillinase-producing (PPNG), and nearly all (96.6%) showed 
chromosomal resistance to ciprofloxacin (QRNG); levels of resistance to ceftriaxone and 
spectinomycin were very low (≤1%) among these isolates (20). Another study indicates that 
reduced susceptibility to ceftriaxone, however, is highly prevalent (26).  Data from the  
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Figure 1.2 History of AMR in N. gonorrhoeae (modified from Unemo and Shafer, 2011). 
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Gonorrhoeae Antimicrobial Surveillance Program (GASP) in the WHO’s Western Pacific region 
showed that decreased susceptibility to oral cephalosporins has been noted in Hong Kong, and 
that 30-40% of strains in China have decreased susceptibility to ceftriaxone (47).  
1.4.2 AMR in Canada and Saskatchewan 
In Canada, AMR is monitored using the passive National N. gonorrhoeae Surveillance Program, 
which relies upon voluntary submission of N. gonorrhoeae isolates to the National Microbiology 
Lab (NML) by provincial labs. Isolates are submitted if the provincial lab identifies resistance to 
at least one antibiotic, or where AMR testing is not carried out at the provincial level (48).  
Rates of AMR in Canada are relatively low, compared to those in China. However, according to 
a 2015 report, laboratory surveillance data for N. gonorrhoeae isolates submitted to the National 
Microbiology Lab (NML) indicate that rates of AMR have been on the rise since 2009 (49). In 
2013, of the 3,195 isolates cultured, 36.1% were resistant to at least one antibiotic. Specifically, 
24.3% were resistant to erythromycin, 18.9% to penicillin, 33% to tetracycline, and 29.3% to 
ciprofloxacin. The proportion of isolates with decreased susceptibility to ceftriaxone (at 0.125 
mg/L) and/or cefixime (at 0.25 mg/L) was 3.9%, a decrease from previous years. Only 1.2% of 
isolates showed resistance to azithromycin—an increase from 0.4% in 2009. (Figure 1.3a) (49) 
In Saskatchewan, antimicrobial susceptibility testing is carried out by the provincial 
Saskatchewan Disease Control Laboratory (SDCL) on cultured samples. In spite of being 
recommended by the Saskatchewan Ministry of Health (19), cultures are rarely performed; 
therefore, only a small number of gonorrhea cases are included in surveillance of AMR in the 
province. It is unknown what percentage of total cases in the province is represented in AMR 
surveillance data.  
Based on the available data, Saskatchewan’s rates of AMR are substantially lower than those of 
the rest of the country (50) (Figure 1.3b). As shown in Figure 1.3b, rates of resistance to 
penicillin, ciprofloxacin, and azithromycin were quite low from 2003-2009. A spike in resistance 
to ciprofloxacin and azithromycin was observed in 2010, but by 2012 only tetracycline (5% in 
2011) and ciprofloxacin (12% in 2012) resistance remained above the recommended 5% 
threshold (32).  
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Sources: PHAC (Canada) and Dev, 2013 (Saskatchewan) 
Figure 1.3 Levels of AMR in Canada and Saskatchewan, for selected antibiotics (2003-
2012) 
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1.5 Gonorrhea transmission 
1.5.1 Basic reproductive rate 
The spread of infection is often characterized by describing the basic reproductive rate, R0, 
which indicates the average number of new infections generated by the initial case in a 
completely susceptible population. The effective reproductive rate, R*, is the average number of 
new infections generated by the initial case in the current epidemiologic context and therefore 
also considers the proportion of the population that is susceptible to disease. For an infection to 
be sustained in a population over time, R* must equal at least 1 (e.g., on average each case 
successfully transmits the infection to one new susceptible individual). For STIs, R* for any 
given infection relies upon the probability of infection transmission per contact (β), the contact 
rate (c) in the population, the duration of infection (d), and the proportion of susceptible people 
(S). This relationship is expressed by equation 1.1: 
 R* = R0*S = βcd*S         (1.1) 
Control of STIs therefore relies upon reduction in one of these parameters. For example, it may 
be possible to reduce the probability of infection transmission per episode of sexual contact by 
an increase in the use of condoms. Alternatively, behavioral interventions could result in a 
decrease in the rate of partner changes (e.g., reduction in c).  
1.5.2 Core groups 
For gonorrhea to persist in a population, R0 must remain at 1 or above, if we assume the 
proportion of susceptible individuals in the population at risk approaches 1 and R* approximates 
R0. This is a reasonable assumption for gonorrhea because there is no sustained resistance to 
infection in individuals that have recovered from infection, and no effective vaccine. Brunham 
(51) notes that there is a critical threshold for the rate of partner change in population required to 
maintain an STI in a population. By rearranging the equation for the basic reproductive rate, he 
derives this critical threshold (Ct) as equation 1.2: 
  Ct = 1/βd          (1.2) 
and suggests that Ct for gonorrhea is roughly 4 (51). This partner change rate is found in only a 
small segment of the overall population, known as the “core group,” which is defined both by the 
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behavior of its members and the connectivity between them (51). There are many definitions for 
the core group (52), and the term has come to be synonymous with “high risk.” It may be used to 
describe those in the sex trade, or those who are street-involved, or exhibit other high risk 
behaviors. Generally, however, core groups are made up of individuals who have multiple 
concurrent partners, high rates of partner change, and high rates of infection (51–55).  Because of 
the role of the core group in driving infection transmission, identification of such groups is a 
fundamental component of effective disease control in any population (32).  
In addition to the core group, bridging populations—those low risk individuals who form links 
between the high risk core, and the general population—are also important for disease 
transmission (31). Figure 1.4 shows a schematic diagram of the positions and roles of the core 
group, bridging population, and general population, as it relates to STIs. 
 
 
Source: WHO 2007 
Figure 1.4 Transmission of STIs in the population 
1.5.3 Sexual networks 
Gonorrhea is a network disease, meaning it requires direct sexual connections between 
individuals for transmission. Sexual networks are comprised of groups of individuals who are 
connected to one another—either directly, or indirectly—by sexual contact. Individual members 
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in a network are known as nodes, or actors, while the connections between them are called ties or 
edges (56). Study of the structure of networks as they pertain to the flow of disease (or 
information) is known as social network analysis (SNA); in the case of STIs, the “social 
network” of primary concern is necessarily a sexual network. 
Jolly and Wylie describe three network types related to the transmission of STIs (57):  
1. Sexual networks are those in which the members have sex with one another, but members 
may or may not have an STI;  
2. Transmission and infection networks are those in which at least some members are 
infected and transmitting infection; and 
3. Disease networks are those in which members have symptomatic, diagnosed infections.  
Wasserheit and Aral (58) offer another way of describing networks, related to epidemic versus 
endemic disease. Spread networks are those in which R* > 1, and disease is actively spreading. 
They postulate that these networks comprise subpopulations with high rates of concurrency and 
high numbers of partners. Maintenance networks, in contrast, are described as those in which R* 
= 1, and members of these networks have lower rates of partner change, fewer partners, and 
lower rates of concurrency. 
1.6 Epidemiologic tools for gonorrhea control 
A variety of epidemiologic tools are available to support research into gonorrhea transmission 
dynamics and evaluate the effectiveness of interventions for control. Statistical analysis has been 
the cornerstone of epidemiology for hundreds of years (59), and most epidemiologic studies rely 
upon biostatistical analytic methods. For example, simple descriptive statistics are useful in 
providing a deeper understanding of a dataset, and for hypothesis generation, while analytical 
methods aim to identify associations between causes and outcomes (60). More recently, powerful 
computer-based techniques have become available to enhance the strength of epidemiologic 
approaches to understanding disease transmission and control. SNA and dynamic simulation 
modeling are two newer approaches that are becoming more commonly used in epidemiologic 
studies. 
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1.6.1 Social network analysis 
SNA refers to the study of social structure (61), and has been used in the social sciences for 
decades (62). In recent years, interest in network theory methods has been expanding into 
various other fields, including physics, epidemiology, and biology (63). Social networks consist 
of a set of individuals or groups who are connected by links that represent their relationships to 
one another (56). In the case of the spread of STIs, the relationships are sexual, and the links 
represent sexual contact between individuals. Traditional contract tracing approaches reflect 
network concepts, in that they attempt to uncover the extent of individuals in the STI 
transmission chain related to each identified case. The resultant “collection” of individuals 
represents the sexual network at risk of contracting (or transmitting) infection (64).   
Research indicates that network structure has a strong influence on disease transmission, and 
several studies hypothesize how network structure can be used to inform appropriate 
interventions (65–69). Uncovering the complete sexual network of interest can be difficult, 
however, depending on the extent of disease spread and the data collection method employed. 
There are two basic approaches to establishing sexual networks (70). Egocentric networks are 
built based upon an initial contact’s description of his or her partners; the partners themselves are 
not followed up, thereby eliminating the possibility of discovering subsequent branches of the 
network. In contrast, sociometric network approaches aim to elucidate a more complete network 
by tracing the named contacts and then asking them to name their contacts, in turn. While both 
study designs have limitations, and uncovering the entire extent of the network is unlikely for 
large networks, SNA still offers a powerful tool to enhance traditional approaches to the control 
of gonorrhea, and has been applied in various settings (55,67,70–79). Further, network analysis 
approaches can be substantially strengthened by combining molecular biological strain 
information and epidemiologic data (72,75,76,80). 
1.6.2 Dynamic simulation modeling 
Dynamic simulation modeling offers another powerful approach for the analysis of health data. 
In the late 1970s, Hethcote, Yorke, and Nold developed a mathematical framework by which to 
describe the transmission dynamics of N. gonorrhoeae (53,54). Since that time, this framework 
has continued to form the foundation from which other gonorrhea transmission models have 
been built (81), although modeling techniques have grown more sophisticated over time. 
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Presently, several different software packages exist to support various different modeling 
approaches.    
There are two main categories of dynamic simulation models of relevance here: system 
dynamics models and agent-based models (82). System dynamics models—including closely 
related and mathematically identical compartmental models—are highly quantitative, and use 
stocks and flows to model the complexities of a given system. These models are based in the 
concept of feedback and the ways in which it affects the system (83). Such models have been 
applied to public health questions for almost 50 years (84). Agent-based models are newer, and 
differ in several ways. Instead of using stocks and flows, agent-based models allow for the 
modeling of discrete individuals (agents) and their interactions with their environment and one 
another (85). These models allow for stochastic effects, representation of network and spatial 
context, longitudinal trajectories of individuals, and the emergence of phenomena based on agent 
behavior (82); this makes them particularly are well-suited for modeling and evaluating targeted 
interventions that rely upon an individual’s behavior, or position in the network.  Agent-based 
models typically require more time, cost, and skill to build than do system dynamic models, but 
also offer more flexibility, and enable the modeler to include the effects of stochastics, which is 
more representative of the real world. The choice of modeling approach, therefore, requires 
considering the research question and anticipated outcomes in light of these trade-offs.   
Models enable researchers to generate and test hypotheses, compare the potential impact of 
interventions, and predict disease trends under various scenarios, all without requiring access to 
an actual study population. In this way, models offer an approach that is both time-saving and 
cost-saving. Depending on the availability of empirical data to inform structure and parameters, 
and the ultimate goals of the study, models may be more useful for hypothesis generation than 
providing direct evidence to inform policy decisions. Both are valuable, however, and have great 
potential to contribute to our understanding of disease transmission and control. Over the last 15 
years, a small number of studies have used dynamic simulation models to investigate a questions 
related to gonorrhea, including AMR development (86,87) and cost-effectiveness of screening or 
treatment approaches (88–92). Dynamic simulation models offer a unique and valuable 
opportunity to generate and test hypotheses related to identifying the best possible strategies for 
the control of gonorrhea—information that is urgently needed.  
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1.7 Goals and objectives of research 
Gonorrhea remains a significant public health concern. Traditional approaches to prevention and 
control can be strengthened through enhanced understanding of the dynamics of transmission, 
the potential effect of interventions among different groups, and the factors influencing the 
development of AMR. Gonorrhea persistence relies on a combination of factors, including both 
behavioral and biological elements.  Successful control methods need to address 
sociodemographic risk factors for infection and consider rising rates of AMR to be successful. 
There are a wide variety of epidemiologic tools available for the analysis of these and other 
issues related to gonorrhea. The body of research presented in this thesis explores the 
applicability of several epidemiologic methods to improving control of gonorrhea in China and 
Saskatchewan. Several of the chapters in this dissertation have been published as manuscripts in 
peer-reviewed journals, and are included in their published form. Approaches presented herein 
include—alone and in combination—traditional  statistical modeling, multi-level statistical 
modeling, social network analysis, and dynamic simulation modeling, as applied to questions 
relating to several aspects of gonorrhea control, in different disease settings. The techniques were 
applied to research questions ranging from the ability to identify sociodemographic risk factors 
for AMR development in China, to predictors of repeat infection and coinfection in 
Saskatchewan, to the potential development of AMR N. gonorrhoeae in Saskatchewan, in an 
effort to contribute to existing knowledge about these integral components of disease control. It 
was hypothesized that the relative power of each approach would be dependent upon the local 
epidemiology of disease, as well as the availability and robustness of data.  
Specific goals of this research included: 
1.7.1 Assess the potential of using sociodemographic characteristics to predict the likelihood of 
infection with AMR N. gonorrhoeae, where rates of resistant infection are high 
With rates of AMR increasing globally, and the emergence of resistance to last-line 
recommended drugs, enhanced understanding of factors contributing to the development of 
resistance is essential. The research presented in Chapter 2 uses multilevel modeling and focuses 
on identification of behavioral and demographic risk factors for AMR among a sample of STI 
clinic clients in Shanghai, China. To date, there are only a small number of published studies on 
this topic, as reviewed in a paper that I co-authored (93). The studies that do exist are based in a 
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variety of settings, include different antibiotics, and include a mix of different risk factors, 
making it difficult to draw any general conclusions (93). The manuscript presented here 
demonstrates that advanced statistical techniques, such as multilevel multinomial modeling, can 
be used to elucidate associations between behavioral and demographic characteristics and 
resistance to antibiotics—even in a population where rates of AMR are extremely high. 
Additionally, this research illustrates the utility of rigorous statistical techniques for the 
investigation of complex questions related to sociodemographic variables and mechanisms of 
AMR. 
1.7.2 Identify predictors of bringing a partner to testing and treatment, and safe sex behaviors, 
where rates of resistant infection are high 
Safe sex behaviors and partner follow-up are primary components of STI control. The third 
chapter of this dissertation focuses on using generalized estimating equations (GEE) to identify 
predictors of bringing a partner to testing/treatment and use of condoms among a sample of STI 
clinic clients in Shanghai, China. Identification of such associations can be used to tailor 
approaches to partner notification as well as target safe sex education to those groups at highest 
risk, which is particularly important in urban China, where rates of both infection and AMR are 
high. This chapter contributes new information about the potential value of patient referral 
partner notification in China. 
1.7.3 Identify predictors of repeat gonorrhea and coinfection with gonorrhea/chlamydia in a 
setting with high infection rates, and low AMR 
Chapter 4 presents a study undertaken in a Saskatchewan health region, which aimed to identify 
risk factors for repeat gonorrhea, as well as for being coinfected with chlamydia at the time of 
gonorrhea diagnosis. It is one of only two published epidemiologic studies of gonorrhea in 
Saskatchewan. Using statistical methods including multivariable logistic regression, and mixed-
effects multivariable logistic regression, associations between demographic and behavioral 
characteristics and repeat or coinfection were identified. This research demonstrates the utility of 
such analysis to inform disease control efforts. The findings presented in this manuscript can be 
used to inform approaches to counseling and treatment during a clinical visit. 
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1.7.4 Evaluate the potential contribution of social network analysis to enhancing understanding 
of gonorrhea transmission dynamics in a setting with high infection rates and low AMR 
Chapter 5 focuses on leveraging data derived through SNA to strengthen and clarify previously 
identified associations between demographic and behavioral characteristics, and the risk of 
repeat or coinfection (Chapter 4). In addition to providing a visual depiction of the structure of 
the STI network in the Regina Qu’Appelle Health Region for the first time, this research 
illustrates the additional contribution of SNA to traditional statistical epidemiologic methods. 
Further, it highlights the considerable limitations to robust analysis imposed by the current 
method of STI data collection and storage in Saskatchewan, in contrast to protocols in place in 
other provinces. This manuscript is the first study to apply SNA to STI transmission in Canada 
outside of the provinces of Alberta or Manitoba. 
1.7.5 Use dynamic simulation modeling to explore scenarios related to the development of AMR 
in a setting with high infection rates and low AMR 
Chapter 6 presents the results of a study to evaluate the contribution of system dynamics 
modeling to predicting future development of AMR in N. gonorrhoeae in Saskatchewan, where 
infection rates are high, but rates of AMR are low. Based on national trends, it is likely that 
cephalosporin-resistant N. gonorrhoeae will become more and more common in Saskatchewan. 
Therefore, proactively exploring the potential effects on disease prevalence is prudent. Grounded 
in empirical data from Saskatchewan, this manuscript builds from the only two published studies 
that apply system dynamics modeling techniques to questions related to AMR N. gonorrhoeae. 
The results present provocative questions about the potential effects of current treatment and 
follow-up policies in the context of AMR, as well as further indicate that current systems of STI 
data collection and storage substantially hinder the utility of such data for epidemiologic 
analysis.  
 
 
  
 19 
 
References cited 
1.  Sparling PF Biology of Neisseria gonorrhoeae. In: Holmes KK, Sparling PF, Stamm WE, 
Piot P, Wasserheit JN, Corey L, et al., eds. Sexually Transmitted Diseases. 4th ed. New 
York (NY):McGraw-Hill, Inc.;2008 p. 607–26. 
2.  Ligon BL. Albert Ludwig Sigesmund Neisser: Discoverer of the cause of gonorrhea. Semin 
Pediatr Infect Dis. 2005;16(4):336–41. 
3.  Mayor MT, Roett MA, Uduhiri KU. Diagnosis and management of gonococcal infections. 
Am Fam Physician. 2012;86(10):931–8. 
4.     Hook EW and Handsfield HH. Gonococcal infections in the adult. In. Holmes KK, Sparling 
PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et  al., eds. Sexually Transmitted Diseases. 
4th ed. New York (NY):McGraw-Hill, Inc.; 2008  p. 627–46. 
5.  Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea 
in men. New Engl J Med. 1974;290(3):117–23. 
6.  McCormack W, Johnson K, Stumacher R, Donner A, Rychwalski R. Clinical spectrum of 
gonococcal infection in women. Lancet. 1977;309(8023):1182–5. 
7.  Soper DE. Pelvic inflammatory disease. Obstet Gynecol. 2010;116(2, Part 1):419–28. 
8.  Woods CR. Gonococcal infections in neonates and young children. Semin Pediatr Infect 
Dis. 2005;16(4):258–70. 
9.     Klein EJ, Fisher LS, Chow AW, Guze LB. Anorectal gonococcal infection. Ann Intern 
Med. 1977;86(3):340–6. 
10.  Wiesner PJ, Tronca E, Bonin P, Pedersen AHB, Holmes KK. Clinical spectrum of 
pharyngeal gonococcal infection. New Engl J Med. 1973;288(4):181–5. 
11.  Lyss SB, Kamb ML, Peterman TA, Moran JS, Newman DR, Bolan G, et al. Chlamydia 
trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually 
transmitted disease clinics in the United States. Ann Intern Med. 2003;139(3):178–85. 
12.  Kahn RH, Mosure DJ, Blank S, Kent CK, Chow JM, Boudov MR, et al. Chlamydia 
trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering 
selected US juvenile detention centers, 1997-2002. Sex Transm Dis. 2005;32(4):255–9. 
13.  Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the 
genital tract: A systematic review and meta-Analysis. Sex Transm Dis. 2008;35(11):946–
59. 
14.  Wasserheit, Judith. Epidemiological synergy: Interrelationships between human 
immunodeficiency virus and other sexually transmitted diseases. SexTransm Dis. 
1992;19(2):61–77. 
 20 
 
15.  Dillon J-AR. Sustainable antimicrobial surveillance programs essential for controlling 
Neisseria gonorrhoeae superbug. Sex Transm Dis. 2011;38(10):899–901. 
16.   Centers for Disease Control and Prevention (CDC). Screening tests to detect Chlamydia 
trachomatis and Neisseria gonorrhoeae infections--2002. MMWR. 2002;51(1-40). 
17.   Public Health Agency of Canada. Gonococcal infections: Revised July 2013 - Section 5 - 
Management and treatment of specific infections. Ottawa (ON); 2013. 
18.  Singh AE, Gratrix J, Martin I, Friedman DS, Hoang L, Lester R, et al. Gonorrhea treatment 
failures with oral and injectable expanded spectrum cephalosporin monotherapy vs dual 
therapy at 4 Canadian sexually transmitted infection clinics, 2010–2013. Sex Transm Dis. 
2015;42(6):331–6. 
19.  Government of Saskatchewan, Ministry of Health. Guidelines for testing and treatment of 
gonorrhea in Saskatchewan. [Internet]. Regina (SK);2014. [cited 2015 Jan 16]. Available 
from: http://www.health.gov.sk.ca/adx/aspx/adxGetMedia.aspx?DocID=fb8126c0-30ee-
4a51-adfd-af986da1b106&MediaID=8614&Filename=FAQs-Gonorrhea-
GuidelinesforTesting-Treatment.pdf&l=English. 
20.  Chen X-S, Peeling RW, Yin Y-P, Mabey DC. The epidemic of sexually transmitted 
infections in China: Implications for control and future perspectives. BMC Medicine. 
2011;9(1):111. 
21.   Public Health Agency of Canada. The Chief Public Health Officer’s Report on the State of 
Public Health in Canada, 2013: Infectious disease—The never-ending threat.[Internet]. 
Ottawa(ON);2013 [cited 2015 May 7]. Available from: http://www.phac-
aspc.gc.ca/cphorsphc-respcacsp/2013/sti-its-eng.php. 
22.  Center for Strategic and International Studies. China’s capacity to manage infectious 
diseases.[Internet]. Washington (DC);2009 [cited 2015 May 7]. Available from: 
http://csis.org/publication/chinas-capacity-manage-infectious-diseases. 
23.   Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections - 
Updated January 2010. [Internet]. Ottawa (ON);2013 [cited 2013 May 27]. Available from: 
http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php. 
24.   World Health Organization. Sexually transmitted infections (STIs). Fact sheet no. 110. 
[Internet]. Geneva;2015 [cited 2016 Jan 25]. Available from: 
http://www.who.int/mediacentre/factsheets/fs110/en/. 
25.   Centers for Disease Control and Prevention. Gonorrhea statistics. [Internet]. Atlanta 
(GA);2015 [cited 2015 Apr 25]. Available from: 
http://www.cdc.gov/std/gonorrhea/stats.htm. 
26.  Liao M. Molecular epidemiology and molecular mechanisms of antimicrobial resistance in 
Neisseria gonorrhoeae in China: Implications for disease control. Saskatoon (SK): 
University of Saskatchewan;2011. 
 21 
 
27.  Parish WL, Laumann EO, Cohen MS, et al. Population-based study of chlamydial infection 
in China: A hidden epidemic. JAMA. 2003;289(10):1265–73. 
28.   Public Health Agency of Canada. Report on sexually transmitted infections in Canada: 
2012. Ottawa (ON); 2015. 
29.  Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: Origin, evolution, 
and lessons learned for the future. Ann NY Acad Sci. 2011;1230:E19-E28.  
30.   Dillon JA, Pagotto F. Importance of drug resistance in gonococci: from mechanisms to 
monitoring. Curr Opin Infect Dis. 1999;12(1):35–40. 
31.  Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and 
untreatable gonorrhea. Future Microbiol. 2012;7(12):1401–22. 
32.   World Health Organization. Sexually transmitted diseases: Policies and principles for 
prevention and care. [Internet]. Geneva;1999 [cited 2015 Apr 26]. Available from: 
http://www.who.int/hiv/pub/sti/pubstiprevcare/en/. 
33.  Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st 
century: Past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613. 
34.  Dunlop EMC. Gonorrhoea and the sulphonamides. Br J Vener Dis. 1949;25(2):81–3. 
35.  Mahoney JF, Ferguson C, Buchholtz M, Van Slyke CJ. The use of penicillin sodium in the 
treatment of sulfonamide-resistant gonorrhea in men: a preliminary report. Am J Syph 
Gonor Vener Dis. 1943;27:525–8.  
36.  Willcox RR. A survey of problems in the antibiotic treatment of gonorrhoea. With special 
reference to South-East Asia. Br J Vener Dis. 1970;46(3):217–42. 
37.  Centers for Disease Control (CDC). Tetracycline-resistant Neisseria gonorrhoeae--Georgia, 
Pennsylvania, New Hampshire. MMWR. 1985;34(37):563–4, 569–70. 
38.  Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations 
in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 
1994;14(2):371–80. 
39.  Tanaka M, Kumazawa J, Matsumoto T, Kobayashi I. High prevalence of Neisseria 
gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin 
Med. 1994;70(2):90–3. 
40.  Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria 
gonorrhoeae. Emerging Infect Dis. 1997;3(1):33–9. 
41.  Knapp JS, Ohye R, Neal SW, Parekh MC, Higa H, Rice RJ. Emerging in vitro resistance to 
quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob 
Agents Chemother. 1994;38(9):2200–3. 
 22 
 
42.  Centers for Disease Control and Prevention (CDC). Update to CDC’s sexually transmitted 
diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for 
treatment of gonococcal infections. MMWR. 2007;56(14):332–6. 
43.  Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical 
failures using internationally recommended first-line cefixime for gonorrhoea treatment, 
Norway, 2010. Euro Surveill. 2010;15(47). 
44.   Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria 
gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 
2013;309(2):163–70. 
45.  Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with 
resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 
2011;16(43). 
46.  Hvistendahl M. China takes aim at rampant antibiotic resistance. Science. 
2012;336(6083):795. 
47.   World Health Organization. Gonorrhoea Antimicrobial Surveillance Programme (GASP). 
[Internet]. Geneva;2015 [cited 2015 Apr 26]. Available from: 
http://www.wpro.who.int/hiv/topics/gasp/en/index4.html. 
48.  Public Health Agency of Canada. National surveillance of antimicrobial susceptibilities of 
Neisseria gonorrhoeae annual summary 2012. [Internet]. Ottawa (ON);2014 [cited 2015 
April 26]. Available from: http://publications.gc.ca/collections/collection_2014/aspc-
phac/HP57-3-2012-eng.pdf. 
49.   Martin I, Sawatzky P, Mulvey MR. Antimicrobial resistance to Neisseria gonorrhoeae in 
Canada: 2009-2013. CCDR. 2015;41-02. 
50.   Dev S. Molecular mechanisms of antimicrobial resistance and population dynamics of 
Neisseria gonorrhoeae in Saskatchewan (2003-2011). Saskatoon (SK): University of 
Saskatchewan;2013. 
51.  Brunham RC. Core group theory: a central concept in STD epidemiology. Venereology. 
1997;10(1):34.  
52.  Giguère K, Alary M. Targeting core groups for gonorrhoea control: feasibility and impact. 
Sex Transm Infect. 2015;91(4):241-4. 
53.  Yorke JA, Hethcote HW, Nold A. Dynamics and control of the transmission of gonorrhea. 
Sex Transm Dis. 1978;5(2):51–6. 
54.  Hethcote HW, Yorke JA. Gonorrhea transmission dynamics and control. [Internet]. 1984 
[cited 2013 Jun 17]. Available from: http://yorke.umd.edu/papers/. 
 23 
 
55.  Jolly AM, Wylie JL. Gonorrhoea and chlamydia core groups and sexual networks in 
Manitoba. Sex Transm Infect. 2002;78(Supplement 1):i145–51. 
56.  Hawe P, Webster C, Shiell A. A glossary of terms for navigating the field of social network 
analysis. J Epidemiol Community Health. 2004;58(12):971–5. 
57.  Jolly AM, Wylie JL. Sexual networks and sexually transmitted infections; “The strength of 
weak (long distance) ties.” In: Aral SO, Fenton KA, Lipshutz JA, eds. The New Public 
Health and STD/HIV Prevention. New York (NY): Springer;2013. p. 77–109. 
58.  Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: 
Implications for prevention strategies. J Infect Dis. 1996;174(Supplement 2):S201–13. 
59.  Cornell RG. Biostatistics and epidemiology. Commun Stat A--Theor. 1982;11(5):445–8. 
60.  Mortimer JA, Borenstein AR. Tools of the epidemiologist. Alzheimer Dis Assoc Disord. 
2006;20(3 Supplement 2):S35–41. 
61.  Wellman B. Network analysis: Some basic principles. Sociol Theor. 1983;1:155–200. 
62.  Borgatti SP, Mehra A, Brass DJ, Labianca G. Network analysis in the social sciences. 
Science. 2009;323(5916):892–5. 
63.  Borgatti SP, Halgin DS. On network theory. Organ Sci. 2011;1–14. 
64.  Jolly A, Muth S, Wylie J, Potterat J. Sexual networks and sexually transmitted infections: A 
tale of two cities. J of Urban Health. 2001;78(3):433–45. 
65.  Ward H. Prevention strategies for sexually transmitted infections: Importance of sexual 
network structure and epidemic phase. Sex Transm Infect. 2007;83(Supplement 1):i43–9. 
66.  Parker M, Ward H, Day S. Sexual networks and the transmission of HIV in London.  J 
Biosoc Sci. 1998;30(01):63–83. 
67.  Potterat JJ, Muth SQ, Rothenberg RB, Zimmerman-Rogers H, Green DL, Taylor JE, et al. 
Sexual network structure as an indicator of epidemic phase. Sex Transm Infect. 
2002;78(Supplement 1):i152–8. 
68.  Rothenberg R. How a net works: implications of network structure for the persistence and 
control of sexually transmitted diseases and HIV. Sex Transm Dis. 2001;28(2):63–8. 
69.  Bearman PS, Moody J, Stovel K. Chains of affection: The structure of adolescent romantic 
and sexual networks. Am J Sociol. 2004;110(1):44–91. 
70.  Doherty IA, Padian NS, Marlow C, Aral SO. Determinants and consequences of sexual 
networks as they affect the spread of sexually transmitted infections. J Infect Dis. 
2005;191(s1):S42–54. 
 24 
 
71.  Fichtenberg CM, Muth SQ, Brown B, Padian NS, Glass TA, Ellen JM. Sexual network 
structure among a household sample of urban African American adolescents in an endemic 
sexually transmitted infection setting. Sex Transm Dis. 2009;36(1):41–8. 
72.  Day S, Ward H, Ison C, Bell G, Weber J. Sexual networks: the integration of social and 
genetic data. Soc Sci Med. 1998;47(12):1981–92. 
73.  Ghani AC, Ison CA, Ward H, Garnett GP, Bell G, Kinghorn GR, et al. Sexual partner 
networks in the transmission of sexually transmitted diseases. An analysis of gonorrhea 
cases in Sheffield, UK. Sex Transm Dis. 1996;23(6):498–503. 
74.  Ward H, Goan U, Parker M, Kinghorn G, Claydon E, Weber J, et al. Sexual histories, 
partnerships and networks associated with the transmission of gonorrhoea. Int J STD AIDS. 
1998;9(11):666–71. 
75.  Choudhury B, Risley CL, Ghani AC, Bishop CJ, Ward H, Fenton KA, et al. Identification 
of individuals with gonorrhoea within sexual networks: A population-based study. Lancet. 
2006;368(9530):139–46. 
76.  Risley CL, Ward H, Choudhury B, Bishop CJ, Fenton KA, Spratt BG, et al. Geographical 
and demographic clustering of gonorrhoea in London. Sex Transm Infect. 2007;83(6):481–
7. 
77.  Wylie JL, Jolly A. Patterns of chlamydia and gonorrhea infection in sexual networks in 
Manitoba, Canada. Sex Transm Dis. 2001;28(1):14–24. 
78.  De Rubeis E, Wylie JL, Cameron DW, Nair RC, Jolly AM. Combining social network 
analysis and cluster analysis to identify sexual network types. Int J STD AIDS. 
2007;18(11):754–9. 
79.  De P, Singh AE, Wong T, Yacoub W, Jolly AM. Sexual network analysis of a gonorrhoea 
outbreak. Sex Transm Infect. 2004;80(4):280–5. 
80.  Ward H, Ison CA, Day SE, Martin I, Ghani AC, Garnett GP, et al. A prospective social and 
molecular investigation of gonococcal transmission. Lancet. 2000;356(9244):1812–7. 
81.  Garnett GP, Mertz KJ, Finelli L, Levine WC, Louis MES. The transmission dynamics of 
gonorrhoea: Modelling the reported behaviour of infected patients from Newark, New 
Jersey. Phil Trans R Soc Lond B. 1999;354(1384):787–97. 
82.   Scholl HJ. Agent-based and system dynamics modeling. [Internet]. [cited 2015 Aug 18]. 
Available from: 
http://computationalmodelingblogs.stanford.edu/winter2012/files/2012/01/School-ABM-
and-SD-A-call-for-cross-study.pdf 
83.  Sterman J. Business dynamics. 1st ed. New York (NY): McGraw-Hill, Inc.;2000. 
 25 
 
84.  Homer JB, Hirsch GB. System dynamics modeling for public health: Background and 
opportunities. Am J Public Health. 2006;96(3):452–8. 
85.  Macal CM, North MJ. Tutorial on agent-based modelling and simulation. J of Sim. 
2010;4(3):151–62. 
86.  Chan CH, McCabe CJ, Fisman DN. Core groups, antimicrobial resistance and rebound in 
gonorrhoea in North America. Sex Transm Infect. 2012; 88(3): 200-4. 
87.  Trecker MA, Hogan DJ, Waldner CL, Dillon J-AR, Osgood ND. Revised simulation model 
does not predict rebound in gonorrhoea prevalence where core groups are treated in the 
presence of antimicrobial resistance. Sex Transm Infect. 2014; 91(4):300-2. 
88.  Tuli K, Kerndt PR. Preventing sexually transmitted infections among incarcerated men who 
have sex with men: A cost-effectiveness analysis: Sex Transm Dis. 
2009;36(Supplement):S41–8. 
89.  Vickerman P, Watts C, Peeling RW, Mabey D, Alary M. Modelling the cost effectiveness 
of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted 
infections among female sex workers. Sex Transm Infect. 2006;82(5):403–12. 
90.  Gopalappa C, Huang Y-LA, Gift TL, Owusu-Edusei K, Taylor M, Gales V. Cost-
effectiveness of screening men in Maricopa County jails for chlamydia and gonorrhea to 
avert infections in women: Sex Transm Dis. 2013;40(10):776–83. 
91.  Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-
effectiveness of screening men who have sex with men for rectal chlamydial and 
gonococcal infection to prevent HIV infection. Sex Transm Dis. 2013;40(5):366–71. 
92.  Wilson DP, Heymer K-J, Anderson J, O’Connor J, Harcourt C, Donovan B. Sex workers 
can be screened too often: a cost-effectiveness analysis in Victoria, Australia. Sex Transm 
Infect. 2010;86(2):117–25. 
93.  Trecker MA, Dillon JR. Identification of demographic and behavioral risk factors for 
antibiotic resistant gonorrhea infections to combat the emergence of potentially untreatable 
infections. Sex Transm Dis. 2014;41(12):730–1. 
  
 
 26 
 
 
 
 
 
 
 
 
 
CHAPTER 2: BEHAVIORAL AND SOCIOECONOMIC RISK FACTORS 
ASSOCIATED WITH PROBABLE RESISTANCE TO CEFTRIAXONE AND 
RESISTANCE TO PENICILLIN AND TETRACYCLINE IN NEISSERIA 
GONORRHOEAE IN SHANGHAI 
 
(Reproduced, with minor edits for the purpose of inclusion, under license; originally published 
as: Trecker MA, Waldner C, Jolly A, Liao M, Gu W, Dillon JR. Behavioral and socioeconomic 
risk factors associated with probable resistance to ceftriaxone and resistance to penicillin and 
tetracycline in Neisseria gonorrhoeae in Shanghai. PLoS ONE. 2014;9(2): e89458. 
doi:10.1371/journal.pone.0089458. My contribution to this work included conception of the 
analysis, data compilation, data analysis, and writing the manuscript.) 
 
 
This chapter demonstrates the potential of identifying sociodemographic characteristics of 
gonorrhea patients associated with antimicrobial resistant (AMR) infection. It establishes the 
value and power of rigorous statistical modeling as a key component of better understanding 
gonorrhea transmission and control. The analysis presented in this chapter illustrates the utility of 
such an approach, even in a setting where both disease rates, and rates of AMR, are high. The 
results presented in this chapter lay the groundwork for future studies to identify client attributes 
that may be associated with AMR infection; this could have a substantial impact on the control 
of disease in both regions like China, where AMR is prevalent, and those like Saskatchewan, 
where AMR is currently low. 
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2.1 Abstract 
Globally, incidence of Neisseria gonorrhoeae infection is once again the highest of the bacterial 
sexually transmitted infections. The bacterium can produce serious complications in those 
infected, and emerging resistance to third generation cephalosporins could usher in an era of 
potentially untreatable gonorrhea. This research aimed to identify risk factors for antibiotic 
resistant gonorrhea among clients at a Shanghai sexually transmitted infection clinic over two 
time periods, 2004-2005 and 2008-2011. Demographic and risk factor behavior data, and 
biological samples for antimicrobial resistance analysis, were collected. Statistical models were 
built to identify risk factors associated with probable resistance to ceftriaxone and resistance to 
penicillin and tetracycline. High levels of ciprofloxacin resistance (98%) in our sample precluded 
examining its risk factors; all isolates were susceptible to spectinomycin. Overall (P<0.001), 
chromosomal (P<0.001), and plasmid-mediated (P=0.01) penicillin resistance decreased from the 
first to second period of the study. For tetracycline, chromosomal resistance decreased (P=0.01) 
and plasmid-mediated resistance increased (P<0.001) between the first and second periods of 
study. In multi-level multivariable regression models, male gender (P=0.03) and older age 
(P=0.01) were associated with increased minimum inhibitory concentrations to ceftriaxone. Male 
gender (P=0.03) and alcohol use (P=0.02) were associated with increased odds of overall 
tetracycline resistance. Male gender was associated with increased odds of chromosomally-
mediated tetracycline resistance (P=0.04), and alcohol use was associated with increased odds of 
plasmid-mediated tetracycline resistance (P=0.02). Additionally, individuals in middle-salary 
categories were found to have lower odds of plasmid-mediated resistance to tetracycline 
compared with those in the lowest salary category (P≤0.02). This study is one of the first to use 
multilevel analysis to consider the association between risk factors for gonorrhea and 
mechanisms of resistance to individual antibiotics. Such information is urgently needed to 
combat the growing threat of untreatable gonorrhea.  
2.2 Introduction 
Infections caused by N. gonorrhoeae have afflicted human beings for centuries. The organism 
causes localized infections of the throat, rectum, or urogenital tract and has the potential for 
serious complications including pelvic inflammatory disease and ectopic pregnancy in women as 
well as infertility in both sexes (1). Transmission to newborns can lead to serious complications 
including blindness. Infection with N. gonorrhoeae also facilitates HIV transmission (2). 
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Gonorrhea has become, once again, the most commonly transmitted bacterial sexually 
transmitted infection (STI) globally (3); it is estimated that 106.1 million cases occur annually 
around the world (3). Because gonorrhea is often asymptomatic, the true burden of disease is 
likely much higher.  
While gonorrhea has generally been effectively treatable with a single antibiotic dose, drug 
resistance has emerged to each class of therapeutic agent introduced since the 1940s. Recently, 
treatment failures to the last-line recommended drugs — third generation cephalosporins — have 
been reported globally (4–7). The threat of untreatable gonorrhea (8) poses a significant public 
health challenge both through its associated effects on fertility, birth outcomes, and HIV 
transmission rates, as well as the potential for increased transmission and complications of 
infections. Identification of factors associated with antimicrobial resistance (AMR) could help 
combat this growing epidemic by informing policies around antimicrobial use and targeting 
intervention programs to those at heightened risk for AMR infection. Behavioral and 
socioeconomic factors are well known to affect STI transmission (9–12). More research is 
needed to understand the influence of socioeconomic and behavioral factors on the resistance of 
N. gonorrhoeae isolates to specific antibiotics such as ceftriaxone, including their mechanisms of 
resistance. 
Research into antibiotic resistant N. gonorrhoeae infections is particularly relevant in China, 
where years of over-the-counter antibiotic availability, coupled with poor antibiotic management 
and prescribing practices, have resulted in widespread antimicrobial resistance (13). We 
examined the influence of demographic factors as well as previous STIs, use of over the counter 
antibiotics, and risky sexual practices on the probability of infection with N. gonorrhoeae with 
reduced susceptibility or probable resistance to ceftriaxone, or resistance to penicillin or 
tetracycline.  These analyses are valuable in identifying characteristics that could be used to 
better target interventions based on risk factor profiles, potentially reducing the need for complex 
and expensive susceptibility testing in resource limited regions. We combine epidemiologic and 
previously published biologic data in multi-level analyses for the first time to identify behaviors 
and client attributes that are associated with an increased risk of infection with AMR N. 
gonorrhoeae.  
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2.3 Methods 
2.3.1 Sample 
Epidemiologic and demographic information were obtained from two cross-sectional samples of 
symptomatic male patients who tested positive for gonorrhea at the Shanghai Sexually 
Transmitted Infection and Skin Disease Hospital during 2004-2005 and 2008-2011. Partners 
brought in for evaluation and who consented to participate in the study were also included. Study 
design and survey descriptions for the first phase of the study (n=483 primary interviews) have 
been previously published; the second phase (n=299 primary interviews) followed a similar 
structure (14–18). The analysis presented here included a convenience subsample of 384 cases 
with complete antimicrobial resistance data.  
2.3.2 Epidemiologic data 
Staff at the Shanghai Sexually Transmitted Infection and Skin Disease Hospital collected 
information on demographic variables, including gender, birthdate, salary over the last three 
months, residency status in Shanghai, district of residence, and level of education attained, as 
well as STI history, history of antibiotic use, sexual practices, number of partners, and use of 
alcohol and drugs. Membership in a cluster was abstracted to account for pairs or triples present 
in the dataset, which arose when any index patient subsequently brought one or more partners to 
treatment. 
2.3.3 Isolate identification and antimicrobial susceptibility determination 
The collection, isolation, and identification of N. gonorrhoeae isolates has been described 
previously, as have methods for the determination of minimum inhibitory concentrations (MICs)  
to ceftriaxone, penicillin, tetracycline, ciprofloxacin, and spectinomycin (18,19). β-lactamase 
production was determined using nitrocefin and MIC breakpoints were those recommended by 
the Clinical and Laboratory Standards Institute (CLSI) (19).  MIC data were retrieved from data 
reported earlier (15–17). 
2.3.4 Statistical analysis 
Two MIC breakpoints were used to explore risk factors for reduced susceptibility (0.03 µg/mL) 
(20–22) or probable resistance (0.125 µg/mL) (23) to ceftriaxone; separate models were 
constructed for each breakpoint. The World Health Organization classifies isolates of N. 
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gonorrhoeae with ceftriaxone MICs of ≥0.125 as representing “probable resistance” (23). Two 
different outcomes were examined for penicillin and tetracycline: overall resistance versus 
susceptibility, and mechanism of resistance — plasmid-mediated and chromosomally-mediated 
— versus susceptibility. For penicillin, any isolate with an MIC value < 2.0 µg/mL was 
classified as susceptible (19) and all other isolates were classified as resistant. Of these resistant 
isolates, any that were β-lactamase positive were classified as having plasmid-mediated 
resistance while all others were classified as having chromosomally-mediated resistance (19). 
For tetracycline, any isolate with an MIC value < 2.0 µg/mL was classified as susceptible, while 
all others were classified as resistant (19). A breakpoint of 16 µg /mL was used to separate 
chromosomally-mediated resistance (≥2 and <16 µg/mL) from plasmid-mediated resistance (≥ 
16 µg/mL) (19).  
Data were managed in Microsoft Excel and Microsoft Access, while all statistical analyses were 
performed using Stata IC/12.1 (24). Comparisons of demographic characteristics of participants 
in Phase 1 and Phase 2 were made using Chi-square and Mann-Whitney U tests. To identify 
predictors of AMR infection, multi-level regression models were built using the gllamm program 
for generalized linear mixed models (GLMM) in Stata IC/12.1 (24). Six individual models were 
built to investigate the following outcomes: reduced susceptibility to ceftriaxone at 0.03 µg/ml, 
probable resistance to ceftriaxone at 0.125 µg/ml, resistance to penicillin, mechanism of 
penicillin resistance, resistance to tetracycline, and mechanism of tetracycline resistance. 
We used logistic regression to investigate the presence or absence of reduced susceptibility or 
resistance based on MIC data, and multinomial regression models to examine mechanisms of 
resistance (25). The analysis was limited to relevant independent variables with frequencies > 
5% and < 95%, which resulted in a set of 11 variables to be tested (Table 2.1). Phase of study 
was also initially included as a variable in each model. The continuous predictor variables age 
and salary were categorized into quintiles for analysis: 14-26 years (n=86), 27-31 years (n=73), 
32-37 years (n=69), 38-45 years (n=76), and 46-83 years (n=74) and (in Chinese Yuan) 0-1200 
(n=85), 1300-2000 (n=70), 2200-3500 (n=84), 4000-5500 (n=69), and 6000-200000 (n=74). 
Intra-class correlation coefficients (ICC) were calculated to determine the amount of variability 
in the null models for each of the six outcomes accounted for by testing phase of study, 
membership in a dyad in the dataset, and district of residence as random effects (26). The null 
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models with the lowest Akaike Information Criterion (AIC) values were selected for building the 
final models, all of which included district as a random intercept. If < 3% of observations were 
missing for a particular covariate, listwise deletion was used; otherwise, non-responses were 
considered as a unique response category. 
Only potential risk factors unconditionally associated with the outcome (p ≤ 0.3) were 
considered as candidates for inclusion in multivariable models (Table 2.2). Manual backwards 
elimination was used to build the final model for each outcome. Only significant independent 
risk factors (p<0.05) and potential confounders for each outcome, including age, gender, and 
study phase, were retained in the final multivariable models. Confounding was recognized when 
the difference between crude odds ratio for a risk factor-outcome association of interest and the 
same odds ratio adjusted for the potential confounder was > 10%. After establishing main effects 
models for each outcome, all possible two-way interactions were considered; only interactions 
significant at p<0.05 were retained in the final models. 
Intraclass Correlation Coefficients (ICCs) were estimated as σ2district / (σ2district + π2/3) for 
each final model (27). Plots of standardized residuals were examined for each model to check for 
outliers. 
2.3.5 Ethics statement 
Ethical approval for this study was obtained from the Ottawa Hospital Research Ethics Board, 
the Ethics Committee of the Shanghai Municipal Bureau of Public Health, and the University of 
Saskatchewan Biomedical Research Ethics Board. Written consent was obtained from all 
participants. Minors under the age of 18 provided their own consent to participate as they are 
regarded as emancipated when they take responsibility for seeking reproductive health care.  All 
participants were treated according to Canadian and Chinese STI standard recommendations; no 
extra procedures were given, other than the time to complete the questionnaire.   
2.4 Results 
2.4.1 Summary of the study population and AMR findings 
Antimicrobial susceptibility data were available for 189 N. gonorrhoeae isolates from the first 
phase of the study and 195 from the second phase for a total of 384 isolates; 337 isolates were 
from index cases and 47 were from partners brought to treatment. The participants came from 19 
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different districts of Shanghai; the mean number of cases per district was 11.3 with a range of 1 
to 57. Only 16 (4.2%) reported being residents of Shanghai for fewer than 6 months.  
There was no significant difference in mean age, education level, previous STI history, use of 
alcohol or drugs during sex, or reported number of partners in the previous three months between 
participants from the two study phases. Clients ranged in age from 14 to 83, with a mean age of 
35.6 years; 6 clients did not disclose their age. The majority (67.0%) of participants had at least a 
high school education, and 36 percent of cases reported having had at least one previous STI. 
Just over one-third (37.3%) of participants reported using alcohol during sex (1 missing), and 
7.3% reported using drugs during sex (2 missing). Slightly over half (54.7%) of participants 
indicated they had 2 or more sexual partners in the last 3 months, and 39.1% said they had only 
one partner in that time (24 individuals did not respond). (Table 2.1)  
For five variables, there were significant differences between phases. Median salary over the 
previous 3 months reported by Phase 2 participants was higher (3500 Yuan) than that reported by 
Phase 1 participants (2500 Yuan) (p≤0.001). In the sample population overall, most cases were 
male (87.5%); 12.5% of cases were female partners subsequently brought to treatment. However, 
female partners comprised 17.5% of the Phase 1 population and only 7.7% of the Phase 2 
population (p=0.004). A higher proportion (31.8%) of participants in Phase 2 as compared to 
Phase 1 (16.4%) reported having had a previous bacterial STI (p≤0.001), and 84.6% of Phase 2 
participants compared to 64% of Phase 1 participants indicated that they washed their genitals 
before and/or after intercourse (p≤0.001); 11 did not respond. Lastly, 19% of Phase 2 
participants and 9% of Phase 1 participants indicated previous use of over the counter antibiotic 
agents (p≤0.001) (data missing for 74 individuals or 19.3%). (Table 2.1)  
Ceftriaxone MICs in our sample ranged from 0.004 to 0.25 µg/mL (Table 2.3). The majority of 
isolates (75.8%) had reduced susceptibility to ceftriaxone at the 0.03 µg/mL breakpoint, and 
10.9% showed probable resistance at the 0.125 µg/mL breakpoint (Table 2.4). Penicillin MICs 
ranged from 0.125 to 64 µg/mL (Table 2.3). Based on CLSI MIC breakpoints (19), overall, 
13.5% of isolates were classified as susceptible to penicillin and 86.5% were resistant over the 
two time periods tested (Table 2.4). Chromosomally-mediated resistance to penicillin was 
identified in 36.2% of cases overall, and 50.3% had an isolate with plasmid-mediated penicillin 
resistance (Table 2.4). Tetracycline MICs ranged from 0.06 to 64 µg/m (Table 2.3). Tetracycline 
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resistance was present in 54.7% of isolates overall and 45.3% were susceptible based on MIC 
data (Table 2.4). Chromosomally-mediated resistance to tetracycline was exhibited by 23.7% of 
isolates overall and plasmid-mediated resistance was found in 31% (Table 2.4).  
Because all isolates were susceptible to spectinomycin (MIC range: 2-64 µg/mL) and 98.2% 
were resistant to ciprofloxacin (MIC range: 0.016-64 µg/mL) (Table 2.3), associations of socio-
demographic variables and resistance were not explored for these antibiotics. 
2.4.2 Unconditional or crude analysis of predictors for AMR 
Level of education, salary, male gender, having reported using drugs during sex, and number of 
partners reported were unconditionally associated with reduced susceptibility to ceftriaxone at 
the 0.03 µg/mL breakpoint  (Table 2.2); taking over the counter antibiotics, age, male gender, 
and drug use were unconditionally associated with reduced susceptibility at the 0.125 µg/mL 
breakpoint. Phase of study, level of education, having reported a previous bacterial STI, 
practicing genital washing before or after sex, and taking over the counter antibiotics were 
associated with overall penicillin resistance; the same variables, along with age and salary, were 
unconditionally associated with the mechanism of penicillin resistance (Table 2.2). Level of 
education, salary, previous STI, previous bacterial STI, male gender, and reported alcohol use 
during sex were unconditionally associated with overall tetracycline resistance (Table 2.2). Phase 
of study, level of education, salary, previous bacterial STI, male gender, and alcohol use were 
unconditionally associated with the mechanism of tetracycline resistance exhibited (Table 2.2).   
2.4.3 Final models of factors associated with reduced susceptibility and probable resistance to 
ceftriaxone  
In the final multivariable models for reduced susceptibility to ceftriaxone (Table 2.5a), men were 
more likely to be infected with a strain with reduced susceptibility to ceftriaxone with MIC≥0.03 
µg/mL (OR=2.2) than women.   
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Table 2.1 Selected demographic characteristics and risk behaviors of a sample of clients 
from the Shanghai Sexually Transmitted Infection and Skin Disease Hospital (n= 384) 
Mean (SD), Median (IQR), or N (%) 
Variable Phase 1 (n=189) Phase 2 (n=195) Overall 
Mean age (years) 1 34.5 (10.0) 36.7 (12.1) 35.6 (11.2) 
Median salary (Yuan)* 2500 (1200,4500) 3500 (2000,5500) 3000 (1500,5000) 
Gender† 
    Male 156 (82.5) 180 (92.3) 336 (87.5) 
    Female 33 (17.5) 15 (7.7) 48 (12.5) 
Education level 
    None/less than primary 5 (2.6) 2 (1.0) 7 (1.8) 
    Primary/middle 61 (32.2) 59 (30.3) 120 (31.3) 
    High school 63 (33.3) 49 (25.1) 112 (29.2) 
    Above high school 60 (31.7) 85 (43.6) 145 (37.8) 
Previous STI history 69 (36.5) 70 (35.9) 139 (36.2) 
Previous bacterial STI* 31 (16.4) 62 (31.8) 93 (24.2) 
Wash genitals before or after 
sex*2 121 (64.0) 165 (84.6) 286(74.5) 
Take over the counter 
antibiotics ever*3 17 (9.0) 37 (19.0) 54(14.1) 
Use alcohol during sex ever4 76 (40.2) 67 (34.4) 143(37.3) 
Use drugs during sex ever5 10 (5.3) 18 (9.2) 28(7.3) 
Number of partners in 
previous 3 months6 
    One 82 (43.4) 68 (34.9) 150 (39.1) 
    Two 50 (26.5) 66 (33.8) 116 (30.2) 
    Three or more 45 (23.8) 49 (25.1) 94 (24.5) 
*Significant difference between phases at p<0.001 
†Significant difference between phases at p=0.004 
16 missing 211 missing 374 missing 41 missing 52 missing 624 missing 
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Table 2.2 P-values for the unconditional associations between participant demographic characteristics, risk behaviors, and 
resistance to penicillin, tetracycline, and ceftriaxone* from a sample of clients from the Shanghai Sexually Transmitted 
Infection and Skin Disease Hospital 
Ceftriaxone 
MIC>0.03 
Ceftriaxone 
MIC>0.125 
Penicillin 
Resistance 
Penicillin Resistance 
Mechanism 
Tetracycline 
Resistance 
Tetracycline Resistance 
Mechanism 
Variable 
Decreased 
susceptibility 
Decreased 
susceptibility Resistant Chromosomal Plasmid Resistant Chromosomal Plasmid 
Phase of the study (2 : 1) 0.96 0.91 0.00 0.00 0.00 0.37 0.01 0.00 
Education (3 df)  0.10 0.47 0.09 0.22 0.01 0.05 
Less than primary or  
        no education 
Reference category for education 
Primary/middle school  0.51 0.21 0.50 0.23 0.79 0.20 0.29 0.31 
High school  0.84 0.12 0.82 0.64 0.56 0.65 0.57 0.85 
Above high school  0.72 0.18 0.82 0.65 0.55 0.83 0.68 0.97 
Salary (4 df) 0.23 0.94 0.61   0.06 0.12 0.02 
<1300 Yuan Reference category for salary 
1300-2000 Yuan 0.38 0.68 0.84 0.22 0.67 0.86 0.84 0.69 
2200-3500 Yuan 0.06 0.98 0.46 0.52 0.45 0.06 0.51 0.01 
4000-5500 Yuan 0.83 0.58 0.14 0.05 0.33 0.13 0.53 0.07 
6000-200000 Yuan 0.09 0.58 0.51 0.65 0.41 0.95 0.28 0.55 
Previous STI 0.87 0.34 0.42 0.38 0.52 0.12 0.32 0.42 
Previous bacterial STI 0.88 0.75 0.22 0.26 0.27 0.14 0.52 0.09 
Wash genitals before or after sex 0.85 0.40 0.11 0.03 0.37 0.66 0.70 0.73 
Wash genitals (refused) 0.99 1.00 0.33 0.50 0.22 0.64 0.34 0.95 
Take over the counter antibiotics 0.47 0.28 0.67 0.56 0.77 0.64 0.72 0.67 
Take over the counter antibiotics 
(refused) 0.91 0.14 0.01 0.02 0.01 0.82 0.52 0.40 
Age (4 df) 0.76 0.04 0.95   0.18 0.83 0.70 
14-26 years Reference category for age 
27-31 years 0.56 0.77 0.88 0.88 0.78 0.41 0.36 0.62 
32-37 years 0.44 0.77 0.91 0.32 0.48 0.99 0.59 0.60 
38-45 years 0.71 0.29 0.42 0.52 0.43 0.90 0.41 0.69 
46-83 years 0.47 0.02 0.78 0.42 0.92 0.46 0.41 0.67 
Male: Female 0.06 0.27 0.81 0.89 0.83 0.11 0.08 0.37 
Use alcohol during sex 0.58 0.85 0.48 0.62 0.42 0.01 0.03 0.05 
Use drugs during sex 0.22 0.24 0.46 0.57 0.53 0.51 0.68 0.50 
Number of partners (3 df) 0.20 0.43 0.47 0.33 0.83 0.43 
   One partner last 3 months Reference category for number of partners 
    2 partners in last 3 months 0.33 0.42 0.63 0.64 0.72 0.58 0.67 0.21 
    3+ partners in last 3 months 0.77 0.46 0.40 0.64 0.28 0.47 0.47 0.09 
    Refused  0.10 0.40 0.33 0.80 0.11 0.81 0.80 0.88 
*Reference category for all outcomes was susceptibility as determined by MICs. Variables shown in bold (p≤0.3) were retained for consideration in building the final multivariable 
model for each outcome.
  
 
36 
Table 2.3 MICs of 384 N. gonorrhoeae isolates from Shanghai to ceftriaxone, ciprofloxacin, spectinomycin, penicillin, and 
tetracycline 
 
 MIC N (cumulative %) 
Antibiotic 0.004 0.008 0.016 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 
Ceftriaxone 
3 
(0.8) 
24 
(7.0) 
66 
(24.2) 
133 
(58.9) 
116 
(89.1) 
40 
(99.5) 
2 
(100) -- -- -- -- -- -- -- -- 
Ciprofloxacin1 
-- -- 
1 
(0.3) -- 
1 
(0.5) -- -- 
4 
(1.6) 
10 
(4.2) 
40 
(14.6) 
69 
(32.6) 
121 
(64.2) 
103 
(91.1) 
32 
(99.5) 
2 
(100) 
Spectinomycin 
-- -- -- -- -- -- -- -- -- 
2 
(0.5) 17 (4.9) 
44 
(16.7) 
159 
(47.8) 
150 
(96.9) 
12 
(100) 
Penicillin 
-- -- -- -- -- 
1 
(0.3) 7 (2.1) 
12 
(5.2) 
32 
(13.5) 
67 
(31.0) 
48 
(43.5) 
22 
(49.2) 
9 
(51.6) 
18 
(56.3) 
168 
(100) 
Tetracycline 
-- -- -- -- 
4 
(1.0) 
20 
(6.3) 
31 
(14.3) 
35 
(23.4) 
84 
(45.3) 
59 
(60.7) 
23 
(66.7) 
9 
(69.0) 
26 
(75.8) 
40 
(86.2) 
53 
(100) 
1N=383 for ciprofloxacin 
Distribution of MICs for 384 N. gonorrhoeae isolates to ceftriaxone, ciprofloxacin, spectinomycin, penicillin, and tetracycline. Number of isolates and 
cumulative percent for each MIC breakpoint are shown for each antibiotic. 
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Table 2.4 Prevalence of resistance or reduced susceptibility to ceftriaxone, penicillin, and 
tetracycline in a sample of clients from the Shanghai Sexually Transmitted Infection and 
Skin Disease Hospital 
 
Phase 1 
N (%) 
Phase 2 
 N (%) 
Overall$ 
 N (%) 
Total isolates available 189 195 384 
Ceftriaxone 
Reduced susceptibility at 
MIC≥0.03 µg/ml  143 (75.7) 148 (75.9) 291 (75.8) 
Probable resistance at 
MIC≥0.125 µg/ml† 21 (11.1) 21 (10.8) 42 (10.9) 
Penicillin    
Susceptible(MIC<2 µg/ml)* 14 (7.4) 38 (19.5) 52 (13.5) 
Resistance overall  175 (92.5) 157 (80.5) 332 (86.5) 
Chromosomal resistance 78 (41.3) 61 (31.3) 139 (36.2) 
Plasmid-mediated 
resistance 97 (51.3) 96 (49.2)  193 (50.3) 
Tetracycline 
Susceptible(MIC<2 µg/ml)* 90 (47.6) 84 (43.1) 174 (45.3) 
Resistance overall 99 (52.4) 111 (56.9) 210 (54.7) 
Chromosomal resistance 62 (32.8) 29 (14.9) 91 (23.7) 
Plasmid-mediated 
resistance 37 (19.6) 82 (42.1) 119 (31.0) 
†WHO 2012 *CLSI 2009; $Phases 1 and 2 combined 
The range of MIC values for each antibiotic were as follows: ceftriaxone 0.004-0.25, penicillin 0.125-64, 
tetracycline 0.06-64. 
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Table 2.5 (a,b) Results of multivariable analysis for reduced susceptibility and probable 
resistance to ceftriaxone among a sample of clients from the Shanghai Sexually 
Transmitted Infection and Skin Disease Hospital (odds ratios (OR) and 95% confidence 
intervals (95%CI)) 
 
a. 
Ceftriaxone reduced susceptibility 
(MIC≥0.03  µg/mL) (n=378) 
Variable OR p-value 95% CI 
Male : Female 2.18 0.03 1.10-4.32 
Age (4 df) 0.58 
  14-26 years Reference category 
  27-31 years 0.72 0.40 0.34-1.53 
  32-37 years 0.63 0.23 0.29-1.34 
  38-45 years 0.98 0.95 0.45-2.14 
  46-83 years 0.62 0.21 0.29-1.32 
ICC Residential district: 3.6 x 10-15 
    
b. 
Ceftriaxone probable resistance 
(MIC≥0.125  µg/mL) (n=378) 
Variable OR p-value 95% CI 
Male : Female 1.64 0.45 0.46-5.84 
Age (4 df) 0.02 
  14-26 years Reference category 
  27-31 years 1.18 0.80 0.35-3.83 
  32-37 years 0.79 0.73 0.21-2.99 
  38-45 years 1.51 0.47 0.50-4.57 
  46-83 years 3.83 0.01 1.33-11.01 
Take OTC antibiotics (2 df) 0.03 
Do not take OTC antibiotics Reference category 
Take OTC antibiotics  1.64 0.24 0.71-3.82 
Take OTC antibiotics (refused to answer) 0.25 0.03 0.07-0.88 
ICC Residential district: 2.0 x 10-23 
Final models for reduced susceptibility to ceftriaxone with significant predictors shown in bold 
ICC = Intraclass Correlation Coefficient  
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Participants who were over 46 years of age were almost 4 times more likely than those from age 
14-26 to have probable resistance to ceftriaxone (MIC≥0.125 µg/mL) (Table 2.5b). In addition, 
those who did not answer the question regarding over the counter antibiotic use were less likely 
(OR=0.25) to have probable resistance compared to those who did not report over the counter 
antibiotic use (Table 2.5b). Based on the extremely small ICC values, the effect of district on 
reduced susceptibility or probable resistance to ceftriaxone was not important after accounting 
for other risk factors. 
2.4.4 Final models of factors associated with penicillin resistance 
In the final multivariable models for penicillin resistance (Table 2.6), phase of the study was the 
only significant predictor. Clients who were in Phase 2 of the study were less likely than those in 
Phase 1 to be infected with any penicillin resistant strain (OR=0.31), a strain with chromosomal 
resistance to penicillin (OR=0.26), or a strain with plasmid-mediated resistance to penicillin 
(OR=0.36).  District of residence accounted for 7-8% of the unexplained variance in the 
penicillin outcomes in the final model (Table 2.6). 
2.4.5 Final models of factors associated with tetracycline resistance 
While phase was not a significant predictor of tetracycline resistance versus susceptibility (Table 
2.7a), the occurrence of plasmid- and chromosomally-mediated resistance to tetracycline did 
vary based on the phase of the study in the final multivariable model (Table 2.7b). During Phase 
2 of the study, individuals were less likely to carry chromosomally-mediated resistant strains 
than in Phase 1 (OR=0.48), but were more likely to carry plasmid-mediated resistant strains 
(OR=2.9). The odds of carrying plasmid-mediated resistant strains compared to chromosomally-
mediated resistant strains were 5.5 times greater [95%CI 2.96-10.28, p<0.01 (data not shown)] in 
Phase 2 than in Phase 1.  
Male gender was a significant predictor of overall tetracycline resistance and chromosomal 
resistance to tetracycline, but not plasmid-mediated tetracycline resistance. The odds of finding 
overall tetracycline resistance were 2.1 times higher in men than in women (Table 2.7a); for 
chromosomal resistance compared to no resistance, the odds were 2.7 times higher in men than 
women (Table 2.7b).  
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Table 2.6 Results of multivariable analysis of factors associated with resistance to penicillin based on MIC classification and 
type of penicillin resistance based on molecular data from a sample of clients from the Shanghai Sexually Transmitted 
Infection and Skin Disease Hospital (odds ratios (OR) and 95% confidence intervals (95%CI)) 
Penicillin Resistance (n=378) Penicillin Resistance Type (n=378) Chromosomal : Susceptible Plasmid : Susceptible 
Variable OR 
p-
value 95% CI OR p-value 95% CI OR p-value 95% CI 
Phase 2 of the study : 
Phase 1  0.31 <0.001 0.16-0.62 0.26 <0.001 0.12-0.54 0.36 0.01 0.18-0.73 
ICC Residential district: 0.07 ICC Residential district for chromosomally-mediated:  0.07 
   
ICC Residential district for plasmid-mediated:  0.08 
 
Phase of study was the only significant predictor of penicillin outcomes. ICC = Intraclass Correlation Coefficient
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Table 2.7 (a,b). Results of multivariable analysis for overall and type of tetracycline 
resistance from a sample of clients from the Shanghai Sexually Transmitted Infection and 
Skin Disease Hospital (resistance (odds ratios (OR) and 95% confidence intervals (95%CI)) 
a. Tetracycline Resistance (n=376) 
Variable OR p-value 95% CI 
Male : Female 2.12 0.03 1.06-4.25 
Education (4 df) <0.001 
  Less than primary or   
  no education  Reference category 
  Primary/middle school  2.23 0.35 0.44-10.39 
  High school  1.02 0.98 0.21-5.01 
  Above high school  0.76 0.74 0.15-3.78 
 Alcohol use 1.69 0.02 1.08-2.64 
ICC Residential district: 4.4 x 10-10 
 
b. Tetracycline Resistance Type (n=376) 
Chromosomal : 
Susceptible Plasmid : Susceptible 
Variable OR 
p-
value 95%CI OR 
p-
value 95% CI 
Phase 2 of the study : 
Phase 1 0.48 0.01 0.27-0.84 2.85 <0.001 1.65-4.91 
Male: Female 2.73 0.04 1.06-7.05 1.18 0.70 0.52-2.66 
Alcohol use 1.68 0.07 0.96-2.93 1.93 0.02 1.13-3.32 
Salary (4 df) 0.01 
  <1300 Yuan Reference category 
  1300-2000 Yuan 0.78 0.57 0.33-1.84 0.99 0.98 0.46-2.16 
  2200-3500 Yuan 0.78 0.54 0.35-1.72 0.28 <0.001 0.12-0.64 
  4000-5500 Yuan 0.77 0.55 0.33-1.81 0.34 0.02 0.14-0.81 
  6000-200000 Yuan 0.57 0.24 0.22-1.47 0.96 0.91 0.42-2.16 
ICC Residential district for chromosomally-mediated: 7.6 x10-22   
ICC Residential district for plasmid-mediated: 8.9 x 10-22    
Final models for tetracycline outcomes with significant predictors shown in bold. 
ICC = Intraclass Correlation Coefficient   
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Both overall tetracycline resistance (OR=1.7) and plasmid-mediated resistance to tetracycline 
(OR=1.9) were more common among those who reported alcohol use during sex (Table 2.7a,b).  
Study participants who earned between 2200 and 5500 Yuan—the middle salary categories—
were less likely than those in the lowest salary category (<1300 Yuan) (OR=0.3) to carry strains 
that exhibit plasmid-mediated resistance to tetracycline. The effect of district on tetracycline 
resistance was not important based on the extremely small ICC values (Table 2.7 a,b). 
2.5 Discussion 
This study complements and extends previous work aimed at understanding predictors for AMR 
in clients with gonorrhea (28–35). The focus of this research, however, was to identify risk 
factors for resistance or reduced susceptibility to three specific antibiotics, and to identify 
associations between behavioral factors and mechanisms of resistance to penicillin and 
tetracycline. Further, we employed a rigorous statistical approach in our analysis, allowing us to 
better understand the association of individual variables to AMR infection in the presence of a 
complex set of potential risk factors.  
Thirty-six percent of participants in this study reported a previous STI, and 55% reported 2 or 
more sexual partners in the last three months. While these fractions are higher than several 
previous studies that have considered prior STI infection status and number of sexual partners 
among Chinese participants (12,36,37), studies in other countries have noted similar percentages 
(38). Neither of these factors was associated with an increased risk of infection with reduced 
susceptibility to ceftriaxone or resistance to penicillin or tetracycline in this study. While 
previous STIs would plausibly predispose individuals to treatment with antibiotics and potential 
development of resistance, once an individual has cleared the resistant infection and stopped 
taking the medication, his or her risk should return to baseline. The absence of the anticipated 
association between multiple sexual partners and AMR in the present study could be related to 
misclassification due to social acceptability bias and the relatively high non-response rate for this 
question. 
Probable resistance to ceftriaxone was most common among those in the older age groups.  Cole 
et al. (30) found a similar effect for cefixime in Europe, and Ota et al. (35) found a similar effect 
for quinolone resistant gonococcal infection in Ontario, Canada. It is possible that this age group 
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is associating with sex partners of a different demographic than those of the younger age groups, 
or has other risk factors that were not captured in our study. The possibility of increased risk of 
resistance at older ages could have important implications for prevention policy in Shanghai, 
especially in this era of rapidly emerging cephalosporin resistance. Further work to better 
understand this association is needed; however, this finding does highlight the importance of 
including a broad range of ages of participants in studies addressing risk factors for AMR. 
The findings related to over the counter antibiotic use and probable resistance to ceftriaxone are 
intriguing. While one might expect to find a relationship between use of antibiotics and AMR 
infections, we were unable to elucidate such a relationship. The only significant predictor was 
having failed to provide a response to the question, which cannot be clearly interpreted; this 
finding is likely related to the relatively high nonresponse rate for this question. 
Our results show differences in the prevalence of resistance and type of resistance to penicillin, 
and to type of tetracycline resistance between the two phases of the study. Because the location 
of the study clinic moved (within Shanghai) between the two phases of data collection, it is 
possible that this change over time is the result of unmeasured differences in the populations 
sampled during the two phases. We were able to control for the influence of the variables listed 
in Table 2.1 through our multivariable analysis, indicating that the remaining significance of 
study phase is likely related to unmeasured factors. Clarification of the causes and monitoring of 
such apparent temporal changes in resistance mechanisms using serial cross sectional and cohort 
studies could better inform policies around treatment protocols in Shanghai and help to separate 
the effects of temporal changes from those related to potential unmeasured demographic shifts.  
In contrast to our findings for penicillin and tetracycline, there was no apparent difference in the 
susceptibility to ceftriaxone between the two time periods. Nevertheless, the levels of reduced 
susceptibility (75.8% at 0.03 µg/mL) were high, and indicate that continued surveillance is 
critical. Additionally, the 10.9% overall prevalence of isolates with ceftriaxone MICs≥0.125 
µg/mL, which is classified as probable resistance by the World Health Organization (23), calls 
for an alert to be raised at the regional level. 
While there has been much research into the association of men who have sex with men (MSM) 
and antibiotic resistance (28,29,34,39), we found an independent association of male gender 
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(compared to female) with resistance to tetracycline and reduced susceptibility to ceftriaxone 
among a sample of men who reported female partners. This could indicate that heterosexual 
males in Shanghai are at higher risk for tetracycline AMR in general, as well as chromosomally-
mediated tetracycline resistance specifically, and ceftriaxone reduced susceptibility compared to 
females. This finding is consistent with that of Ota et al. (35), who found an unconditional 
association of quinolone resistant N. gonorrhoeae infection in males as compared to females 
among a population from Ontario, Canada. Further research exploring male gender as a risk 
factor for AMR is needed to understand what might influence the apparent association in this 
population. Our results could also indicate that some of the men in this study population were, in 
fact, MSM.  This is especially important in China because stigma and discrimination against 
MSM might prevent men from truthfully answering questions about sexual partnerships or serve 
as barriers to seeking health services (40), potentially complicating the association between male 
gender and AMR. Additionally, the proportion of MSM who also have sex with females has 
been shown to be high (41), highlighting the need to better understand this population and 
potential risk for AMR N. gonorrhoeae infections in the population as a whole.    
The association between alcohol use and tetracycline resistance, both overall and plasmid-
mediated, could suggest that those with riskier behaviors were more prone in this population to 
acquiring plasmid-mediated tetracycline-resistant gonococcal infection. Previous studies have 
shown that alcohol use is positively correlated with risky sexual behaviors such as having 
multiple sex partners, risky partners, never using condoms, and infection with STIs (42–45). 
While the relationship between alcohol use and risky sexual practices and STIs is relatively well-
established, the association of alcohol use with plasmid-mediated tetracycline resistance is new. 
This finding must be considered in the absence of observed associations with other more 
proximate risk behaviors such as use of over the counter antibiotics and high numbers of 
partners.  It is possible that alcohol use served as a marker for other risk behaviors in our study. 
For example, those using alcohol could be members of a network of individuals who have a 
higher risk of STIs, are using antibiotics for treatment, and, consequently, are more likely to 
carry resistant strains. The relationship we found between alcohol and plasmid-mediated 
tetracycline resistance, specifically, could reflect that the predominant strains being passed 
through this network at the time of the study had plasmid-mediated tetracycline resistance, given 
there is no biologically plausible explanation for an association between alcohol use and 
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mechanisms of resistance. At the least, our findings suggest the need to further explore the 
relationship of such risk behaviors and exposure to AMR in general as well as to specific types 
of AMR strains to clarify this relationship. Such information would be especially useful in 
settings where individuals do not provide complete or truthful answers to questions about more 
immediate risk factors.  
The finding that plasmid-mediated tetracycline resistance was less common in middle salary 
categories compared to those in the lowest salary category could be related to socio-demographic 
factors. However, this relationship was not found for the other outcomes under investigation. 
There is a possibility that individuals with mid-level incomes are associating with partners with 
different exposure histories than those with lower incomes. Associations of income category to 
infections with STIs /HIV have been found in other studies (11,12); however, further, targeted 
research would be needed to explore the association identified in our study.  
This study had several limitations. Foremost, the relatively small sample size of participants with 
characterized N. gonorrhoeae isolates, drawn from a population where antimicrobial resistance is 
extremely prevalent (14), limited the potential to explore outcomes within this dataset to the 
three antibiotics that exhibited some variability in resistance patterns. The participants were all 
drawn from the same medical clinic, and had very similar questionnaire responses. As well, the 
study population consisted of all male index cases, and their recruited female partners, which 
precludes direct comparison of the characteristics of male and female index cases. Missing data 
also limited the initial choice of variables to be considered for model building from the more 
substantial list of the original questions. It is also likely that there was under-reporting of some 
risk behaviors (46). Further, because the location of the clinic moved between the two phases of 
data collection, it is difficult to differentiate temporal shifts in AMR prevalence from other 
unmeasured differences between the two populations. However, we tested all of the variables 
listed in Table 2.1 as part of the model building process, and included in the final model any 
variables shown to have a confounding effect. This analytical approach controls for the influence 
of measured differences in the two populations related to these factors on the other variables in 
the final models. Also, it is likely that the relatively high rate of nonresponse related to antibiotic 
use contributed to the failure to see an association between over the counter antibiotic use and 
reduced susceptibility or resistance.  
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In conclusion, although there was a high prevalence of resistance in the isolates tested (18), we 
were able to identify several risk factors for infection with gonococcal infection with reduced 
susceptibility or probable resistance to ceftriaxone, resistant to penicillin and tetracycline, and 
also for the mechanism of resistance to penicillin and tetracycline. The use of multi-level 
regression analysis to account for potential clustering in the data and explore multinomial 
outcomes strengthens the study and represents a thorough and sophisticated approach to analysis 
of such data. We have laid the groundwork for further studies to better understand behavioral 
factors associated with infection with resistant N. gonorrhoeae —knowledge that is central to 
tailoring effective policies for combatting the emergence of untreatable gonorrhea focused on 
targeting behavioral risk factors.    
 47 
 
References cited 
1. Hook EW and Handsfield HH. Gonococcal infections in the adult. In. Holmes KK, Sparling 
PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et  al., eds. Sexually Transmitted 
Diseases. 4th ed. McGraw-Hill, Inc.; 2008 p. 627–46. 
2.   Wasserheit, J. Epidemiological synergy: interrelationships between human 
immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 
1992;19(2): 61–77. 
3.   World Health Organization. Global incidence and prevalence of selected curable sexually 
transmitted infections [Internet]. Geneva;2008. [cited 2013 Nov14] Available from: 
http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf.  
4.   Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al.  Neisseria 
gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 
2013;309(2):163–70. 
5.   Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal 
infection. N Engl J Med. 2012;366(6): 485–7. 
6.  Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical 
failures using internationally recommended first-line cefixime for gonorrhoea treatment, 
Norway, 2010. Microscopy. 2010; 120:A121N 
7.   Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with 
resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 
2011;16(43):19998. 
8.  Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and 
untreatable gonorrhea. Future Microbiol. 2012;7(12):1401–22. 
9.   Pflieger JC, Cook EC, Niccolai LM, Connell CM. Racial/ethnic differences in patterns of 
sexual risk behavior and rates of sexually transmitted infections among female young 
adults. Am J Public Health. 2013;103(5):903–9. 
10.   Salerno J, Darling-Fisher C, Hawkins NM, Fraker E. Identifying relationships between 
high-risk sexual behaviors and screening positive for chlamydia and gonorrhea in school-
wide screening events. J Sch Health. 2013; 83(2):99–104. 
11.   Kretzschmar M, Zhang W, Mikolajczyk RT, Wang L, Sun X, Kraemer A, et al. Regional 
differences in HIV prevalence among drug users in China: potential for future spread of 
HIV? BMC Infect Dis. 2008; 8(1):108. 
12.   Wong SPY, Yin Y-P, Gao X, Wei W-H, Shi M-Q, Huang P-Y, et al. Risk of syphilis in STI 
clinic patients: a crosssectional study of 11 500 cases in Guangxi, China. Sex Transm 
Infect. 2007; 83(5):351–6. 
13.   Hvistendahl M. China takes aim at rampant antibiotic resistance. Science. 
2012;336(6083):795. 
 48 
 
14.   Liao M. Molecular epidemiology and molecular mechanisms of antimicrobial resistance in 
Neisseria gonorrhoeae in China: implications for disease control. Saskatoon (SK): 
University of Saskatchewan;2011.  
15.   Liao M, Bell K, Gu W-M, Yang Y, Eng NF, Fu W, et al. Clusters of circulating Neisseria 
gonorrhoeae strains and association with antimicrobial resistance in Shanghai. J 
Antimicrob Chemother. 2008; 61(3):478–87. 
16.   Liao M, Helgeson S, Gu W-M, Yang Y, Jolly AM, Dillon JR. Comparison of Neisseria 
gonorrhoeae multiantigen sequence typing and porB sequence analysis for identification of 
clusters of N. gonorrhoeae isolates. J Clin Microbiol. 2009; 47(2):489–91. 
17.   Liao M, Gu W-M, Yang Y, Dillon JR. Analysis of mutations in multiple loci of Neisseria 
gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to 
ceftriaxone. J Antimicrob Chemother. 2011;66(5):1016–23. 
18.   Yang Y, Liao M, Gu W-M, Bell K, Wu L, Eng NF, et al. Antimicrobial susceptibility and 
molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from 
Shanghai. J Antimicrob Chemother. 2006;58(4):868–72. 
19.   Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial 
susceptibility tests for bacteria that grow aerobically. Wayne (PA): 2009 
20.   Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, et al. Molecular 
analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from 
Ontario, Canada. Antimicrob Agents Chemother. 2011;55(2): 703–12. 
21.  Thakur SD, Starnino S, Horsman GB, Levett PN, Dillon JR. Unique combined 
penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and 
cefixime MIC increases in a “susceptible” Neisseria gonorrhoeae population. J Antimicrob 
Chemother. 2014;69(6):1510-6 
22.   Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, et al. Reduced 
susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, 
P551S and P551L in the gonococcal penicillin binding protein 2. J Antimicrob Chemother. 
2010;65(8):1615–8. 
23.   World Health Organization .Global action plan to control the spread and impact of 
antimicrobial resistance in Neisseria gonorrhoeae [Internet]. Geneva; 2012. [cited 2014 Jan 
20] Available from: 
http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/. 
24.   StataCorp. Stata Statistical Software: Release 12.  College Station (TX): StataCorp, 2011. 
25.   Rabe-Hesketh S, Skrondal A, Pickles A. GLLAMM manual. UC Berkeley Division of 
Biostatistics Working Paper Series [Internet]. Berkeley (CA);2004. [cited 2013 Nov 14] 
Available from: http://biostats.bepress.com/ucbbiostat/paper160.  
26.   Snijders TAB, Bosker RJ. Multilevel analysis: an introduction to basic and advanced 
multilevel modeling. Los Angeles: Sage; 2012. 
 49 
 
27.   Dohoo IR, Martin SW, Stryhn H. Methods in epidemiologic research. Charlottetown: VER 
Inc; 2012. 
28.   Bauer HM, Mark KE, Samuel M, Wang SA, Weismuller P, Moore D, et al.  Prevalence of 
and associated risk factors for fluoroquinolone-resistant Neisseria gonorrhoeae in 
California, 2000–2003. Clin Infect Dis. 2005;41(6): 795–803. 
29.   de Vries HJC, van der Helm JJ, Schim van der Loeff MF, van Dam AP. Multidrug-resistant 
Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in 
men who have sex with men, Amsterdam, the Netherlands. Euro Surveill. 2009; 14(37):3. 
30.   Cole MJ, Spiteri G, Town K, Unemo M, Hoffmann S,van de Laar M, et al. O03.1 Risk 
factors for antimicrobial resistant Neisseria gonorrhoeae in Europe. Sex Transm Infect. 
2013; 89(S1): A30. 
31.   Goldstein E, Kirkcaldy RD, Reshef D, Berman S, Weinstock H, Sabeti P, et al. Factors 
related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs 
in Neisseria gonorrhoeae, United States. Emerg Infect Dis. 2012;18(8): 1290–7. 
32.   Hook EW, Brady WE, Reicbart CA, Upchurch DM, Sherman LA, Wasserheit JN. 
Determinants of emergence of antibiotic-resistant Neisseria gonorrhoeae. J Infect Dis. 
1989;159(5): 900-7. 
33.   Klausner JD, Aplasca M-R, Mesola VP, Bolan G, Whittington WL, Holmes KK. Correlates 
of gonococcal infection and of antimicrobial-resistant Neisseria gonorrhoeae among 
female sex workers, Republic of the Philippines, 1996–1997. J Infect Dis. 
1999;179(30:729–33. 
34.   Koedijk FDH, van Veen MG, de Neeling AJ, Linde GB, van der Sande MA. Increasing 
trend in gonococcal resistance to ciprofloxacin in The Netherlands, 2006–8. Sex Transm 
Infect. 2010;86(1):41–5. 
35.   Ota KV, Jamieson F, Fisman DN, Jones KE, Tamari IE, Ng L-K, et al. Prevalence of and 
risk factors for quinolone-resistant Neisseria gonorrhoeae infection in Ontario. CMAJ. 
2009;180(3):287–90. 
36.   Hong Y, Fang X, Zhou Y, Zhao R, Li X. Factors associated with sexually transmitted 
infection underreporting among female sex workers in China. J Womens Health. 
2011;20(1):129–36. 
37.   Zhou H, Chen X-S, Hong F-C, Pan P, Yang F, Cai Y-M, et al.  Risk factors for syphilis 
infection among pregnant women: results of a case-control study in Shenzhen, China. Sex 
Transm Infect. 2007;83(6):476–80. 
38.   Hughes G, Catchpole M, Rogers PA, Brady AR, Kinghorn G, Mercey D, et al. Comparison 
of risk factors for four sexually transmitted infections: results from a study of attenders at 
three genitourinary medicine clinics in England. Sex Transm Infect. 2000;76(4):262-7. 
39.   Centers for Disease Control and Prevention (CDC). Increases in fluoroquinolone-resistant 
Neisseria gonorrhoeae among men who have sex with men--United States, 2003, and 
 50 
 
revised recommendations for gonorrhea treatment, 2004. Morb Mortal Wkly Rep. 
2004;53(16):335–8. 
40.   Feng Y, Wu Z, Detels R. Evolution of MSM community and experienced stigma among 
MSM in Chengdu, China. J Acquir Immune Defic Syndr. 2010;53(S1): S98–103. 
41.   Tang H, Zhang W, Lv F. Behavioral features of men who have sex with men (MSM) in 
Harbin, China. World Med Health Policy. 2010;2(1):317–30. 
42.   Bjekić M, Vlajinac H. Effect of alcohol consumption on recurrence of venereal diseases. 
Med Pregl. 2000;53(11-12):600–2. 
43.   Cook RL, Clark DB. Is there an association between alcohol consumption and sexually 
transmitted diseases? A systematic review. Sex Transm Dis. 2005;32(3):156–64. 
44.   Seth P, Wingood GM, DiClemente RJ, Robinson LS. Alcohol use as a marker for risky 
sexual behaviors and biologically confirmed sexually transmitted infections among young 
adult African-American women. Womens Health Issues. 2011;21(2):130–5. 
45.   Thompson JC, Kao T-C, Thomas RJ. The relationship between alcohol use and risk-taking 
sexual behaviors in a large behavioral study. Prev Med. 2005;41(1):247–52. 
46.   Fenton KA, Johnson AM, McManus S, Erens B. Measuring sexual behaviour: 
methodological challenges in survey research. Sex Transm Infect. 2001;77(2):84–92. 
  
 51 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: FEMALE PARTNER NOTIFICATION IS A PROMISING PREVENTION 
STRATEGY FOR CONTROLLING STIS IN SHANGHAI: DEMOGRAPHIC AND 
BEHAVIORAL DATA FROM A SHANGHAI CLINIC 
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promising prevention strategy for controlling sexually transmitted infections in Shanghai: 
Demographic and behavioral data from a Shanghai clinic. Sex Transm Dis. 2014;41(12):702-5. 
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and writing the manuscript.) 
 
 
In both China and Saskatchewan, rates of gonorrhea remain high. Partner notification, along with 
safe sex behaviours, and appropriate, effective treatment, is a key component of disease control. 
This manuscript demonstrates that partner notification has potential as a strategy for STI control 
in China, where it is currently not widely-implemented. Additionally, robust statistical analysis is 
shown to be useful for the identification of characteristics of male gonorrhea patients that were 
associated with the presentation of an associated female partner, and the use of condoms with the 
partner. Identification of client attributes that can be used by the clinicians to tailor their 
approach to contact tracing or counseling may provide an additional, useful approach to disease 
control in settings where incidence is high.   
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3.1 Abstract 
We identified predictors of partner presentation and condom use among male gonorrhea patients 
in Shanghai, China. Stable relationships, intercourse in the preceding week, and longer duration 
of symptoms were associated with partner presentation. Men were more likely to use condoms 
with their spouse and if they were 35 or under.  
3.2 Introduction 
While intensive efforts by the Chinese government to eliminate sexually transmitted infections 
(STIs) initially resulted in low prevalence during the middle of the 20th century, there has been a 
resurgence in incidence since the 1980s (1). Encouraging partner notification is an important 
case-finding strategy for controlling STI transmission (2). The objectives of this study were to 
identify factors associated with partner presentation after STI diagnosis and factors associated 
with condom use among male STI clinic clients with laboratory confirmed gonorrhea in 
Shanghai, China, where rates of gonorrhea are particularly high (3).  
3.3 Methods 
We used a convenience sample of symptomatic male patients who tested culture positive for 
Neisseria gonorrhoeae at the Shanghai Sexually Transmitted Infection and Skin Disease 
Hospital (SSTISDH) during two periods—2004 to 2005 and 2008 to 2011—who also agreed to 
provide epidemiologic and demographic information. The SSTISDH is the only facility in 
Shanghai specializing in STIs, and the only one accredited by the standards of Western 
Medicine. The SSTISDH diagnoses roughly 700-800 gonorrhea cases per year, representing 14-
16% of the city’s annual gonorrhea case load. Participating patients were referred to trained 
interviewers by attending physicians. A consent form and an anonymous questionnaire were 
administered to each patient to gather demographic information, STI history, and information 
related to sexual practices. Patients were also asked to identify (by name, alias, or initial) up to 
10 partners they had sex with in the last three months, and to describe the relationship using a 
standard questionnaire. Roughly 30% of culture positive cases consented to an interview; the 
most common reason for declining was lack of time because of the need to get back to work.  
The interviewers asked patients to inform their partners of potential STI exposure and to 
encourage them to present at the clinic. They were provided with cards with the clinic address 
and contact information for the study, as well as an ID number linking the card to the index case, 
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to give to their sex partners to invite them to participate. Each partner was tested and completed a 
questionnaire similar to that of the index case, with the exception of partner-specific questions. 
Data were analyzed using Stata IC/12.1 (4) and SPSS 21.0 (5). Differences between the index 
males and their presenting partners were examined using Chi-square and Mann-Whitney U tests. 
The brought-to-treatment index (BTI) (6) was calculated by dividing the number of new cases 
brought to treatment by the number of index cases interviewed and advised to notify their 
partner. To account for presentation of more than one partner, generalized estimating equations 
(GEE) with a logit link function were used to examine risk factors associated with bringing a 
partner to treatment and for not using condoms. The final multivariable models were built using 
manual backwards elimination considering only potential risk factors unconditionally associated 
with the outcome where p ≤ 0.2. Only significant independent risk factors (p<0.05) and potential 
confounders for each outcome were retained in the final multivariable models. 
3.4 Results 
The 567 index male clients in our study ranged in age from 14 to 83 years, with a mean age of 
35.8 years. Just under half of index cases (40.2%) reported having a previous STI. The median 
duration of symptoms reported was 3 days. Of those with symptoms, 22.4% reported having had 
sex while symptomatic. Only 18.2% of index cases reported “ever” using condoms with their 
partner, and just 7.6% reported using a condom at last sex with their partner. (Table 3.1a) 
Of the 567 index male cases included in the study population, 136 men (Table 3.1b) 
subsequently referred 158 female partners for testing and treatment (Table 3.1c). There were 
significant differences in the mean age, median income over the last 3 months, residency status 
in Shanghai, education level, job type, previous STI status, duration of symptoms, current 
symptomatic status, sexual contact while symptomatic, and alcohol use reported between the 
men and their partners (Table 3.1b,c).  
The 567 index males described 765 heterosexual relationships (Table 3.2). Of these, 158 female 
partners subsequently presented for testing and treatment, 107 of whom (68%) were culture 
positive for gonorrhea. A BTI of 0.19 was calculated based on the number of positive female 
partners identified from the interviews completed with index male clients. Per index case  
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Table 3.1 Demographic and behavioral characteristics of 567 index males, 136 males with 
presenting partners, and 158 female partners from a sample of clients from the Shanghai 
Sexually Transmitted Infection and Skin Disease Hospital 
Characteristics [n (%), mean 
(SD), or median (IQR)] 
a) All index males 
n=567 
b) Males with 
presenting 
partners n=136 
c) Presenting 
female partners 
n=158 
Mean age* 35.8 (11.0) n=563 34.1 (10.3) n-134 29.6 (9.5) n=156 
Median income in last 3 months* 3000 (2000,5000) n=565 3000 (1650,5500) 2000 (600, 3000) 
Official resident of Shanghai* 389 (69.0) n=566 95 (69.9) 75 (47.5) 
Highest level of education* 
     Primary or below 124 (21.9) n=564 9 (6.6)  30 (19.0) 
     Middle/Highschool 235 (41.5) 69 (50.7) 97 (61.4) 
     Above Highschool 208 (36.7) 58 (42.7) 31 (19.6) 
Type of work† 
     Laborers 88 (15.6) n=563 29 (21.3) n=135 15 (9.7) 
     Service Industry 63 (11.2) 19 (14.0) 13 (8.4) 
     Professional 337 (59.9) 71 (52.2) 75 (48.4) 
     Other 8 (1.4) 2 (1.5) 7 (4.5) 
     No job/retired 67 (11.9) 14 (10.3) 35 (22.6) 
     CSW -- -- 10 (6.5) 
Median age at first sex 21 (19,24) n=539 20 (18,22) n=135 21 (19,23) n=153 
Previous STI ever* 
     Yes 228 (40.2) 64 (47.4) n=135 11 (7.0) 
     No 336 (59.3) 71 (52.6) 147 (93.0) 
     Unsure 3 (0.5) 0 (0) 0 (0) 
Median duration of symptoms 
(days)* 3 (2,5) n=561 3 (2,5) n=135 12 (7,24.5) n=84 
Currently symptomatic* 562 (99.1)  136 (100) 81 (51.3) 
Sex while symptomatic  (% of 
those symptomatic)* 127 (22.4) 45 (33.1) 44 (54.3) 
Alcohol before or during sex last 
12 months* 233 (41.1)  53 (39.0) 31 (19.6) 
Psychogenic drugs before or 
during sex last 12 months 55 (9.7) 12 (8.8) 7 (4.4) 
"Ever" condom use with this 
partner 87 (18.2) n=477 25 (19.7) n=127 -- 
Condom use at last sex with this 
partner 39 (7.6) n=516 14 (10.3) -- 
Given something in exchange for 
sex 255 (49.5) n=515 44 (32.4) -- 
Received something in exchange 
for sex 45 (8.7) n=515 16 (11.8) -- 
Characteristics of all index males, subset index males with presenting partners, and female partners who presented 
for testing. Significant difference among characteristics between population of males who brought partners and their 
female partners indicated by: * p<0.001, † p=0.002 
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interviewed, 0.19 new cases were identified and treated; in other words, 5.3 index cases needed 
to be interviewed to find one new case in this study population. 
Odds of partner presentation were higher if the partner was classified as a temporary unpaid 
partner (OR 1.92), a “lover” (OR 4.12), or a spouse (OR 2.67), as compared to temporary paid 
relationships (Table 3.3). There was no difference in the odds of presentation between temporary 
unpaid partners and spouses (OR 0.72, 95%CI 0.39 to 1.32, p=0.29) or between presenting a 
“lover” compared to a spouse (OR 1.55, 95%CI 0.94 to 2.55, p=0.09). Partner presentation was 
also more likely if the index case reported having had sex with the partner in the last week (OR 
2.42) or having experienced symptoms for longer than 3 days (OR 1.89) (Table 3.3). 
Increasing age was associated with decreasing odds of reporting “ever” use of condoms with the 
partner. Compared to clients more than 45 years old, those from age 14-25 (OR 9.51), 26-29 (OR 
6.16), and 30-35 (OR 5.71) years were more likely to report “ever” using condoms (Table 3.4). 
Condom use was more likely (OR 3.45) when the partner was identified as a spouse compared to 
a temporary paid sex partner (Table 3.4). Clients were also more likely (OR 2.13, 95%CI 1.27-
3.56, p=0.004) to use a condom with a spouse than with a lover. “Ever” condom use (OR 1.06) 
increased with increasing age in years at sexual debut (p=0.05) (Table 3.4), and confounded the 
relationship of age and “ever” condom use. 
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Table 3.2 Partners described and brought to testing and treatment by 567 index males with 
gonorrhea diagnosed at the Shanghai Sexually Transmitted Infection and Skin Disease 
Hospital 
 Number of Partners who Presented  
 0 1 2 3 Total Total Described 
N
um
be
r 
of
 
Pa
rt
ne
rs
 D
es
cr
ib
ed
 0 48 3 0 0 51 0 
1 250 69 2 1 322 322 
2 103 40 4 0 147 294 
3 23 12 2 3 40 120 
4 3 2 0 1 6 24 
5 0 1 0 0 1 5 
Total 427 127 8 5 567 765 
 Total 
Presented 0 127 16 15 158 
 
 
A total of 567 index males described 765 heterosexual relationships. 158 female partners were subsequently brought 
for testing. Note that for some cases, female partners presented at the clinic even though the associated index male 
did not provide descriptive information about any partners. 
 
Table 3.3 Final multivariable model of predictors of partner presentation among a sample 
of clients from the Shanghai Sexually Transmitted Infection and Skin Disease Hospital.  
Variable OR p-value 95% CI 
Relationship type (4 df )  <0.001 
     Temporary paid reference category 
     Temporary unpaid 1.92 0.04 1.02-3.60 
     Lover 4.12 <0.001 2.31-7.37 
     Spouse 2.67 <0.01 1.41-5.02 
     Refused/unsure 0.56 0.29 0.20-1.60 
Sex this week 2.42 <0.001 1.60-3.68 
Symptoms for more than 3 
days 1.89 <0.01 1.26-2.85 
Variables in bold are significant at p<0.05. 
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Table 3.4 Final multivariable model of predictors of “ever” condom use among a sample of 
clients from the Shanghai Sexually Transmitted Infection and Skin Disease Hospital.  
Variable OR p-value 95% CI 
Age (4 df)  <0.001 
Age 14-25 9.51 <0.001 3.90-23.21 
Age 26-29 6.16 <0.001 2.55-14.87 
Age 30-35 5.71 <0.001 2.49-13.06 
Age 36-44 1.3 0.57 0.52-3.25 
Age 45+ reference category 
Relationship type (4 
df ) <0.001 
     Temporary paid reference category 
     Temporary unpaid 0.67 0.36 0.28-1.58 
     Lover 1.62 0.09 0.93-2.82 
     Spouse 3.45 <0.001 1.98-6.02 
     Refused/unsure 1.2 0.68 0.52-2.78 
Age at sexual debut 1.06 0.05 1.00-1.13 
Variables in bold are significant at p<0.05. 
3.5 Discussion 
Our BTI estimate is comparable to other gonorrhea studies in the region (7), and slightly lower 
than Brewer’s reported median of 0.25 (range: 0.09-0.58) from a review of 21 reports from 
developed nations between 1975 and 2004 (2). However, it is high given the unaccustomed 
invasion of privacy, lack of partner notification guidelines, and limited time and training levels 
of staff (7). In addition, the 68% of evaluated partners who were culture positive for gonococcal 
infection in our study is higher than the median 37.9% diagnosed with an STI from a recent 
systematic review of partner notification uptake in China (7), indicating patient referral partner 
notification could play an important role in reducing STIs in urban China, if it were more widely 
utilized. In addition to increased efforts focused on populations less likely to refer their partners, 
provider referral (whereby healthcare providers notify the partners) or conditional referral 
(whereby cases are given the chance to notify their partners, but follow-up is carried out by 
healthcare providers) could further increase partner presentation success rates in urban Chinese 
settings. 
Our finding that identifying the partner as a “lover” was associated with greatest odds of partner 
presentation when compared to a temporary paid partnership, and that men were no more likely 
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to refer a spouse than a temporary partner for testing, were surprising. In a 2002 study of male 
STI patients in China (8), only 23% of men who lived with their spouse indicated that they were 
willing to inform them of their STI status. For a man to inform his spouse that he has an STI 
could suggest infidelity, which is generally considered to be unacceptable in Chinese society, 
though not uncommon (9). Focusing counselling efforts—found to improve success of partner 
notification (10)—on those in relationships where the partner is least likely to be notified could 
potentially increase effectiveness. Our finding that men who had not had sexual contact in the 
previous week, and those who had symptoms for fewer than three days, were less likely to bring 
a partner for testing are concerning. Because men can have asymptomatic infections, or delayed 
onset of symptoms (11), even men who had not engaged in sexual contact in the last week could 
have infected their partners unknowingly. Those who had only recently become symptomatic 
could similarly have infected their partners before symptom onset, making notification of 
partners even more important. 
Our finding that condom use was more likely with a spousal partner was unexpected, since 
others have found that likelihood of condom use decreases with increasing permanence of 
relationship (12–14). Our study shows the opposite effect, and we are aware of only one other 
study in China that shows a similar finding (15). Low condom use with casual/paid partners 
versus spouses in our study, coupled with overall low use of “ever” condom use among this 
population, highlights the potential for transmission of STIs and HIV among paid, casual, and 
spousal partners. Our finding that younger age groups are much more likely to use condoms than 
older age groups is supported by previous studies in China (16), and is concerning because older 
individuals in China represent a growing proportion of the country’s total STI burden (16).  
Because participants were from the same medical clinic, the generalizability of the findings is 
limited. Specific questions about MSM status were not included in the survey, due to an 
anticipated low response rate to such questions based on stigma (17), so we were unable to 
explore the potential influence of men who have both male and female sex partners. Also, we did 
not elicit further contacts from partners who presented, limiting the extent of the network-at-risk. 
Additionally, it is possible that bias may have been introduced into the study based on potential 
differences between responders and non-responders; unfortunately, demographic information 
about non-responders was not collected. Lastly, it is possible that partners of infected cases may 
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have been informed and either presented elsewhere, or not self-identified upon presentation, 
which could result in an underestimate of our BTI. 
In spite of the study limitations and current low levels of implementation (18), our results 
indicate that patient referral partner notification could be an important case-finding strategy in 
Shanghai. This is also one of few studies reporting higher likelihood of condom use with spouses 
than with temporary paid partners. These findings are especially important in Shanghai, and 
potentially other urban Chinese settings, in the context of growing resistance to cephalosporins 
by N. gonorrhoeae (19).  In addition to adopting a provider or contract referral approach, control 
of STIs in this population can potentially be improved by focusing increased partner notification 
efforts on men who are in temporary relationships, have recently developed symptoms, and who 
have not had sexual contact in the preceding week. Older STI clients and those in temporary or 
paid sexual relationships would benefit most from education on condom use. 
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CHAPTER 4: DEMOGRAPHIC AND BEHAVIOURAL CHARACTERISTICS 
PREDICT BACTERIAL STI REINFECTION AND COINFECTION AMONG A CROSS 
SECTIONAL SAMPLE OF LABORATORY-CONFIRMED GONORRHEA CASES IN A 
LOCAL HEALTH REGION FROM SASKATCHEWAN, CANADA 
(Reproduced, with minor edits for the purpose of inclusion, with permission; originally published 
as: Trecker MA, Dillon JR, Lloyd K, Hennink M, Waldner CL. Demographic and behavioural 
characteristics predict bacterial STI reinfection and coinfection among a cross-sectional sample 
of laboratory-confirmed gonorrhea cases in a local health region from Saskatchewan, Canada. 
Can J Public Health. 2015;106(2), e17-e21. My contribution to this work included conception of 
the study, obtaining ethics certification, onsite collection of all included data, data analysis, and 
writing the manuscript.) 
 
In Saskatchewan, rates of gonorrhea are high, while antimicrobial resistance is relatively rare. 
Current strategies for disease control have failed to result in lower disease rates, indicating new 
approaches may be warranted. Similar to the findings from China, this chapter provides further 
evidence that certain client attributes, which can be elicited during a clinic visit, can help 
clinicians tailor an appropriate approach to treatment and counseling. In urban Saskatchewan, 
using such attributes to guide the use of presumptive dual antibiotic therapy and/or expedited 
partner therapy could have important implications for the control of gonorrhea. Using client 
characteristics to better tailor an approach could provide improved disease control in contrasting 
regions, such as China and Saskatchewan.  
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4.1 Abstract 
Objectives: We aimed to identify demographic and behavioural determinants associated with risk 
of repeat STI infection and coinfection with gonorrhea and chlamydia in the Regina Qu’Appelle 
Health Region, Saskatchewan. 
Methods: We extracted data from a cross-sectional sample of laboratory-confirmed gonorrhea 
cases between 2003 and 2012 from the notifiable disease files of the Regina Qu’Appelle Health 
Region.  Risk factors for repeater status were examined using logistic regression and for 
coinfection with gonorrhea and chlamydia using mixed-effects logistic regression to account for 
multiple diagnoses for individual clients. 
Results: Data from 1143 cases (representing 1027 unique individuals), and 1524 reported 
contacts (representing 1383 unique individuals) were extracted from the 10-year period. Factors 
associated with repeat infection entries in the database included younger age at first visit 
(p=0.01), coinfection (p=0.01), and sex trade involvement (p<0.01). Factors associated with 
coinfection at the time of diagnosis included younger age at diagnosis (p<0.001) and reported 
alcohol or drug abuse (p=0.04). 
Conclusion: In one of the first epidemiologic studies on gonorrhea in Saskatchewan, we have 
identified age, engagement in the sex trade, and drug and alcohol abuse as potential markers to 
identify clients with a high risk of reinfection and coinfection in the Regina Qu’Appelle Health 
Region. This information can help health care professionals in Saskatchewan’s urban centres 
personalize their approach to counseling and treatment to optimize patient outcomes and disease 
control efforts, including potentially using expedited partner therapy, and/or dual therapy where 
indicated. 
4.2 Introduction 
In spite of the apparent progress to curb gonorrhea during much of the 1990s, reported cases 
have been slowly increasing in Canada since 1999.  According to 2011 data, Saskatchewan’s 
gonorrhea rate of 71.7 per 100,000 is second only to Manitoba among the provinces—more than 
twice that of Ontario and Quebec, as well as the Canadian national average of 33.1 per 100,000 
(1). In addition to possible complications such as pelvic inflammatory disease, infertility, 
disseminated infection, and the potential for vertical transmission (2), gonococcal infection also 
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results in an estimated 3-5-fold increase in HIV transmission rates (3). Saskatchewan’s 
extremely high and increasing rates of gonorrhea, coupled with its burgeoning HIV epidemic (4), 
illustrates the critical need for better understanding and control of gonorrhea transmission in the 
province, especially in light of the emerging threat of untreatable gonorrhea (5). A first step 
toward identifying why gonorrhea rates are increasing in Saskatchewan is to characterize the 
current STI population in the province. However, to date there has been only one published 
epidemiologic study of STIs in Saskatchewan (6).  
The objectives of this research were to describe demographic and behavioural risk factors from 
gonorrhea cases in the Regina Qu’Appelle Health Region (RQHR), and to identify predictors of 
repeat infection and coinfection with gonorrhea and chlamydia.  
RQHR is located in south-central Saskatchewan and serves 260,000 residents, including those of 
Saskatchewan’s capital city, Regina. It is the second largest health region in Saskatchewan, and 
has recorded an average of roughly 100 cases of gonorrhea and 1000 cases of chlamydia each 
year since 2008. 
4.3 Methods 
4.3.1 Sample 
Gonorrhea is a notifiable disease in all Canadian provinces; in Saskatchewan, all cases confirmed 
by the provincial Saskatchewan Disease Control Laboratory (SDCL) are reported to public 
health authorities. In accordance with national guidelines, contact tracing is initiated in the event 
of a positive laboratory diagnosis, and includes individuals who were contacts within 60 days 
prior to the test date. Contact tracing is generally carried out by public health staff in the event 
that index cases do not notify their contacts. 
We accessed the notifiable STI files from RQHR to extract the records for all laboratory-
confirmed gonorrhea cases—including those concurrently infected with chlamydia—from 
January 1, 2003 to December 31, 2012. Every positive gonorrhea case recorded in RQHR over 
this time period was included in the dataset. The files contain demographic information including 
name, health services number (HSN), age, date of birth, and address; event-related information 
including diagnosing facility, laboratory tests reported, and type and date of treatment; and, risk 
factor information including sexual history, drug and alcohol use, and number of partners. 
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Information on sexual contacts and their follow-up was also recorded. Information on all 
contacts who presented and had a laboratory-confirmed infection also became part of the case 
file.  
4.3.2 Data management and analysis 
Microsoft Access (7) was used to create a digital database that preserved the linkage between 
cases and their named contacts. Because files were in hardcopy format for the first eight years of 
the dataset, all data abstraction was done on-site at health region offices. This study was 
approved by the research ethics boards of both the University of Saskatchewan and RQHR (No. 
12-323 and 12-98, respectively). Prior to removal from health region offices, personal identifiers, 
including last name and address, were removed. Additionally, an algorithm was applied to 
scramble clients’ HSNs to anonymize them while preserving the ability to recognize repeat 
occurrences of disease in individuals during the 10-year study period. Urban versus rural place of 
residence was abstracted using the first three digits of cases’ reported postal codes; a “0” as the 
middle digit indicates a rural area, while any other number indicates an urban area (8). 
After the data were de-identified, descriptive analyses were carried out using Microsoft Excel (9) 
and Stata IC/12.1 (10). The continuous variable age was categorized prior to analysis. For the 
purpose of this analysis, we defined “repeater” as someone who appeared two or more times in 
the 10-year database. For repeat infections occurring at intervals of 2 months or less, we verified 
that appropriate, observed therapy (dual azithromycin and cefixime) was administered for the 
prior infection, to rule out persistent infection as opposed to repeat infection. Based on 
Saskatchewan’s extremely low levels of antibiotic resistance (11), treatment failure is unlikely in 
these cases. Differences in characteristics between males and females were investigated using 
chi-square tests. Observations for two cases with outlying ages (4 months and 78 years of age) 
were dropped prior to multivariable analysis. 
A multivariable logistic regression model was built to identify factors associated with having 
repeat entries in the database, using one entry per person, based on characteristics at first entry 
and controlling for amount of follow-up time.  
To identify variables associated with being coinfected with gonorrhea and chlamydia at the time 
of visit, a mixed-effects multivariable logistic regression model was built using a random 
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intercept to account for clustering by participant identification (anonymized HSN) due to repeat 
entries.  
Both models were built using manual backwards elimination and only potential risk factors 
unconditionally associated with the outcome (p0.2) were considered as candidates in building 
the final multivariable models for each outcome. For multiple-category predictors, inclusion in 
the model was based on the results of a type 3 Wald test. Only significant independent risk 
factors (p<0.05) and important confounders were retained in the final multivariable model for 
each outcome. Confounding was recognized when the difference between crude odds ratio for a 
risk factor-outcome association of interest and the same odds ratio adjusted for the potential 
confounder was > 10%. After establishing main effects models for each outcome, all possible 
two-way interactions were considered; only interactions significant at p<0.05 were retained in 
the final models. 
The intraclass correlation coefficient (ICC) was estimated as σ2patientID / (σ2patientID + π2/3) 
for the final coinfection model (12). Plots of standardized residuals were examined for each 
model to check for outliers. 
4.4 Results 
4.4.1 Study population 
There were 1143 occurrences of laboratory-confirmed gonococcal infection in the health region 
from 2003-2012, representing 1027 unique individuals. From these 1143 case visits, 1524 
contacts were elicited, representing 1383 unique individuals. Just over half of cases (55.2%) 
were female. Male cases were older than female cases (p<0.001) and were less likely to be 
coinfected than females (p<0.01) (Table 4.1). The mean age difference between partners was 4 
years (SD 4.9 years, data not shown).  Most cases came from urban areas. Roughly 8% of female 
cases were pregnant at the time of diagnosis. The most frequently reported risk factors for both 
sexes were unprotected sex and having had two or more partners in the last 6 months. Least 
frequently reported risk factors were sex trade involvement (for either the case or their contact) 
and same sex partnerships. Males were more likely than females to report same sex partners 
(p<0.001) and less likely to have had a previous STI (p<0.01). The majority of cases were treated 
at locations other than an STI clinic (e.g., family physician’s office).  (Table 4.1) 
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Table 4.1 Demographic and behavioural characteristics 1143 cases of gonorrhea reported 
to the Regina Qu’Appelle Health Region’s notifiable STI files from 2003-2012 
Characteristic Male Female P 
512 (44.8%) 631 (55.2%)  
Age (years)  <0.001 
     ≤19 119 (23.2%) 295 (46.8%)  
     20-24 157 (30.7%) 193 (30.63%)  
    ≥25 236 (46.1%) 142 (22.5%)  
Urban 449 (89.1%) 537 (86.8%) 0.22 
Infection type <0.01 
     Gonorrhea 308 (60.2%) 325 (51.5%)  
     Gonorrhea/chlamydia coinfection 204 (39.8%) 306 (48.5%)  
Provided information on contacts 456 (89.1%) 565 (89.5%) 0.80 
Pregnant -- 52 (8.2%)  
Risk factors    
     Reported 2 or more contacts 176 (34.4%) 192 (30.4%) 0.16 
     Same sex partner 45 (8.8%) 5 (0.8%) <0.001 
     Unprotected Sex 318 (62.1%) 387 (61.3%) 0.79 
     Sex trade 15 (2.9%) 28 (4.4%) 0.18 
     Alcohol and/or drug abuse 69 (13.5%) 75 (11.9%) 0.42 
     Previous STI  44 (8.6%) 87 (13.8%) <0.01 
Location of initial visit   0.16 
     STI clinic 189 (37.0%) 208 (33.0%)  
     Other 323 (63.1%) 423 (67.3%)  
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4.4.2 Repeated gonococcal infection 
Of the 1027 unique individuals represented in the dataset, 934 appeared once only, while 93 
(9%) had repeat entries (either single infections or coinfections with gonorrhea and chlamydia). 
These 93 repeaters represented 209 infections, or 18% of the total infections reported during the 
study period (data not shown). Table 4.2 presents a comparison of repeaters and non-repeaters in 
the database. Based on unconditional or univariable analysis, repeaters were younger (p=0.001), 
and were more likely to be coinfected (p=0.001), to have reported 2 or more partners in the last 6 
months (p=0.03), to have reported sex trade involvement (either case or contact) (p=0.001), and 
to have reported alcohol or drug abuse (p=0.02). In the final multivariable model (Table 4.3) 
being under age 20 (OR 2.3), being coinfected with gonorrhea and chlamydia (OR 1.8), and 
reporting sex trade involvement (OR 3.6) were associated with identified repeat infection during 
the 10-year study period.   
4.4.3 Coinfection with gonorrhea and chlamydia 
Of the 1143 cases of gonorrhea reported between 2003 and 2012, just under half (45%) were 
coinfected with chlamydia. Table 4.4 presents a comparison of singly infected and coinfected 
cases in the database. Based on unconditional or univariable analysis, coinfected individuals 
were younger (p<0.001), and more likely to be female (p<0.01), to have reported 2 or more 
partners in the last 6 months (p=0.04), and to have reported alcohol or drug abuse (p<0.01). 
Those who reported a same sex partnership were less likely to be coinfected (p=0.01). 
In the final multivariable model (Table 4.5), being under age 25 (OR 2-3.5) and reporting alcohol 
or drug abuse (OR 1.5) were significantly associated with being coinfected with chlamydia at the 
time of diagnosis. Reporting a same sex partner was associated with a lower odds (OR 0.5) of 
being coinfected. 
4.5 Discussion 
Among our study population, roughly 36% of cases overall (and 46% of female cases) were 19 
or under, and 67% were under 25 years of age, at the time of diagnosis, which is reflective of 
Canadian national data that indicates that the largest proportion of gonorrhea cases is among 
people under 30 (1).  In our dataset, the overall ratio of male cases to female cases was 0.8:1. 
While Canada’s overall male-to-female rate ratio for gonorrhea was 1.3:1.0, our male-to-female 
case ratio is closer to the rate ratio of 0.7:1.0 reported for the province of Saskatchewan as a  
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Table 4.2 Unconditional analysis of characteristics at time of first reported diagnosis of 
individuals with single and repeat infections (n=1027 individuals) from the Regina 
Qu’Appelle Health Region’s notifiable STI files from 2003-2012 
 Non-Repeaters 
(n=934, 91%) 
Repeaters 
(n=93, 9%) 
  
 n (%) n (%) OR (CI) P 
Age (years)  <0.01 
     ≤19 324 (34.7) 48 (51.6) 2.71 (1.54-4.75) 0.001 
     20-24 280 (30.1) 27 (29.0) 1.76 (0.95-3.27) 0.07 
    ≥25 329 (35.3) 18 (19.4) reference category 
Gender 
     Male 439 (47.0) 34 (36.8) reference category 
     Female 495 (53.0) 59 (63.4) 1.54 (0.99-2.40) 0.06 
Infection 
    Gonorrhea 528 (56.5) 36 (38.7) reference category 
    Ct/Gc Coinfection 406 (43.5) 57 (61.3) 2.05 (1.33-3.19) 0.001 
Received Correct Treatment 
     No 143 (15.31) 10 (10.75) reference category 
     Yes 791 (84.69) 83 (89.25) 1.50 (0.76-3.0) 0.24 
Number of Sex Partners in 
Last 6 months     
     1 639 (68.4) 53 (57.0) reference category 
     ≥ 2 295 (31.6) 40 (43.0) 1.63 (1.06-2.52) 0.03 
*Previous STI 
     No 919 (98.4) 93 (100) reference category 
     Yes 15 (1.6) -- 0.47 (0-2.21) 0.27 
Sex Trade Involvement 
     No 907 (97.1) 84 (90.3) reference category 
     Yes 27 (2.9) 9 (9.7) 3.60 (1.64-7.91) 0.001 
Alcohol or Drug Abuse 
     No 826 (88.4) 74 (79.6) reference category 
     Yes 108 (11.6) 19 (20.4) 1.96 (1.14-3.38) 0.02 
Same Sex Relationship 
Reported     
     No 891 (95.4) 90 (96.8) reference category 
     Yes 43 (4.6) 3 (3.2) 0.69 (0.21-2.27) 0.54 
Place of Residence 
     Rural 125 (13.6) 6 (6.6) reference category 
     Urban 792 (86.4) 85 (93.4) 2.24 (0.96-5.23) 0.06 
Initial Visit Location 
     Clinic 325 (34.8) 30 (32.26) reference category 
     Other  609 (65.2) 63 (65.4) 0.89 (0.57-1.40) 0.62 
*Previous STI statistics calculated using exact logistic regression. 
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Table 4.3 Final multivariable model for predictors of repeat infection (n=1005) among 
cases of gonorrhea reported to the Regina Qu’Appelle Health Region’s notifiable STI files 
from 2003-2012 
Variable OR P 95% CI 
Age (2 df) 0.01 
     12-19 2.30 0.01 1.28-4.13 
    20-24 1.45 0.26 0.76-2.74 
    25+  Reference category 
Coinfection 1.81 0.01 1.14-2.87 
Urban 2.31 0.06 0.98-5.46 
Sex trade 
involvement 3.62 <0.01 1.61-8.15 
 
whole in 2010 (13). The higher rates of infection among women than among men in 
Saskatchewan is the opposite of those reported by many other jurisdictions, including the United 
States, Australia, and the United Kingdom (14–16), and implies that female-focused prevention 
efforts should be considered, especially those aimed at young women, i.e., under 20 years of age. 
The finding that 9% of individuals in the database were subsequently reinfected during the 10-
year study period is similar to the findings from a 2007 study in Alberta, Canada (17), as well as 
from a 2009 systematic review of reinfection rates among industrialized nations (18). The 
association between being under 20 at initial diagnosis and increased risk of reinfection (OR 2.3) 
also supports previous reports (17–21). Our finding that coinfection at time of initial diagnosis 
was associated with increased odds (OR 1.8) of repeat infection could indicate that being 
coinfected is a marker for riskier sexual behaviours, making individuals more susceptible to 
repeat infection based on sexual network. While the relatively high risk of reinfection in the 
context of sex trade involvement is not surprising, and has been reported before (20), it does 
underscore the need to rapidly and appropriately treat individuals reporting such risk factors. 
Targeted efforts among those at greatest risk, such as follow-up screening and enhanced contact 
tracing efforts, could reduce the risk and subsequent transmission of reinfection among these risk 
groups. Current Canadian recommendations include rescreening 6 months after treatment (22); 
however, for those clients reporting sex trade involvement, or other circumstances where 
partners are impossible to reach (many are single encounters and unknown by the case),  
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Table 4.4 Unconditional analysis of characteristics of gonorrhea- and 
gonorrhea/chlamydia-coinfected cases (n= 1143) reported to the Regina Qu’Appelle Health 
Region’s notifiable STI files from 2003-2012 
  Gonorrhea 
(n=633, 55%) 
Coinfection 
(n=510, 45%) 
  
 n (%) n (%) OR (CI) P 
Age (years)  <0.001 
     ≤19 169 (26.7) 245 (48.1) 3.67 (2.73-4.94) <0.001 
     20-24 193 (30.5) 157 (30.8) 2.06 (1.52-2.80) <0.001 
     ≥25 271 (42.8) 107 (21.0) reference category 
Gender 
     Male 308 (48.7) 204 (40.0) reference category 
     Female 325 (51.3) 306 (60.0) 1.44 (1.12-1.85) <0.01 
Number of Sex Partners in 
Last 6 months     
     1 446 (70.5) 329 (64.5) reference category 
     ≥2 187 (29.5) 181 (45.5) 1.33 (1.02-1.73) 0.04 
Previous STI 
     No 556 (87.8) 456 (89.4) reference category 
     Yes 77 (12.16) 54 (41.2) 0.78 (0.50-1.22) 0.28 
Sex Trade Involvement 
     No 611 (96.5) 489 (95.9) reference category 
     Yes 22 (3.5) 21 (4.1) 1.20 (0.63-2.29) 0.6 
Alcohol or Drug Abuse 
     No 570 (90.1) 429 (84.1) reference category 
     Yes 63 (10.0) 81 (15.9) 1.72 (1.19-2.47) <0.01 
Same Sex Relationship 
Reported     
     No 596 (94.2) 497 (97.5) reference category 
     Yes 37 (5.9) 13 (2.6) 0.41 (0.21-0.81) 0.01 
Place of Residence 
     Rural 71 (11.5) 66 (13.20) reference category 
     Urban 552 (88.6) 434 (86.8) 0.84 (0.57-1.22) 0.36 
 72 
 
Table 4.5 Final multivariable model for predictors of coinfection with gonorrhea and 
chlamydia (n=1140) among cases of gonorrhea reported to the Regina Qu’Appelle Health 
Region’s notifiable STI files from 2003-2012 
Variable OR P 95% CI 
Age (2 df) <0.001 
    12-19 3.52 <0.001 2.61-4.75 
    20-24 2.02 <0.001 1.48-2.75 
    25+  Reference category 
Alcohol and/or drug abuse 1.48 0.04 1.02-2.13 
Same sex partner 0.52 0.05 0.27-1.00 
ICC for patient ID: 4.5081E-12 
 
expedited partner therapy (EPT)—whereby a case is given medication to provide directly to 
his/her partner(s)—could provide an effective approach to reducing the risk of reinfection from 
an untreated partner (23). The Centers for Disease Control and Prevention in the United States 
recommend EPT as an effective partner management strategy (24); it is currently not an 
implemented policy in RQHR.  
It is not surprising that a large proportion of our sample population was coinfected with both 
gonorrhea and chlamydia; this supports the findings of previous North American studies (25,26) 
and Canadian national guidelines that gonorrhea should be treated with combination therapy 
(ceftriaxone or cefixime with azithromycin) to target both infections (22). Our finding that 
individuals under age 25 had increased odds of coinfection (OR 2-3.5) also supports previous 
research (25–27) and could be a related to the fact that younger women are thought to be more 
susceptible to chlamydia than are older women, due to increased cervical ectopy (28). This could 
also account for younger males being more likely to be coinfected, if the local sexual networks 
exhibit age homogeneity, as implied by our finding that the mean age difference between cases 
and their contacts was just four years. The increased odds of coinfection among those who 
reported alcohol or drug abuse does not have a plausible biological explanation. However, it 
could be a marker for sexual network, indicating that coinfection is more prevalent in networks 
of individuals with higher risk behaviors, such as alcohol or drug abuse.  
 Last, the apparent protective influence of having reported a same sex partnership on the risk of 
coinfection is also not clearly related to any biologically plausible phenomenon, although it has 
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been reported previously (29). It is possible that this association could result from memberships 
in sexual networks in which chlamydia infections are less common.  
Low positive response rates for some risk factors, including sex trade involvement and a history 
of same sex partners, could have limited the power to evaluate the effect of these factors on the 
outcomes of interest. Also, because this study used previously-collected information from 
notifiable disease files, the collection of risk factor and other information from patients was not 
standardized. A large number of health care workers from different facilities recorded data over 
the study period. Different approaches could have affected the amount or quality of information 
gathered from patients presenting at different times and different facilities. Also, potential 
movement from one health region to another could have limited our ability to identify repeat 
infections over the study period, as could asymptomatic or other undiagnosed infection. Finally, 
potentially stigmatizing behaviors, including alcohol and drug use or purchasing commercial sex, 
could have been under- or misreported (30). 
We were able to identify several factors associated with increased risk of reinfection and 
coinfection with gonorrhea and chlamydia among STI patients in RQHR, and our findings are 
directly relevant to prevention and control efforts in the region—and, potentially, in other 
Saskatchewan health regions with larger urban centres. Because the risk of reinfection is 
heightened among those individuals who are under 20 years of age, who are coinfected, or who 
report sex trade involvement for themselves or their partners, health care workers in RQHR 
could use this information to guide their counselling and treatment choices. Targeted counselling 
efforts focused on those at high risk of reinfection could have an effect on reinfection rates; 
however, factors beyond the control of the individual, such as external pressures and group 
norms, will likely still play a strong role in influencing choices. Treatment protocols could have 
a great effect. For example, EPT might be an appropriate choice for clients with these risk factors 
to prevent potential reinfection from untreated partners (23). Similarly, clients who are under 25 
or report alcohol or drug abuse could be good candidates for presumptive dual therapy, given the 
increased odds of coinfection among this demographic. Additionally, regular review of some of 
the parameters identified here to be associated with reinfection and coinfection could assist in 
measurement of STI intervention effectiveness in RQHR.   
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CHAPTER 5: ASSESSMENT OF THE UTILITY OF SOCIAL NETWORK ANALYSIS 
FOR THE CONTROL OF BACTERIAL SEXUALLY TRANSMITTED INFECTIONS IN 
SASKATCHEWAN 
(unpublished) 
 
 
 
As in China, rates of gonorrhea remain high in Saskatchewan. In contrast to China, levels of 
antimicrobial resistance are currently low. High rates of disease in the province do indicate, 
however, that the current approach to disease control is not effective. Novel methods are 
warranted to better understand and control transmission, especially before AMR becomes 
established in the province. Social network analysis is a powerful tool, which has been 
demonstrated to provide a significant contribution to the understanding of STI transmission 
dynamics in many jurisdictions. It was hypothesized that a SNA approach would provide 
additional information related to the transmission of gonorrhea in the Regina Qu’Appelle Health 
Region, which could better position policy makers to both control disease and be proactive in 
delaying AMR emergence. Unfortunately, the current system of data collection and storage in 
Saskatchewan largely limited the utility of an otherwise powerful approach.   
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5.1 Introduction 
In spite of declining during the early 1990s, rates of bacterial STIs have been increasing in 
Canada since 1999. Data from 2011 indicate that Saskatchewan’s gonorrhea rate of 71.7 per 
100,000 is second only to that of Manitoba, among the Canadian provinces, and more than twice 
the rate of Ontario, Quebec, and Canada as a whole (1). The very real potential of multi-drug 
resistant, untreatable gonorrhea (2), coupled with the synergistic relationship between Neisseria 
gonorrhoeae and HIV (3), make it imperative that gonorrhea control efforts are improved and 
transmission of disease reduced. Improved understanding of transmission dynamics, along with 
evaluation of systems and tools currently in place to address disease transmission, are of utmost 
importance to address the growing burden of disease in the province.  
Information routinely collected on STI cases and contacts forms the basis from which sexual 
networks can be described, making social network analysis (SNA) a potentially powerful tool for 
understanding transmission dynamics and appropriate control efforts for STIs. SNA has been 
applied to gonorrhea in various settings (4) including Colorado Springs (5,6), San Francisco (7), 
the United Kingdom (8–12), Manitoba (6,13–17), and Alberta (18). Such studies demonstrate 
that SNA provides a powerful tool to enhance our understanding of disease transmission 
dynamics, potentially offering new information relevant to targeted control efforts. For example, 
network studies have enhanced understanding of core groups and network members (13–15), 
been applied to determining the epidemic phase of STIs in a given population (5–7), been used to 
illustrate the importance of location in disease transmission (18), enabled researchers to identify 
geographic bridges for disease transmission (14), and been combined with molecular techniques 
to support the strength of SNA methods (8,9,11-17). The objectives of the study presented here 
were to evaluate the potential contribution of SNA to improve understanding of gonorrhea 
transmission in Saskatchewan.  
Data on all cases of gonorrhea recorded in the Regina Qu’Appelle Health Region (RQHR) from 
2003 to 2012 were included. RQHR is located in south-central Saskatchewan and serves 260,000 
residents, including those of Saskatchewan’s capital city, Regina. It is the second largest health 
region in Saskatchewan, and has recorded an average of 100 cases of gonorrhea and 1000 cases 
of chlamydia each year since 2008. This study builds on my previously published epidemiologic 
study (Chapter 4) using the same dataset, and was designed to determine the potential of SNA to 
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enhance understanding of gonorrhea transmission dynamics in this population (19). It is the first 
study of SNA as applied to gonorrhea transmission in Canada outside of the provinces of Alberta 
or Manitoba. 
5.2 Methods 
5.2.1 Sample 
In Saskatchewan, Regional Health Authorities send specimens for testing to the Saskatchewan 
Disease Control laboratory (SDCL); all confirmed gonorrhea cases are reported to the 
appropriate public health authorities. In accordance with national guidelines, contact tracing is 
initiated in the event of a positive laboratory diagnosis, and includes individuals who were 
contacts within 60 days prior to the test date. Contact tracing, which is triggered by the 
notification being filed, is generally done by public health staff in the case’s home health region. 
If a contact resides in a different health region, a referral is made and follow-up is the 
responsibility of public health staff in that region. We accessed the notifiable STI files within the 
RQHR and extracted the records for all laboratory confirmed gonorrhea cases—including those 
concurrently infected with chlamydia—from January 1, 2003 to December 31, 2012. This study 
was approved by the research ethics boards of both the University of Saskatchewan and the 
RQHR (no. 12-323 and 12-98, respectively). 
In the RQHR, the majority of diagnostic tests for gonorrhea currently use urine-based nucleic 
acid amplification (NAAT). Antimicrobial susceptibility testing is carried out on cultured 
samples, but cultures are rarely performed, in spite of being recommended by the Saskatchewan 
Ministry of Health (20). Every positive gonorrhea case recorded in RQHR over this time period 
was included in the dataset. The RQHR files contained demographic information including 
name, health services number (HSN), age, date of birth, and address; event-related information 
including diagnosing facility, laboratory tests reported, and type and date of treatment; and, risk 
factor information including sexual history, drug and alcohol use, and number of partners. 
Information on sexual contacts and their follow-up was also recorded. All contacts who 
presented and had a laboratory-confirmed infection were also included in the extracted list of 
gonorrhea cases. 
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5.2.2 Data management and analysis 
Microsoft Access (21) was used to create a relational database that preserved the linkage 
between cases and their named contacts. To maintain security and confidentiality of client files, 
all data abstraction and initial processing was done on-site at health region offices. Original files 
were in hardcopy format for the first eight years of the study period. Prior to any information 
being moved off site, all personal identifiers including last name and address were removed. An 
algorithm was applied to scramble and anonymize clients’ HSNs while preserving the ability to 
recognize repeat occurrences of disease in individuals during the 10 year study period. 
After the data were de-identified, descriptive analyses were carried out using Microsoft Excel 
(22) and Stata IC/12.1 (23). Age was categorized prior to analysis. For the purpose of this 
analysis, we defined “repeater” as someone who appeared two or more times in the 10-year 
database. For repeat infections occurring at intervals of 2 months or less, we verified that 
appropriate, observed therapy (dual azithromycin and cefixime) was administered for the prior 
infection, to rule out persistent infection instead of repeat infection. Because Saskatchewan has 
extremely low levels of antibiotic resistance (24), treatment failure was considered unlikely. 
5.2.3 Social network analysis 
The database was stratified by year to allow for the creation of sexual network maps for each of 
the 10 years of data. The file for each year included all cases diagnosed in that calendar year, as 
well as any named contacts reported by each case at that visit (even if the contact occurred 
previous to that calendar year). A freeware program called “createpajek” (http://vlado.fmf.uni-
lj.si/pub/networks/pajek/howto/excel2Pajek.htm) was used to convert long format Excel files to a 
format that can be read by both Pajek (25) and NetDraw (26). The resulting files were then used 
to create network maps and calculate measures including network density, component size, and 
degree, for each year. Density measures the total number of connections in a network divided by 
the total possible number of connections (27); a very dense network is one in which many nodes 
are connected to one another. A component is a subgroup in a network in which all nodes are 
connected by at least one tie (27), and component size refers to the total number of nodes in the 
given component. Degree indicates the total number of connections a node has (27); in this case, 
degree represents the number of sexual contacts reported by the node, or who named that node.  
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A network map was also created and the same measures calculated considering the entire 10-year 
period, reflecting all cases presenting during the 10 year period, and a summary of their contact 
history as reported at each visit. For example, if a case presented for testing and treatment in 
2005 and reported 3 distinct contacts, and in 2007 and reported 2 more distinct contacts, the case 
was included once, and all 5 contacts reported were included as linked to that case. 
5.2.4 Statistical modeling 
The data included in this analysis were previously analyzed to identify socio-demographic 
characteristics associated with repeated gonorrhea and coinfection with gonorrhea and chlamydia 
(Chapter 4) (19). The data were reanalyzed here to identify any potential benefit associated with 
the addition of network position measures to the previously described risk factors, and to identify 
the potential advantages of using a SNA approach in addition to traditional epidemiologic data 
analysis. Prior to multivariable model building, observations for two cases with outlying ages (< 
6 months and >75 years) were dropped.  
The unconditional association between each SNA measure and both repeated gonorrhea and 
coinfection with gonorrhea and chlamydia were examined to identify potentially useful 
predictors of infection status. All SNA measures were linear in the logit, and were included as 
continuous variables for the analysis of repeat infections. For the coinfection outcome, degree 
was not linearly associated with the logit and was categorized before analysis. For SNA 
measures based on the 10-year network, degree and component size were included as continuous 
variables for the repeater and coinfection outcomes, respectively; all others were categorized.  
A multivariable logistic regression model was built to identify factors associated with having 
repeat entries in the database, using one entry per person, based on characteristics at first entry 
and controlling for amount of follow-up time.  
To identify variables associated with being coinfected with gonorrhea and chlamydia at the time 
of visit, a mixed-effects multivariable logistic regression model was built using a random 
intercept to account for clustering by participant identification (anonymized HSN) due to repeat 
entries.  
Starting with the risk factors identified from the multivariable analysis in the previous study (19), 
the SNA measures found to be unconditionally associated with the outcome (at p≤0.2), were 
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added to the model. Final models were developed using manual backwards elimination. 
Likelihood ratio tests and comparison of Akaike Information Criteria (AIC) were used to select 
nested and non-nested models, respectively. Only significant independent risk factors (p<0.05) 
and important confounders were retained in the final multivariable model for each outcome. 
Confounding was recognized when the difference between crude odds ratio for a risk factor-
outcome association of interest and the same odds ratio adjusted for the potential confounder was 
> 10%. After establishing main effects models for each outcome, all possible two-way 
interactions were considered; only interactions significant at p<0.05 were retained in the final 
models. 
The Intraclass Correlation Coefficient (ICC) was estimated as σ2patientID / (σ2patientID + π2/3) 
for the final coinfection model (28). Potential collinearity of SNA measures was tested using 
Spearman’s Rho; variables shown to be correlated were not considered eligible for the same 
model. Residual plots were examined for each model to check for outliers. 
5.3 Results 
There were 1143 occurrences of laboratory confirmed gonorrhea in the health region from 2003-
2012, representing 1027 unique individuals. Of these 1143 cases, only 126 (11%) had cultures 
taken at the clinical visit.  From these 1143 case visits, 1524 contacts were elicited, representing 
1383 unique individuals. Table 5.1 shows the frequency of reporting 0-10 partners in any given 
visit, as well as over the 10 year period. The average number of contacts reported by an 
individual in any one year was 1.3 (range 0-7) and over the 10-year period it was 1.6 (range 0-
10).  Just over half of cases (55.2%) were female, and just under half (44.2%) were coinfected 
with chlamydia at the time of diagnosis (19). Three cases had missing data for the year of 
infection, and were therefore not included in the SNA by year. 
5.3.1 Network characteristics 
Visualization of the network for each year revealed a combination of linear and radial 
components. None of the linear components included cycles, which are closed structures or 
“loops” in the network, whereby the path of sexual connections circles back upon itself. The 
final year of the dataset, 2012, included the greatest amount of nodes (304) and the largest 
component (12) (Figure 5.1a). In contrast, in 2009 there were only 156 nodes and the largest  
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Table 5.1 Frequency of cases in the notifiable STI files in the Regina Qu’Appelle Health 
Region reporting 0-10 partners, in a single visit, and over the 10-year period (2003-2012) 
Number of  
Contacts Reported 1 visit (n) 10 years (n) 
0 122 112 
1 670 572 
2 250 282 
3 70 95 
4 19 40 
5 6 13 
6 4 12 
7 2 7 
8 0 4 
9 0 0 
10 0 6 
 
component contained only 6 individuals (Figure 5.1b). Table 5.2 shows the network 
characteristics by year. Network density remained relatively similar throughout the 10 years, 
indicating a considerably fragmented network. The proportion of the network made up of isolates 
(individuals with no observed connections to others) declined throughout the 10 years, while the 
proportion comprised of triads or larger groups varied substantially over time, with no 
discernible pattern (Figure 5.2). Median degree and median component size remained relatively 
stable over the 10-year span.  
When all 10 years of data were considered together, the largest component included 49 
individuals. The median component size was 3 (IQR=2) and the median degree was 1 (IQR=1).  
Both degree and component size measures calculated based on the 10-year network were 
positively associated with repeat infection (p<0.001) and coinfection (p<0.01) in unconditional 
analysis. (Data not shown) 
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a. 
 
b. 
 
Figure 5.1 Network maps from gonorrhea cases and their reported contacts in the Regina 
Qu’Appelle Health Region for 2012 (a) and 2009 (b).  
Blue nodes are those recorded males, pink nodes are those recorded as females, and green nodes are unknown gender. Red circles 
indicate the largest component(s) for each year. 
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Table 5.2 Gonorrhea sexual network characteristics in Regina Qu’Appelle Health Region, from 2003-2012 
 
 
Year 
Total 
nodes 
Presented 
n (%) Density 
Proportion of the network comprised of:    
Isolates  
n (%) 
Dyads  
n (%) 
Triads  
n (%) 
Larger  
n (%) 
Largest 
component 
Median 
component 
size (IQR) 
Median 
degree 
(IQR) 
2003 199 105 (52.7) 0.006 18 (9.0) 74 (37.2) 60 (30.2) 47 (23.6) 10 3 (1) 1 (0) 
2004 235 129 (54.8) 0.005 20 (8.5) 96 (40.9) 72 (30.6) 47 (20.0) 8 3 (1) 1 (0) 
2005 227 111 (48.9) 0.006 15 (6.6) 86 (37.9) 51 (22.5) 75 (33.0) 11 3 (2) 1 (0) 
2006 235 106 (45.1) 0.006 10 (4.3) 78 (33.2) 63 (26.8) 84 (35.7) 7 3 (2) 1 (0) 
2007 180 87 (48.3) 0.008 8 (4.4) 66 (36.7) 54 (30.0) 52 (28.9) 10 3 (2) 1 (0) 
2008 209 102 (48.8) 0.006 11 (5.3) 94 (45.0) 72 (34.4) 32 (15.3) 6 2 (1) 1 (0) 
2009 156 69 (44.2) 0.008 5 (3.2) 68 (43.6) 24 (15.4) 59 (37.8) 6 3 (2) 1 (0) 
2010 243 121 (49.8) 0.006 6 (2.5) 118 (48.6) 45 (18.5) 74 (30.5) 7 2 (2) 1 (0) 
2011 302 139 (46.0) 0.004 7 (2.3) 122 (40.4) 99 (32.8) 74 (24.5) 7 3 (1) 1 (0) 
2012 304 144 (47.4) 0.005 9 (3.0) 116 (38.2) 69 (22.7) 110 (36.2) 12 3 (2) 1 (0) 
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Figure 5.2 Proportion the of the Regina Qu’Appelle gonorrhea sexual network comprised 
of isolates, dyads, triads, and larger components, by year, 2003-2012 
 
5.3.2 Coinfection with chlamydia 
In the unconditional analysis, increases in component size and degree were associated with 
increasing odds of being coinfected with chlamydia (Table 5.3). After accounting for risks 
associated with previously identified sociodemographic variables, only component size was 
associated with being coinfected with chlamydia (OR 1.10) (Table 5.4). For each additional 
person in a component, any member of the component had a 10% greater chance of being 
coinfected, after accounting for all other risk factors. Previously identified risk factors that 
remained significant in the model after accounting for connectivity measures included age and 
same sex partnerships. Being under 25 was positively associated with being coinfected with 
chlamydia (OR 2-3.4). In contrast, reporting a same sex partnership was associated with 
decreased odds (OR 0.5) of being coinfected; the SNA measures examined in this study did not 
confound these associations. The previously identified association between reporting alcohol or 
drug abuse to being coinfected was not significant after accounting for component size. 
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Table 5.3 Unconditional analysis of the relationship of SNA measures to coinfection status, 
among cases of gonorrhea reported to the Regina Qu’Appelle Health Region’s notifiable 
STI files from 2003-2012 
Variable OR P 95% CI 
Degree 0.002 
0 1.21 0.40 0.78-1.87 
1 Reference category 
2 or higher 1.64 0.001 1.24-2.17 
Component Size 1.17 <0.001 1.09-1.26 
 
Table 5.4 Multivariable model for risk factors related to coinfection status among cases of 
gonorrhea reported to the Regina Qu’Appelle Health Region’s notifiable STI files from 
2003-2012 
Variable OR P 95% CI 
Age (2 df) <0.001 
Age 12-19 3.29 <0.001 2.43-4.47 
Age 20-24 1.96 <0.001 1.44-2.68 
Age 25 + Reference category 
Same sex partner 0.50 0.04 0.26-0.96 
Component Size 1.10 <0.01 1.03-1.18 
ICC: 1.29E-10 
 
 
5.3.3 Repeat infection 
Increasing values of component size and degree were also associated with increasing odds of 
repeat infection in the unconditional analysis (Table 5.5). After multivariable analysis, in 
addition to those variables identified in the previous study (17), degree was significantly 
associated with the outcome (OR 1.3, p<0.1) (Table 5.6). This association indicates that for 
every additional contact, odds of repeat infection were 30% higher, after accounting for all other 
risk factors. When component size was included in the final model, in place of degree, the 
associations between the other variables and the outcomes were not significantly changed. In this 
model, component size is shown to be positively associated with repeat infection (OR 1.14, 
p<0.01), although the relationship is not quite as strong as between degree and the outcome. The 
model using degree was chosen as the final model based on its slightly lower AIC. 
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Table 5.5 Unconditional analysis of the relationship of SNA measures to repeat infection 
among cases of gonorrhea reported to the Regina Qu’Appelle Health Region’s notifiable 
STI files from 2003-2012 
Variable OR P 95% CI 
Degree 1.40 <0.01 1.16-1.69 
Component size 1.20 <0.01 1.17-1.58 
 
Table 5.6 Multivariable model for risk factors related to repeat infection among cases of 
gonorrhea reported to the Regina Qu’Appelle Health Region’s notifiable STI files from 
2003-2012 
Variable OR P 95% CI 
Age (2 df) 0.02 
     12-19 2.22 <0.01 1.23-4.01 
    20-24 1.39 0.30 0.73-2.63 
    25+  Reference category 
Coinfection 1.73 0.02 1.09-2.75 
Urban 2.22 0.07 0.94-5.27 
Sex trade 
involvement 3.54 <0.01 1.55-8.06 
Degree 1.32 <0.01 1.08-1.61 
 
5.4 Discussion  
Gonorrhea has been a nationally notifiable disease in Canada since 1924 (29). The requirement 
to report gonorrhea, as well as to follow-up with contact tracing efforts for any person exposed 
within the preceding 60 days, results in a wealth of information related to gonorrhea in the 
Canadian population. In spite of the amount of information collected, and the extremely high 
rates of infection in Saskatchewan, to date only two  epidemiologic studies of gonorrhea in 
Saskatchewan have been published (19,30). The goal of the present study was to evaluate the 
potential value of SNA, a tool that has been successfully applied to STIs in a wide variety of 
settings, in a province where disease rates remain incredibly high, and additional options are 
needed for disease control. This is the first study to apply SNA techniques to STI transmission in 
Saskatchewan. 
Social network analysis of the data collected in the health region over the 10-year period 
examined in this study suggested that the sexual network was substantially fragmented. This type 
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of fragmentation indicates that there are many fewer connections in the network than are possible 
for the given number of nodes, and has been seen in previous SNA studies of gonorrhea and 
chlamydia in the United States (5,7). The mean component sizes of between 2.7 and 3.5 are also 
similar to what has been reported in previous contact tracing studies (5,6,9,10,14,18). Potterat et 
al. (5) argue that fragmented networks comprised of relatively small, acyclic components (e.g., 
those that do not circle back upon themselves) indicate endemic, rather than epidemic disease 
spread. Further, they suggest that such networks are better suited to targeted screening than 
contact tracing, which is the current approach in Saskatchewan. However, it seems plausible that 
the lack of connectivity could also represent limitations of contact tracing in elucidating a 
complete network, especially given the jurisdictional boundaries of contact tracing and data 
storage, discussed below. 
Our finding that in the presence of the component size variable, the previously identified 
relationship between alcohol/drug abuse and coinfection disappeared could support the 
interpretation that the association was a marker for membership in high risk sexual networks 
(19). It is plausible that increasing component size is associated with increasing participation in 
other high risk behaviors. The association between increasing component size and risk of 
coinfection in the present study was not surprising. Potterat et al. (5) found that coinfected 
(gonorrhea/chlamydia) cases were disproportionately represented in larger components in their 
2002 Colorado Spring study. Additionally, they found that cases with repeat chlamydia infection 
were also more common in larger components, similar to our findings of degree or component 
size being associated with repeat gonorrhea. While the Colorado Springs study was substantially 
larger than ours, with a study population of 9114 over the 4-year study period compared to our 
304 in the largest single year (2012), we were able to distinguish similar associations between 
specific SNA measures and likelihood of repeat or coinfection.   
While SNA has been successfully applied in various other jurisdictions, there are several factors 
at work in Saskatchewan that hinder the utility of an otherwise powerful tool like SNA. Firstly, 
in comparison to centralized STI control programs in other areas, Saskatchewan’s data are 
collected and stored individually by each of the province’s 13 regional health authorities. 
Therefore, should an individual who tests positive for gonorrhea in one health region report a 
contact who lives in another, the follow-up is referred to the second health region, and the 
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resultant information effectively lost to the original health region’s database. Similarly, if a case 
or contact is eligible to receive services through Health Canada’s First Nations and Inuit Health 
Branch (FNIHB), the follow-up is carried out and information stored by that agency. It is a 
centralized system like Manitoba’s that allowed Wylie and Jolly (14) to reveal geographic 
bridges for chlamydia and gonorrhea infection transmission spanning a vast area of that 
province, from Winnipeg to northern Manitoba. Because of the number of jurisdictions involved 
in the collection and storage of STI data, such geographic bridging would be difficult to 
impossible to uncover  when data are managed by smaller, individual health authorities as in 
Saskatchewan, and the size of the network that can be described from any one region’s STI data 
is considerably limited. 
Combining molecular and social network data for analysis has also been shown to enhance the 
analytic power of SNA for control of STIs in the United Kingdom (8,9,11,12). As well, 
researchers in Canada have demonstrated the power of such a combined approach as applied to a 
tuberculosis outbreak in British Columbia (31), and STI control in Manitoba (16,17). 
Given the highly fragmented nature of the networks we were able to uncover in this study, it is 
possible that the addition of molecular data could have increased the utility of an SNA approach 
to understanding transmission in RQHR. For example, even if individuals or components appear 
unconnected based on their first-person reports of sex partnerships, the molecular network might 
imply otherwise. While two people infected with the same strain of gonorrhea are not necessarily 
sex partners, it does imply a potential network connection. Previous research involving 
molecular analysis of N. gonorrhoeae isolates from Saskatchewan, through DNA sequencing of 
both specific loci and whole genomes, has revealed a substantial amount of information on the 
distribution and population structure of N. gonorrhoeae in the province (32,33), and indicates 
that strains have spread throughout the province over time. Although molecular analysis was 
carried out on isolates collected during the same study period, strain type information was 
available for only 53 (<5%) of the RQHR cases in the current study. The very small number of 
samples in this study that had available molecular strain typing data precluded the possibility of 
leveraging molecular data to improve our understanding of the networks in RQHR. A more 
proactive approach toward the collection of molecular data, perhaps by making molecular 
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analysis of positive samples a standard procedure, could contribute substantially toward 
improving the potential for SNA to analyze gonorrhea transmission in the province.  
Other serious limitations inherent in the Saskatchewan system are related to the way data are 
collected. For example, the STI notification form (Figure 5.3), required by law to be filled out for 
all laboratory-confirmed positive gonorrhea cases, provides space for listing the information for 
two contacts, with instructions to use additional forms if necessary to include more contact 
information. Anecdotal reports from STI clinic staff indicate that this likely limits the extent to 
which physicians may attempt to elicit contacts from a case; when two names are given, the 
interview may be considered complete. Research into whether a change in the way contacts are 
elicited and recorded resulted in a general increase in contacts named could determine the extent 
to which the current form may be contributing to our limited ability to uncover the network at 
risk.  
Additionally, because there are a variety of locations at which STI testing and diagnosis are 
carried out, there is a similar variety in the level of rigor with which client interviews are carried 
out. The notifiable STI form includes checkboxes for various risk factors (e.g., drug and alcohol 
use, multiple partnerships, same sex partnerships, sex trade work, etc.); many physicians, 
however, generally do not check these boxes, leaving it difficult to determine whether the boxes 
are unchecked because there are no relevant risk factors, or because the interview did not cover 
the topic. The addition of a checkbox indicating that the questions were or were not asked, 
generally, could improve understanding of the strength of risk factor data as indicated on the 
form. 
Further, because filling out the notifiable STI form is triggered by receiving a positive lab result 
(typically a few days after the physician or clinic visit), it may not be practical or possible to 
gather all the required information, and many of the forms are incomplete.  Additionally, the 
contact notification forms are received by public health, and contact tracing initiated, after the 
positive test has been received and notifiable STI form filed, delaying the initiation of contact 
tracing efforts potentially by several days. Such a delay not only increases the likelihood of 
exposed individuals continuing to transmit infections, but also may limit the extent of the 
network that can be identified, as it can be challenging to locate the index case for follow-up 
several days after the initial visit and testing. 
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Figure 5.3 STI Notification form used in Saskatchewan during study period (2003-2012) 
Perhaps the biggest limitation is the complicated system of jurisdictional data collection and 
storage. Further, while connections between the two major centres (Saskatoon and Regina), rural 
and urban areas, and the urban centres and First Nation reserves almost certainly exist, it was not 
possible to demonstrate such connections using the available data. Access to a centralized 
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information system reflecting a more complete history of client contacts would provide enhanced 
ability to identify relationships between network positions and outcomes of interest for disease 
control, as well as potentially reveal important connections between distant communities in the 
province. However, under the current system of data collection and storage, SNA studies of STI 
transmission in Saskatchewan will remain seriously limited. 
Reporting STIs such as gonorrhea is mandated by law, and such reporting necessarily results in 
the collection and storage of a substantial amount of sociodemographic and sexual history data. 
Unfortunately, as demonstrated here, the application of powerful analytical techniques, which 
could greatly improve our understanding of the transmission of gonorrhea is markedly hindered. 
The limited applicability of such a wealth of data that exists across the province, beyond simple 
contact notification, raises ethical questions about the collection of such data. It is important to 
consider the intention of the mandate to report notifiable diseases. Notifiable diseases have been 
identified as priority areas for monitoring and control efforts, which is why the requirements for 
reporting and contact tracing exist. However, if the current state of the system prevents the data 
collected from being used to its full potential in terms of enhancing control efforts, should it be 
collected at all? Currently, the only use of the data collected is to follow up and treat cases and 
contacts. Rates of gonorrhea remain very high, indicating this cycle of identifying and treating 
cases and contacts alone may be insufficient to effectively control disease transmission. 
Improvements could potentially be made if the data were robust enough to inform the 
development of innovative and effective interventions.  
The system-related limitations discussed herein provide a basis from which to begin to consider 
possible improvements to better aide health professionals in effectively combating gonorrhea and 
other STIs. In a province with one of the highest gonorrhea rates in the country, improvements in 
disease control are desperately needed. The mandate to report a disease, and even to carry out 
contact tracing efforts, is clearly not enough when the system is so fragmented. In its current 
state, the STI control system in Saskatchewan greatly limits the application of proven analytical 
techniques to the control of disease transmission. Under these circumstances, the application of 
SNA to gonorrhea transmission in Saskatchewan is unlikely to provide any information for 
meaningful improvements in disease control.  
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CHAPTER 6: PREDICTING THE EFFECTS OF EMERGING ANTIMICROBIAL 
RESISTANCE IN N. GONORRHOEAE IN SASKATCHEWAN USING DYNAMIC 
SIMULATION MODELING 
(unpublished) 
 
Several chapters in this thesis illustrated that client attributes can be useful for clinicians to tailor 
approaches with patients to support more effective overall disease control—both in China, where 
both gonorrhea and AMR rates are high, and in Saskatchewan, where gonorrhea rates are high, 
yet AMR is low. This chapter focuses on the exploration, through dynamic simulation modeling, 
of scenarios related to the emergence of AMR in Saskatchewan, with the goal of identifying 
approaches that would be most effective at preventing the establishment of AMR in the province. 
Given the current low levels of AMR compared to other jurisdictions, such as China, 
Saskatchewan has a unique opportunity to be proactive in preventing the emergence of AMR.  
The identification of effective strategies to prevent AMR emergence is critical if we are to avoid 
a future in which the prevalence of AMR limits treatment options, and pushes disease rates even 
higher. However, limitations inherent to Saskatchewan’s STI data system substantially restrict 
the strength of a dynamic simulation modeling approach grounded in empirical data. In fact, 
data-related limitations identified in the previous chapter proved to be magnified when the data 
were used to inform the model building process.   
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6.1 Introduction 
Rates of gonorrhea are high in Saskatchewan compared to other provinces. Saskatchewan 
reported 71.7 cases per 100,000 population in 2011—more than twice the rate of the provinces of 
Ontario and Quebec, as well as the national rate (1). Although levels of AMR have been 
relatively low in the province to date (2), resistance to penicillin, tetracycline, erythromycin, and 
ciprofloxacin is common nationally; as a result, these antibiotics are no longer recommended for 
treatment in Canada. Further, resistance to ceftriaxone and cefixime, the last recommended 
treatment, is emerging (3). Treatment failures to oral third generation cephalosporins have been 
reported in Canada (4), illustrating the potential of untreatable infections in the future. New 
therapy modalities—such as innovative treatment approaches with currently available antibiotics, 
the discovery of new antibiotics, or the development of vaccines to prevent gonorrhea—are 
needed to avoid this potential outcome. Currently, combination therapy with ceftriaxone (250 mg 
IM) and azithromycin (1 g po) is the recommended first line treatment for uncomplicated 
gonorrhea in Saskatchewan (5). This dual therapy is administered both to delay the emergence of 
resistance to cephalosporins in Neisseria gonorrhoeae and to treat for concomitant chlamydia 
infection (6).  At present, resistance to cephalosporins has not been observed in Saskatchewan 
(2). 
Better understanding of why Saskatchewan experiences such high rates of infection is needed to 
reduce the impact of gonorrhea in the province. To date, there have been few published 
epidemiologic studies of gonorrhea in Saskatchewan (7,8), and none have offered an explanation 
for the province’s inordinately high rates despite low levels of AMR. The previous chapter 
examined the utility of enhancing traditional epidemiologic methods with SNA to advance 
effective disease control approaches in the province. This chapter explores simulation modeling 
as a potential approach for improving understanding of the complexities of gonorrhea 
transmission in the context of emerging AMR. 
Simulation modeling offers a powerful tool for the application of health data to policy decisions. 
For example, models can be used to predict emergence or reemergence of antimicrobial 
resistance, compare and contrast the impact of different contact tracing strategies on disease 
prevalence, evaluate the effectiveness of screening programs, identify the most cost-effective 
disease control strategies, and more. Modeling offers a unique opportunity to generate and test 
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hypotheses related to identifying the best possible strategies for the control of gonorrhea—
information that is urgently needed in a province where rates remain substantially higher than for 
the rest of the country. However, a review of the literature reveals relatively few published 
studies over the past 15 years that apply simulation modeling to problems related to gonorrhea in 
the developed world. Further, only two of these papers focus on AMR gonorrhea (9,10)—one 
that I have coauthored.  
In light of the remarkably high rates of infection in the province, it would be prudent to be 
proactive in preparing for the eventual emergence of AMR in Saskatchewan. Given national 
trends, it is plausible that AMR could complicate gonorrhea control locally in the near future. 
Compounding this risk, international travel and high rates of immigration to Saskatchewan (11) 
also increase the likelihood of introduction of AMR infections. To this end, the objective of this 
chapter was to use simulation modeling to explore potential outcomes related to the introduction 
of AMR into a population where resistance to cephalosporins is not currently observed (2). Ten 
years of data from the Regina Qu’Appelle Health Region’s notifiable STI files provide empirical 
evidence to inform the structure and calibrate the model. 
6.2 Methods 
6.2.1 Model 
The research presented here used a previously published compartmental model designed to 
explore scenarios related to the effects of AMR on gonorrhea prevalence under various treatment 
options. The model was originally published in 2011 (9), and was later modified by our research 
group to better represent infection transmission dynamics in discrete populations (10). Detailed 
descriptions of the original model and how it was initially modified are available in the 
publications referenced. Additional changes to the structure and to model parameters for this 
analysis are described below. 
The model modified for the work presented here was originally created in Vensim DSS (12)—a 
popular numerical software for system dynamics models (constituting ordinary differential 
equations). The same software was used for the additional modifications and analyses described. 
The model was numerically integrated using the Euler method with a time-step of 0.0078125. 
The model uses a susceptible-infectious-susceptible structure, because gonorrhea does not result 
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in long term immunity, and individuals become susceptible to reinfection once they have 
recovered. In the original model, several compartments allowed for individuals to be infected 
with one of four types of infection: infection susceptible to treatment, infection resistant to drug 
A, infection resistant to drug B, and infection resistant to both drugs. The original model was 
risk-stratified, with 97.4% of the population classified as low risk, 2.3% as intermediate risk, and 
the rest as high risk. The total closed population numbered 1 million, and did not include 
demographic characteristics such as age or gender. The duration of infectiousness was 42 days 
and the chance of developing resistance upon treatment was 10-6. Proportional mixing among 
risk groups, with homogenous mixing within risk groups, was represented using a mixing matrix 
(see Appendix 6.A for equations). All parameters and structural features, except those discussed 
below, were reproduced exactly as reported in the original model. 
6.2.2 Sample data source 
Ten years of data from the notifiable STI files of Regina Qu’Appelle Health Region (2003-2012) 
were used to inform the structure and parameters used in this study. The dataset is described in 
detail in our previously published manuscript (8) and in Chapter 5 of this dissertation. Briefly, 
every positive gonorrhea case recorded in RQHR over this time period was included. The RQHR 
files contained demographic information, including name, health services number (HSN), age, 
date of birth, and address; event-related information including diagnosing facility, laboratory 
tests reported, and type and date of treatment; and, risk factor information including sexual 
history, drug and alcohol use, and number of partners. Information on sexual contacts and their 
follow-up was also recorded. All contacts who presented and had a laboratory-confirmed 
infection were also included in the extracted list of gonorrhea cases.  
These data were used to build maps of the sexual network for each year, and SNA measures 
including network density, component size, and degree were calculated for each year. Density 
measures the total number of connections in a network divided by the total possible number of 
connections (13); a very dense network is one in which many nodes are connected to one 
another. A component is a subgroup in a network in which all nodes are connected by at least 
one tie (13), and component size refers to the total number of nodes in the given component. 
Degree indicates the total number of connections a node has (13); in this case, degree represents 
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the number of sexual contacts reported, and is based on naming a contact, and/or being named by 
someone else.  
6.2.3 Modifications 
Several modifications to the previously published model were made before running any 
scenarios. The modifications were made mainly to enhance the model’s representativeness in 
characterizing gonorrhea transmission in populations of interest. Specifically, the modified 
model was designed to better represent the population of STI clinic attendees in the Regina 
Qu’Appelle Health Region, using empirical data gathered through our previous studies among 
this population (8).  
RQHR records an average of 100 cases of gonorrhea and 1000 cases of chlamydia per year. A 
population size of 11,000 was used, to approximate the number of STI notifications filed in 
RQHR for gonorrhea and chlamydia over the 10-year period from which the data were gathered. 
The model population was stratified into the two risk categories—high and intermediate—that 
plausibly make up most of the STI notifications (and their contacts) over the study period. 
Degree (calculated by SNA) values for cases were used to determine the appropriate proportions 
represented by each of these categories, with degree 2 or below representing intermediate risk 
and degree 3 or above representing high risk.  
Values for contact rates were also modified from the original model, based on the cases’ degree 
values from the RQHR data. The mixing matrix was adapted to account for only two risk groups, 
using values based on the SNA of the RQHR data. The proportion of each population stratum 
that received treatment was also abstracted from the RQHR data. Lastly, the original model used 
a treatment delay of one year. A treatment delay of 3 months was used here, to better reflect the 
various factors affecting when a person might present for treatment. For example, symptomatic 
males would likely present for treatment soon after symptom onset, while in other cases 
treatment might result from tracing of asymptomatic contacts, resulting in a longer time from 
infection to treatment. 
Before running any scenarios, the mixing matrix was balanced so that the number of contacts per 
unit time occurring from the intermediate risk population with those in the high risk population 
equaled the number of contacts per unit time occurring from the high risk population with those 
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in the intermediate risk population.  That is, (population proportion of intermediate risk 
individuals * intermediate risk group contact rate * proportion of intermediate cases’ contacts 
with high risk individuals) was equal to (population proportion of high risk individuals * high 
risk contact rate * the proportion of high risk cases’ contacts with intermediate risk individuals).  
Lastly, the original model allowed for combination therapy with two antibiotics; in this study 
only one drug was considered. 
6.2.4 Parameter values 
Based on the results of the SNA, the population was structured such that 90% were classified as 
intermediate risk and 10% high risk individuals. In any given year, the proportion of infected 
individuals the high risk group to receive treatment was 0.82, and the proportion of infected 
individuals in the intermediate risk group to receive treatment was 0.59. Also based on the SNA 
results, using degree values for the index cases, the contact rate for the intermediate risk group 
was 1.19 per year; for the high risk group, it was 3.56 per year. The connections between 
individuals revealed by the SNA indicated that for high risk individuals, 97.1% of contacts were 
with intermediate risk individuals, and 2.9% with other high risk individuals.  For intermediate 
risk individuals, 95.5% of contacts were with other intermediate risk individuals and 4.5% were 
with high risk individuals. 
Based on the raw data, not only was the matrix unbalanced, but the proportion of contacts that 
are high risk was higher among the intermediate risk cases than among the high risk cases. It is 
highly improbable that this reflects the true nature of pairing across risk groups (e.g., it is 
unlikely that intermediate risk cases are more likely to pair with high risk contacts than are high 
risk cases), and indicates an inconsistency in the original data. In reality, the fraction of high-risk 
cases who mixed with high-risk contacts is probably much greater. This underestimate of high 
risk-high risk pairings likely results from censoring at the edges of the network. Because the data 
used for the SNA generally only included first generation contacts, most of the components 
identified were star shaped. This means that information about individuals at the edges of such 
stars was necessarily censored. Contacts were assigned risk categories according to the results of 
the SNA. Most of these nodes, therefore, were assigned to the intermediate risk category, but 
were connected to a high risk case. To account for this misclassification of contacts, correction 
factors were applied to move contacts from the intermediate risk group to the high risk group in 
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the mixing matrix only. To balance the matrix, the proportion of high risk contacts was increased 
by a factor of two for intermediate risk cases, and by a factor of 25 for high risk cases. The 
corrected mixing matrix was structured such that for high risk individuals, 73% of contacts were 
with other high risk individuals, and 27% were with intermediate risk individuals.  For 
intermediate risk individuals, 9% of contacts were with high risk individuals, and 91% were with 
other intermediate risk individuals.  (Table 6.1)  
Additionally, a multiplier of seven was applied to the force of infection, to enable the infection to 
become established in the population at a level similar to what has been reported in empirical 
studies.  
Table 6.1 Dynamic model to investigate antimicrobial resistance scenarios in 
Saskatchewan: parameters and baseline values 
Parameter Symbol Baseline value 
Probability of developing de novo 
resistance on therapy rA, rB 0.000001 
Natural recovery rate (1/year) v 8.67 
High risk Intermediate Risk 
Population size Ni 1100 9900 
Total annual partnerships ci 3.56 1.19 
Proportion of sexual partnerships* 
     High risk p2i 0.73 0.27 
     Intermediate risk p1i 0.09 0.91 
Baseline daily rate of treatment  tAi, tBi, tABi 0.011 0.011 
Proportion treated 0.82 0.59 
*Corrected as explained in text. 
 
6.2.5 Scenarios 
The first scenario established the baseline steady-state prevalence of infection, which resulted 
from the parameters abstracted from the RQHR data. It used a treatment delay of 3 months and 
did not allow for AMR. 
The second set of scenarios examined the effect of varying treatment delays, both in the presence 
of resistance, and without resistance. In the scenarios with AMR, the initial level of resistance 
was set at 1% of infections across both risk strata. Treatment delays explored included 1 year (as 
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structured in the original model), 6 months, 3 months, 2 months, six weeks, and 1 month to 
treatment.  
Finally, a set of scenarios was constructed to evaluate the effect of introducing different levels of 
resistance into the population under different treatment scenarios. These scenarios involved 
trying to determine a “tipping point” for the frequency of resistance introduced to the population 
necessary to affect the steady-state prevalence of infection. These scenarios used a 3 month 
treatment delay, and involved introducing varying levels of resistant infections at the initial time-
step of the model. 
6.3 Sensitivity analyses 
To explore the sensitivity of the model to other changes in selected parameters, scenarios were 
run to examine the effects of increasing population size, and treating 100% of each risk group as 
opposed to the baseline treatment proportions abstracted from the RQHR data. These analyses 
were performed using the baseline conditions with no AMR and a three month treatment delay. 
Increasing the number of individuals in the model by up to a factor of 1000 revealed that the 
model was not sensitive to changes in population size. The model was sensitive to changing the 
proportion of the infected population to receive treatment in a given year, however. When the 
treatment proportion was modeled at 0.5 in each risk stratum, the resultant steady-state 
prevalence was roughly 2,000 per 100,000 higher than the baseline. In contrast, when the entire 
population was treated, the steady-state prevalence was about 2,500 per 100,000 lower than the 
baseline. 
6.4 Results 
6.4.1 Baseline scenario 
In the baseline scenario, after an initial decline, the steady-state prevalence of 9.9% was reached 
within roughly 16 months (Figure 6.1). 
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Figure 6.1 Baseline scenario with no AMR: Steady-state prevalence is 9.9% 
 
6.4.2 Treatment delays without AMR 
Varying the length of delay to treatment without AMR resulted in different levels of steady-state 
prevalence (Figure 6.2). The longer the delay until treatment, the higher the steady-state 
prevalence of the system, and the more quickly it was reached. With a one year treatment delay, 
the steady-state prevalence was 16.5%, and a 6 month delay resulted in a steady-state prevalence 
of 14.5%. The baseline (3 month treatment delay) resulted in a steady-state prevalence of 9.9%. 
When the treatment delay was lowered to 2 months, the resultant steady-state prevalence was 
6.9%.  A six week treatment delay resulted in a steady state prevalence of only 3.4%, while 
treating within one month resulted in the rapid elimination of disease from the population.  
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Figure 6.2 Without AMR, longer treatment delays result in higher steady-state prevalence 
 
6.4.3 Treatment delays with AMR 
Varying the length of delay to treatment when AMR is initially included (in 1% of infections) 
gives notably different results. In all cases, the steady-state prevalence was 19.8%, but the time 
to reach this level varied (Figure 6.3). The longest treatment delay (1 year) resulted in the 
ultimate steady-state prevalence being reached after roughly 10 years. In contrast, with a 
treatment delay of just one month, the steady-state prevalence was reached in under two-and-a-
half years. Additionally, the results indicate that treatment in two months or less affords an initial 
sharp decline in prevalence, followed by a rapid rebound effect. This effect was not seen with 
longer treatment delays. In all of these scenarios, it is the resistant strains that were responsible 
for maintaining the steady-state prevalence. 
6.4.4 Tipping points for AMR 
The results of the last scenario are shown in Figure 6.4. Including just one resistant infection 
among the high risk group resulted in a steady-state prevalence of 19.8% within 4 years. Starting 
the model with higher levels of resistance among the high risk group (e.g., more than one 
individual with resistant infection) resulted in the same steady-state prevalence being reached, 
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but in a shorter amount of time. In contrast, it required 11 AMR initial infections among the 
intermediate risk group to tip the steady-state prevalence to this same level (19.8%).  In these 
scenarios, resistant infections were largely responsible for the steady-state prevalence. Any fewer 
than 11 resulted in the same outcome as the baseline scenario—AMR does not become 
established, and resultant prevalence is maintained by non-resistant infections. As well, when 
AMR was initially included in the intermediate risk group, it took slightly longer to level off at 
this higher level as compared to when AMR occurred in the high risk group. 
 
 
Figure 6.3 In the presence of AMR, faster treatment results in faster establishment of 
steady-state prevalence of infection 
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Figure 6.4 Fewer resistant infections are required—and the effect is faster—if resistance is 
modeled among the high risk versus the intermediate risk group 
6.5 Discussion 
The combination of Saskatchewan’s high rates of gonorrhea, coupled with the threat of 
untreatable infection, makes it crucial that effective disease control policies are in place. The 
present high rates indicate that improved understanding of gonorrhea transmission dynamics in 
the province is urgently needed to inform the development of effective policies, and that the 
current approach could be improved. The very real potential for the development of resistance to 
currently-recommended treatments indicates the importance of being proactive to mitigate the 
possible effects. There have been relatively few recent studies using dynamic simulation 
modeling to explore scenarios related to gonorrhea transmission and control in the developed 
world. Those that have been published in the last 15 years have explored topics including 
treatment approaches (9,10,14), diagnostic testing (15,16), financial aspects of disease control 
(14,16–19), and screening approaches (14,17–19). Only two have focused on AMR—one 
published by our research group (9,10). This is the first study to attempt to model scenarios 
related to the development of AMR in Saskatchewan, using empirical data.  
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The baseline steady-state prevalence of 9.9% is similar to the prevalence of gonorrhea reported 
among core groups in previous studies (20,21). As well, a prevalence of 10% was used for the 
high risk group in the original model (9,10), indicating this is in line with expected values for the 
STI clinic population. 
It was not surprising that increasingly longer treatment delays—in the absence of AMR—
resulted in increasingly higher levels of steady-state prevalence. Notably, a reduction of the time 
to treatment from three months (baseline) to 2 months reduced the steady-state prevalence by 
roughly one-third, while a reduction from 2 months to 6 weeks reduced it by about 50%. The 
difference between a treatment delay of one year and 6 months only reduces steady state 
prevalence by 12%. Within the limitations of the parameter values applied (see below), these 
results suggest that treating within 6 weeks could be key, which has important implications for 
policies related to empirical treatment as well as contact tracing approaches. In jurisdictions 
where identification and treatment of contacts is known to take several weeks, expedited partner 
therapy (EPT) could be a reasonable choice given these findings. 
The opposite effect was shown by varying treatment delays in the presence of AMR. In this case, 
the faster individuals are treated, the faster resistant strains are able to take hold in the 
population, resulting in higher steady-state prevalence. In a population with AMR, in the absence 
of a point of care test to enable the delivery of targeted, effective treatment, a delayed time to 
treatment with a single antibiotic appeared to slow the rise to an eventual steady-state prevalence 
of 19.8%. This underscores the need to develop rapid point-of-care tests for antimicrobial 
susceptibility; being able to deliver appropriate, effective treatment at the initial visit is 
fundamental to controlling disease. 
The results of the exploration of the “tipping points” for AMR taking hold in the population were 
interesting. Starting the model with just one high risk individual with a resistant strain was 
enough to push the steady-state prevalence to 19.8% in 4 years, fueled by AMR infections. In 
contrast, it required 11 times as many individuals with AMR infection in the intermediate risk 
group to have a similar effect. This implies that the high risk group—while substantially smaller 
than the intermediate risk group—is driving the spread of infection in the population. The high 
risk group’s demonstrated influence on infection transmission is in line with core group theory, 
which indicates that a small group of individuals with high risk behaviors play a large role in 
 110 
 
maintaining STI epidemics (22). These results also demonstrate the potential for a very small 
numbers of individuals with resistant infection to tip the balance to a higher overall prevalence of 
infection, quite rapidly.  
Many of the most important implications of this work come from the model building process 
itself. The availability of 10 years of STI data from RQHR enabled elements observed among 
this sample population to be incorporated in the model. As well, the results of SNA of this data 
allowed for the use of parameters (such as contact rates, and mixing preferences) that were 
grounded in empirical data. However, the considerable limitations of the data became apparent at 
the start of the model building process. 
The biggest limitation of using the RQHR data was the misclassification of high risk contacts as 
intermediate risk. This misclassification, as discussed earlier, results from the way in which the 
data on contacts was collected. Because contacts beyond those reported by the index case (e.g., 
the contacts’ contacts) were generally not identified, this necessarily limited the ability of the 
SNA to accurately represent the extent of the network, and, therefore, the risk group of many 
contacts. This is in part related to the lack of a centralized system for STI data collection and 
storage in Saskatchewan (see discussion Chapter 5), which greatly restricts the extent of the 
network that can be uncovered. This first-generation-only contact tracing results in a social 
network map where most of the larger components are star shaped. Individuals on the edges of 
such stars are censored, meaning that the degree measurement calculated from the data—and 
used to abstract risk groups, here—is lower than it likely is in reality. As a result of these star-
shaped components, many high risk individuals (the centers of the stars, with high degree 
measures), are connected to individuals who are classified as intermediate risk, based on this 
censoring. Because of this, the raw data were providing highly inconsistent contacts per unit time 
when viewed from the point of view of the intermediate risk population mixing with the high risk 
population and from the point of view of the high risk population mixing with the intermediate 
risk population.  An adjustment to the raw values was clearly needed to correct for this. The 
correction approach used was chosen to address the fact that the contacts of high risk cases are 
disproportionately affected by censoring, and needed to be substantially increased. The 
correction factors applied were chosen to address this differential effect of censoring and 
establish a more realistic mixing matrix. It is interesting to note that this considerable limitation 
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inherent in the dataset likely would have gone unnoticed had we not attempted to use the SNA 
data to inform our model.  
Underreporting of contact rates was another limitation, and was hypothesized to be the reason a 
multiplier was needed to provoke the establishment of infection in the population. This 
underreporting has a few likely causes. First, the degree values from the SNA are calculated 
based upon the number of unique partnerships reported, and do not account for multiple 
partnering with the same contact, nor for the effect of concurrent partnerships on disease 
transmission. Second, contact tracing is generally known to have inherent limitations to 
uncovering the complete network, based on a wide variety of issues (23); additional factors 
possibly limiting the effectiveness of contact tracing in RQHR were discussed in the previous 
chapter. The need to implement a multiplier might also relate to additional inconsistencies in the 
mixing matrix, beyond the misclassification we attempted to account for. In light of these 
limitations, the need to use a multiplier on the force of infection was not surprising. This adjusted 
force of infection accounts for the underreporting and other issues discussed above, in a 
relatively simplified manner, and speaks to the inability of contact tracing data alone to capture 
adequate information about disease transmission dynamics.  
Another limitation was the lack of available data on the low risk population in RQHR. It is 
plausible that the majority of truly “low risk” individuals rarely, or never, contract an STI. 
Therefore, the notifiable STI files for RQHR likely contain very few such low risk individuals. 
This assumption guided the decision to divide the population into two, rather than three, risk 
strata. However, by limiting the model to intermediate/high risk individuals only, it was not 
possible to investigate broader implications of the emergence of AMR in the population as a 
whole. Data on the proportion of STI contacts who are low risk—along with information about 
their specific risk behaviors, and connections with other risk groups—would allow for a more 
complete analysis, including the entire (sexually active) population. 
In spite of being grounded in empirical data, the model presented here is highly stylized. 
However, by using dynamic modeling to explore the potential effects of AMR in a naïve 
population, this work provides a starting point for discussion and further consideration of the 
potential effects of the emergence of AMR gonococcal infection in Saskatchewan. There are 
substantial public health implications related to the establishment of AMR in N. gonorrhoeae 
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circulating in the province, which could ultimately compromise the effectiveness of current 
contact tracing and treatment policies. Additional questions of interest for future exploration 
could include the modeling of different contact tracing approaches and/or coupling molecular 
strain typing data with traditional contact tracing data. Using the currently available RQHR data 
to inform an agent-based model could serve to expand upon the work presented here. As well, 
this work illustrates the potential need to reconsider the way STI data are collected and stored in 
Saskatchewan; under the current system, the ability of otherwise powerful epidemiologic 
techniques to contribute to disease control approaches is considerably hampered. 
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Appendix 6.A: Original model equations 
											ௗௌ௜ௗ௧ ൌ 	െܵ݅ܿ݅ ቀ݌݅1	 ூ଴ଵାூ஺ଵାூ஻ଵାூ஺஻ଵேଵ
൅ 	݌݅2	 ூ଴ଶାூ஺ଶାூ஻ଶାூ஺஻ଶேଶ
൅ 	݌݅3	 ூ଴ଷାூ஺ଷାூ஻ଷାூ஺஻ଷேଷ 	
ቁ ൅
											ݒሺܫ0݅ ൅ ܫܣ݅ ൅ ܫܤ݅ ൅ ܫܣܤ݅ሻ ൅ ܫ0݅ሾݐܣ݅ሺ1 െ ݎܣሻ ൅ ݐܤ݅	ሺ1 െ ݎܤሻ ൅ ݐܣܾ݅	ሺ1 െ ݎܣݎܤሻሿ ൅
												ܫܣ݅ݐܤ݅ሺ1 െ ݎܤሻ ൅ ܫܤ݅ݐܣ݅ሺ1 െ ݎܣሻ ൅ 	ܫܣ݅ݐܣܤ݅ሺ1 െ ݎܤሻ ൅ 	ܫܤ݅ݐܣܤ݅ሺ1 െ ݎܣሻ   									ሺ6.1ሻ                          
		 
 
										ௗூ଴௜ௗ௧ ൌ 	ܵ݅ܿ݅	 ቀ݌݅1	 ூ଴ଵேଵ
൅ 	݌݅2	 ூ଴ଶேଶ
൅ 	݌݅3	 ூ଴ଷேଷ
ቁ െ 	ݒ	ܫ0݅ െ 	ܫ0݅ሺݐܣ݅ ൅ 	ݐܤ݅ ൅ ݐܣܤ݅ሻ          ሺ6.2ሻ 
 
										݀ܫܣ݅݀ݐ ൌ 	ܵ݅ܿ݅	 ൬݌݅1	
ܫܣ1
ܰ1
൅ 	݌݅2	
ܫܣ2
ܰ2
൅ 	݌݅3	
ܫܣ3
ܰ3
൰ െ 	ݒ	ܫܣ݅ െ 	ݐܣ݅ܫ0݅ݎܣ െ 	ܫܣ݅ሺݐܤ݅ ൅ ݐܣܤ݅ሻ 
    (6.3)                      
 
ௗூ஻௜
ௗ௧ ൌ 	ܵ݅ܿ݅	 ቀ݌݅1	 ூ஻ଵேଵ
൅ 	݌݅2	 ூ஻ଶேଶ
൅ 	݌݅3	 ூ஻ଷேଷ
ቁ െ 	ݒ	ܫܤ݅ ൅ 	ݐܤ݅ܫ0݅ݎܤ െ 	ܫܤ݅ሺݐܣ݅ ൅ ݐܣܤ݅ሻ	  
                (6.4) 
 
										ௗூ஺஻௜ௗ௧ ൌ 	ܵ݅ܿ݅	 ቀ݌݅1	 ூ஺஻ଵேଵ
൅ 	݌݅2	 ூ஺஻ଶேଶ
൅ 	݌݅3	 ூ஺஻ଷேଷ
ቁ െ 	ݒ	ܫܣܤ݅ ൅ 	ݐܣܤ݅ܫ0݅ݎܣܤ ൅
	ܫܣ݅ሺݐܤ݅ ൅ 			ݐܣܤ݅ሻݎܤ ൅ 	ܫܤ݅ሺݐܣ݅ ൅ ݐܣܤ݅ሻݎܣ	       			ሺ6.5ሻ 
 
where Si and Ii are the number of susceptible and infected individuals in each risk group i. 
Subscripts attached to I indicate infection with strains susceptible (0) or resistant to one or more 
strains (A, B, AB). j is used to denote risk groups other than i. (Note that the modified model 
includes only two risk groups and examines scenarios using only one drug.) 
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High rates of infection, coupled with growing AMR, make Neisseria gonorrhoeae a substantial 
public health threat. Understanding the influence of local epidemiology and socio-demographic 
factors on transmission dynamics is integral to developing successful disease control policies. A 
wide variety of epidemiologic tools are available to public health professionals. For successful 
approaches to disease control to be identified and implemented, it is important that the relative 
strengths and weaknesses of available tools be understood. Different disease settings, and 
varying levels of data quality, strongly influence the power of a particular tool in any given 
situation. Novel approaches to disease control, such as SNA or dynamic simulation modeling, 
can theoretically enhance traditional approaches. The objectives of the work presented here were 
to contribute to the current understanding of effective control of gonorrhea, to better understand 
factors related to the development and persistence of AMR, and to evaluate the effect of local 
epidemiology of disease in contrasting geographic regions, coupled with quality of available 
data, on the effectiveness of different analytical tools.  
7.1 Summary of findings 
Traditional approaches grounded in biostatistical analysis remain the cornerstone of 
epidemiologic studies of infectious diseases like gonorrhea. Chapters two through four of this 
dissertation illustrate the power of biostatistical approaches to identifying potential leverage 
points to control disease spread and the development of AMR. Chapters five and six consider the 
contribution of novel epidemiologic tools—SNA and dynamic simulation modeling. 
The first two of these chapters draw upon data from Shanghai, China—a region with very high 
rates of infection and AMR. The analysis presented in Chapter 2 shows that it is possible to 
identify behaviours and client attributes associated with AMR infection using robust statistical 
methods, even where rates of AMR are extremely high. In the absence of point of care testing for 
antimicrobial susceptibility, which would enable the delivery of timely, effective treatment, such 
information could potentially be used to better tailor treatment approaches using risk factor 
profiles. The study presented in Chapter 3 demonstrates that patient behaviours and socio-
demographic characteristics can also be used to predict both safe-sex practices and the likelihood 
of bringing a partner to testing/treatment after a positive gonorrhea diagnosis. This work shows 
that information that can be solicited in a clinical visit may be useful for helping clinicians tailor 
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the most appropriate counseling and/or follow up of a given case—especially important in high-
prevalence regions.  
The remaining chapters draw upon data from Saskatchewan, a setting where disease rates are 
high, but AMR is not currently a large concern. Chapter 4 presents further evidence that 
statistical approaches can reveal associations between socio-demographic characteristics and 
behavior with outcomes of interest for disease control—in this case risk for repeat gonorrhea or 
being coinfected with chlamydia and gonorrhea. Similar to the findings in Chapter 3, these 
results could be useful in helping clinicians tailor approaches to treatment and counseling based 
on factors that can be elicited during a patient visit. This is of particular interest in Saskatchewan, 
where disease rates are high, but only two published epidemiologic studies of gonorrhea exist. 
Chapter 5 presents an attempt to leverage SNA to augment the analytical approach presented in 
Chapter 4. This study represents the first to use SNA to study gonorrhea in Saskatchewan, 
provides new information about the characteristics of the gonorrhea network in RQHR. 
However, incorporation of SNA measures into the previously-published multivariable statistical 
analysis did not result in any major differences in the findings of the original study. This is likely 
related to the inherent limitations of the dataset.  
The work presented in Chapter 6 represents one of relatively few studies over the last 15 years to 
apply dynamic simulation modeling to questions related to gonorrhea transmission. Because 
rates of AMR are currently low in Saskatchewan, a proactive approach to reducing the impact of 
AMR infections is warranted. The model presented in this chapter builds upon previously-
published compartmental models, enhancing them with empirical data from the Regina 
Qu’Appelle Health Region. The model is useful for provoking discussion around appropriate 
treatment and follow-up approaches under various scenarios in the presence of, and without 
AMR strains circulating. While intrinsic limitations of the data restricted the strength of the 
model to provide robust real-world representativeness, the results do provide the groundwork for 
consideration of factors related to the eventual emergence of AMR gonococcal infections in 
Saskatchewan. Perhaps more importantly, this work further underscores the drawbacks of the 
current system of collection and storage of STI data in Saskatchewan. 
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7.2 Limitations  
That data collected in the Shanghai study had some substantial limitations, which precluded the 
generation of findings with definitive and broad public health applications to the control of 
gonorrhea. Large amounts of missing data, lack of heterogeneity in questionnaire responses, and 
low overall response rates likely restricted robustness of analysis. Further, because the index 
cases in the study population were all index males—the only females being those partners who 
presented—did not allow for comparison of male and female index cases in this population. Last, 
because the population was drawn from one STI clinic, generalizability of findings is limited. 
One of the most important findings of this body of work relates to the considerable limitations of 
STI data routinely collected in Saskatchewan for the application of powerful techniques such as 
SNA and dynamic simulation modeling. While this work shows that traditional biostatisical 
approaches to data analysis continue to be useful in identifying associations between risk factors 
and outcomes, SNA and dynamic simulation modeling should offer an additional increase in 
analytical power. As demonstrated in other studies, such methods provide platforms to greatly 
enhance our understanding of the more nuanced elements of the disease system, such as the 
influence of the local sexual network, or the potential effect of the introduction of even small 
numbers of AMR infections to a population. Unfortunately, these methods rely on robust data to 
be exploited to their full potential; the data available in Saskatchewan proved to be far from 
perfect for these applications.    
The fragmented system of data collection and storage, related to jurisdictional boundaries of the 
province’s Regional Health Authorities, and the First Nations and Inuit Health Branch, vastly 
limited the extent of the sexual network that could be examined. This in turn limited the utility of 
the SNA-derived data for informing the AMR model. It was not possible to uncover geographic 
bridging, for example, since the data available for analysis came from just one health region.  
Without a centralized system of data storage for STIs, the true potential of SNA to contribute to 
better understanding of gonorrhea transmission in Saskatchewan will remain limited. The 
strength of these techniques could be greatly enhanced—and the resultant impact on disease rates 
considerable—if Saskatchewan were to adopt a centralized approach to STI control. 
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7.3 Future work 
While the limitations presented by the data restricted the power of SNA and dynamic simulation 
modeling to substantially enhance traditional biostatisical methods, the work presented here 
nevertheless generated some interesting findings. For one, this body of work reinforces that the 
power of a tool is highly dependent upon the availability of appropriate data. The epidemiology 
of gonorrhea in Saskatchewan indicates that improved understanding of disease transmission 
dynamics is needed to enable policy makers to re-evaluate the current approaches to control; 
however, the available data substantially hinder the ability to apply powerful tools such as SNA 
and dynamic modeling.  These results challenge the status quo for case management of 
gonorrhea, as well provincial policies and procedures related to sample collection, analysis, and 
data storage in Saskatchewan.  Put simply, a large amount of personal health information related 
to STIs is being collected and stored in Saskatchewan; the applicability of such data to 
approaches that could considerably improve disease control tactics, however, is considerably 
hampered by the system itself. The only current use of this data is to locate and treat cases and 
contacts—with persistently high disease rates, it may be time to consider alternate policies. A 
standard policy of taking samples for culture, and including both strain typing and antimicrobial 
susceptibility testing on these samples, would improve the potential application of these tools to 
controlling STIs in the province. Point of care testing (for both infection and antimicrobial 
susceptibility) would greatly contribute to disease control efforts, as well as help stave off the 
emergence of AMR infections in currently naïve settings like Saskatchewan. As well, EPT in 
place of—or in addition to—contact tracing might also warrant consideration as a policy option. 
Based on the findings presented here, there are several possible directions for future work: 
7.3.1 Epidemiologic predictors of AMR 
Because of the growing threat of AMR, better understanding of the epidemiologic risk factors for 
AMR infection is urgently needed. To date, there have been only a small number of published 
studies that examine associations between socio-demographic characteristics and AMR infection. 
Future work to identify such associations is needed to better understand the generalizability of 
the findings of the studies to date. Further, rigorous statistical analysis should be a standard for 
such investigations, in order to support development of effective policies to combat AMR. A 
uniform approach to collecting a minimum amount of epidemiologic data on STI cases would 
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increase the potential strength of this approach to identifying socio-demographic risk factors for 
AMR globally. This type of information would be particularly valuable in settings where AMR 
infection is highly prevalent, such as Shanghai. It may also be applicable to preventing AMR 
from taking hold in currently naïve populations.  
7.3.2 Treatment and follow up of gonorrhea in Saskatchewan 
Based on Saskatchewan’s persistently high prevalence of gonorrhea, evaluation of the 
effectiveness of current treatment and follow up approaches are warranted. Further studies in 
other health regions, to validate the factors identified to be related to reinfection and coinfection 
in RQHR, could provide the groundwork for developing alternative strategies. For example, EPT 
may be practical in certain situations, based on the risk factor profile of a given patient.  
 7.3.3 SNA for gonorrhea in Saskatchewan 
As mentioned above, the current system of data collection and storage in Saskatchewan makes it 
challenging to use SNA to its full potential. Future work could focus on enhancing the quality of 
available data. For example, increasing the number of spaces available to record contacts on the 
notifiable STI form could potentially enhance case finding, resulting in a more complete sexual 
network. Additionally, a prospective study to gather samples for molecular information from 
positive gonorrhea cases would allow for molecular strain type information to be superimposed 
on sexual network maps, and the potential contribution of this information to be assessed.  
7.3.4 Dynamic simulation modeling of gonorrhea where AMR rates are low 
In spite of global trends, and high infection rates in general, rates of AMR gonorrhea in 
Saskatchewan remain remarkably low. Therefore, the province presents a unique opportunity to 
consider different strategies for antibiotic use and the potential for eventual emergence of AMR. 
For example, since penicillin resistance is quite low in the province, it may be possible to 
effectively use it to treat gonorrhea locally, although the antibiotic is no longer recommended 
nationally. Dynamic simulation modeling provides a powerful platform for investigating a 
question like this, and could generate valuable information to policy makers who might consider 
creating local treatment guidelines.  
Another recommended future modeling study is to build an agent-based model to represent 
gonorrhea transmission in Saskatchewan, which would increase the model’s ability to 
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incorporate and reflect real-world conditions as compared to the system dynamics model 
presented here. An agent-based model would provide the opportunity to model the influence of 
the sexual network on disease transmission, as well as allow for the effect of stochastics. 
In spite of the limitations of the data discussed above, the work presented herein contributes 
important information related to the control of gonorrhea in two high-prevalence settings. 
Further, it demonstrates the feasibility of using sociodemographic characteristics to discover 
associations with outcomes related to AMR, sexual behavior, likelihood of partner presentation, 
and risk of reinfection/coinfection. The value of SNA and dynamic simulation modeling 
approaches in Saskatchewan is difficult to judge, due to the limitations of data appropriate for 
these purposes. It is likely that their contribution could be substantial, given robust data sources. 
Expanded studies drawing on data from multiple health regions could allow for better evaluation 
of the contribution of these techniques, especially SNA. This would enable the larger sexual 
network to be discovered, which would likely provide more realistic estimates for SNA 
measures. Further, if molecular strain typing became a standard procedure in the province, there 
would be great potential to enhance the information provided by fragmented, incomplete 
networks as the ones derived from the RQHR data. However, at present, this would likely be 
cost-prohibitive.  
The manuscripts presented in this thesis serve to compare and contrast the relative utility of 
several epidemiologic methods, both traditional and novel, as applied to different aspects of the 
control of gonorrhea transmission and the development of AMR. The results of the studies show 
enormous potential for novel or combined approaches to the analysis of STI data. However, they 
also demonstrate the severe limitations encountered for certain methods in certain regions. This 
body of work indicates that there is no one-size-fits-all approach to best address questions related 
to controlling gonorrhea incidence or the emergence of AMR. Rather, careful consideration of 
the research question, available data, and population of interest is required to ensure that the 
most appropriate tools are applied to the specific problem at hand. 
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material used under an exception or limitation to copyright. More considerations for licensors.
Considerations for the public: By using one of our public licenses, a licensor grants the public
permission to use the licensed material under specified terms and conditions. If the licensor’s
permission is not necessary for any reason–for example, because of any applicable exception or
limitation to copyright–then that use is not regulated by the license. Our licenses grant only
permissions under copyright and certain other rights that a licensor has authority to grant. Use of the
licensed material may still be restricted for other reasons, including because others have copyright or
other rights in the material. A licensor may make special requests, such as asking that all changes
be marked or described. Although not required by our licenses, you are encouraged to respect those
requests where reasonable. More considerations for the public.
Creative Commons Attribution 4.0 International Public License
By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and
conditions of this Creative Commons Attribution 4.0 International Public License ("Public License"). To the
extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in
consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in
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consideration of benefits the Licensor receives from making the Licensed Material available under these
terms and conditions.
Section 1 – Definitions.
a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or
based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged,
transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar
Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a
musical work, performance, or sound recording, Adapted Material is always produced where the
Licensed Material is synched in timed relation with a moving image.
b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your
contributions to Adapted Material in accordance with the terms and conditions of this Public License.
c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright
including, without limitation, performance, broadcast, sound recording, and Sui Generis Database
Rights, without regard to how the rights are labeled or categorized. For purposes of this Public
License, the rights specified in Section 2(b)(1)­(2) are not Copyright and Similar Rights.
d. Effective Technological Measures means those measures that, in the absence of proper authority,
may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright
Treaty adopted on December 20, 1996, and/or similar international agreements.
e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to
Copyright and Similar Rights that applies to Your use of the Licensed Material.
f. Licensed Material means the artistic or literary work, database, or other material to which the
Licensor applied this Public License.
g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public
License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed
Material and that the Licensor has authority to license.
h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.
i. Share means to provide material to the public by any means or process that requires permission
under the Licensed Rights, such as reproduction, public display, public performance, distribution,
dissemination, communication, or importation, and to make material available to the public including
in ways that members of the public may access the material from a place and at a time individually
chosen by them.
j. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of
the European Parliament and of the Council of 11 March 1996 on the legal protection of databases,
as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
k. You means the individual or entity exercising the Licensed Rights under this Public License. Your
has a corresponding meaning.
Section 2 – Scope.
a. License grant.
1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a
worldwide, royalty­free, non­sublicensable, non­exclusive, irrevocable license to exercise the
Licensed Rights in the Licensed Material to:
A. reproduce and Share the Licensed Material, in whole or in part; and
B. produce, reproduce, and Share Adapted Material.
2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations
apply to Your use, this Public License does not apply, and You do not need to comply with its
terms and conditions.
3. Term. The term of this Public License is specified in Section 6(a).
4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise
the Licensed Rights in all media and formats whether now known or hereafter created, and to
make technical modifications necessary to do so. The Licensor waives and/or agrees not to
assert any right or authority to forbid You from making technical modifications necessary to
exercise the Licensed Rights, including technical modifications necessary to circumvent
Effective Technological Measures. For purposes of this Public License, simply making
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modifications authorized by this Section 2(a)(4) never produces Adapted Material.
5. Downstream recipients.
A. Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material
automatically receives an offer from the Licensor to exercise the Licensed Rights
under the terms and conditions of this Public License.
B. No downstream restrictions. You may not offer or impose any additional or different
terms or conditions on, or apply any Effective Technological Measures to, the
Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient
of the Licensed Material.
6. No endorsement. Nothing in this Public License constitutes or may be construed as
permission to assert or imply that You are, or that Your use of the Licensed Material is,
connected with, or sponsored, endorsed, or granted official status by, the Licensor or others
designated to receive attribution as provided in Section 3(a)(1)(A)(i).
b. Other rights.
1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are
publicity, privacy, and/or other similar personality rights; however, to the extent possible, the
Licensor waives and/or agrees not to assert any such rights held by the Licensor to the
limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
2. Patent and trademark rights are not licensed under this Public License.
3. To the extent possible, the Licensor waives any right to collect royalties from You for the
exercise of the Licensed Rights, whether directly or through a collecting society under any
voluntary or waivable statutory or compulsory licensing scheme. In all other cases the
Licensor expressly reserves any right to collect such royalties.
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
a. Attribution.
1. If You Share the Licensed Material (including in modified form), You must:
A. retain the following if it is supplied by the Licensor with the Licensed Material:
i. identification of the creator(s) of the Licensed Material and any others
designated to receive attribution, in any reasonable manner requested by the
Licensor (including by pseudonym if designated);
ii. a copyright notice;
iii. a notice that refers to this Public License;
iv. a notice that refers to the disclaimer of warranties;
v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
B. indicate if You modified the Licensed Material and retain an indication of any previous
modifications; and
C. indicate the Licensed Material is licensed under this Public License, and include the
text of, or the URI or hyperlink to, this Public License.
2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the
medium, means, and context in which You Share the Licensed Material. For example, it may
be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that
includes the required information.
3. If requested by the Licensor, You must remove any of the information required by Section
3(a)(1)(A) to the extent reasonably practicable.
4. If You Share Adapted Material You produce, the Adapter's License You apply must not
prevent recipients of the Adapted Material from complying with this Public License.
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed
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Material:
a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and
Share all or a substantial portion of the contents of the database;
b. if You include all or a substantial portion of the database contents in a database in which You have
Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights
(but not its individual contents) is Adapted Material; and
c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the
contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this
Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
a. Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor
offers the Licensed Material as­is and as­available, and makes no representations or
warranties of any kind concerning the Licensed Material, whether express, implied, statutory,
or other. This includes, without limitation, warranties of title, merchantability, fitness for a
particular purpose, non­infringement, absence of latent or other defects, accuracy, or the
presence or absence of errors, whether or not known or discoverable. Where disclaimers of
warranties are not allowed in full or in part, this disclaimer may not apply to You.
b. To the extent possible, in no event will the Licensor be liable to You on any legal theory
(including, without limitation, negligence) or otherwise for any direct, special, indirect,
incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages
arising out of this Public License or use of the Licensed Material, even if the Licensor has
been advised of the possibility of such losses, costs, expenses, or damages. Where a
limitation of liability is not allowed in full or in part, this limitation may not apply to You.
c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner
that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all
liability.
Section 6 – Term and Termination.
a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However,
if You fail to comply with this Public License, then Your rights under this Public License terminate
automatically.
b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your
discovery of the violation; or
2. upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to
seek remedies for Your violations of this Public License.
c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms
or conditions or stop distributing the Licensed Material at any time; however, doing so will not
terminate this Public License.
d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 – Other Terms and Conditions.
a. The Licensor shall not be bound by any additional or different terms or conditions communicated by
You unless expressly agreed.
b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein
are separate from and independent of the terms and conditions of this Public License.
Section 8 – Interpretation. 127
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a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce,
limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made
without permission under this Public License.
b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be
automatically reformed to the minimum extent necessary to make it enforceable. If the provision
cannot be reformed, it shall be severed from this Public License without affecting the enforceability
of the remaining terms and conditions.
c. No term or condition of this Public License will be waived and no failure to comply consented to
unless expressly agreed to by the Licensor.
d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of,
any privileges and immunities that apply to the Licensor or You, including from the legal processes
of any jurisdiction or authority.
Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect
to apply one of its public licenses to material it publishes and in those instances will be considered the
“Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under
the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared
under a Creative Commons public license or as otherwise permitted by the Creative Commons policies
published at creativecommons.org/policies, Creative Commons does not authorize the use of the
trademark “Creative Commons” or any other trademark or logo of Creative Commons without its prior
written consent including, without limitation, in connection with any unauthorized modifications to any of
its public licenses or any other arrangements, understandings, or agreements concerning use of licensed
material. For the avoidance of doubt, this paragraph does not form part of the public licenses.
Creative Commons may be contacted at creativecommons.org.
Additional languages available: Bahasa Indonesia, Nederlands, norsk, suomeksi, te reo Māori,
українська, 日本語. Please read the FAQ for more information about official translations.
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